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ABSTRACT 
Exercise-induced fatigue is a complex, multifactorial process, the physiological 
bases of which are still widely debated. Recent research has implicated pain 
sensation in the aetiology of exercise-induced neuromuscular fatigue.  Indeed, acute 
consumption of acetaminophen (ACT, or paracetamol), a non-specific inhibitor of the 
cyclooxygenase (COX) enzymes which synthesise prostaglandins and sensitise 
group III/IV muscle afferents, has been shown to improve exercise performance 
concomitant with a lower pain and effort sensation.  However, the neurophysiological 
bases for the potential ergogenic effect of acute ACT ingestion, and how this 
influences the power/torque-duration relationship, have yet to be determined.  
Therefore, the purpose of this thesis was to assess the effect of acute consumption 
of the recommended therapeutic dose (1 g of ACT and 400 mg of IBP) of common 
pain-relieving, COX-inhibiting medicines on performance and the mechanisms of 
neuromuscular fatigue development in a variety of different exercise tests.  Study 1: 
Mean torque (61 ± 11 vs. 58 ± 14% pre-exercise MVC) and end-test torque, reflective 
of critical torque, (44 ± 13 vs. 40 ± 15% pre-exercise MVC) were greater in the ACT 
trial compared to placebo (PL) when completing 60 maximum voluntary contractions 
(MVCs) of the knee extensors (both P<0.05). Voluntary activation (VA; a marker of 
central fatigue) and potentiated twitch (pTw; a marker of peripheral fatigue) declined 
at a similar rate in both conditions (both P>0.05). However, the decline in 
electromyography (EMG) amplitude, a marker of muscle activation, was attenuated 
in the ACT trial with EMG being greater compared to PL from 210 s onwards 
(P<0.05). Study 2: Compared to PL, ACT ingestion increased end-test power, 
reflective of critical power (ACT: 297 ± 32 vs. PL: 288 ± 31 W, P<0.001), and total 
work done (ACT: 66.4 ± 6.5 vs. PL: 65.4 ± 6.4 kJ, P<0.05) without impacting Wˈ 
(ACT: 13.1 ± 2.9 vs. PL: 13.6 ± 2.4 kJ, P>0.05) or the M-wave amplitude (P>0.05) 
during a 3-min all-out cycling test. EMG declined throughout the 3-min protocol in 
both the PL and ACT conditions; however, the decline in EMG was attenuated in the 
ACT condition, with the EMG amplitude being greater compared to PL over the last 
60 s of the test (P<0.05). Study 3: Time-to-exhaustion (Tlim) during severe-intensity 
knee extensor exercise in the right leg was 19% shorter after completing prior 
severe-intensity knee extensor exercise to exhaustion in the left leg following 
placebo ingestion (Leg2PL) compared to no prior fatigue in the left leg (Leg2CON) 
(Leg2CON: 385 ± 104 vs. Leg2PL: 311 ± 92 s; P<0.05). ACT ingestion did not improve 
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Tlim in the left leg without prior contralateral fatigue (Leg1ACT) compared to the 
placebo condition (Leg1PL) (Leg1CON: 396 ± 105 vs. Leg1PL: 390 ± 106 vs. Leg1ACT: 
402 ± 101 s; P<0.05).  Moreover, ACT ingestion did not improve Tlim in the right leg 
following prior contralateral fatigue in the left leg (Leg2ACT) compared to the placebo 
condition (Leg2PL) (Leg2ACT: 324 ± 85 vs. Leg2PL: 311 ± 92 s; P>0.05).  There were no 
changes in intramuscular phosphorous substrates and metabolites, ratings of 
perceived exertion or EMG amplitude after ACT ingestion compared to PL ingestion 
in the severe-intensity single-leg knee extensor exercise tests completed with or 
without prior contralateral fatigue.   Study 4: Mean torque (IBP: 60 ± 12 vs. PL: 58 ± 
14% of pre-exercise MVC) and end-test torque (IBP: 41 ± 16 vs. PL: 40 ± 15% of 
pre-exercise MVC) were not different between the IBP and PL conditions when 
completing 60 MVCs of the knee extensors (P>0.05). Similarly, end-test power 
output (IBP: 292 ± 28 W vs. PL: 288 ± 31 W) and work done (IBP: 65.9 ± 5.9 kJ vs. 
PL: 65.4 ± 6.4 kJ) during the 3-min all-out cycling tests were not different between 
the IBP and PL conditions (all P>0.05). Neuromuscular fatigue markers developed at 
a similar rate in both exercise tests in the PL and IBP conditions (all P>0.05). 
 
In conclusion, acute consumption of ACT, but not IBP, increased muscle activation 
and critical torque (and power), and attenuated fatigue development during maximal-
intensity knee extensor and cycle ergometry exercise.  However, acute ACT 
ingestion did not influence Tlim during continuous severe-intensity knee-extension 
exercise completed with or without prior fatigue of the contralateral limb.  The original 
findings from this work suggest that acute ACT ingestion, but not IBP ingestion, 
might have implications for improving performance during maximal-intensity, but 
possibly not severe-intensity constant work rate exercise with these ergogenic 
effects linked to an increase in muscle activation. These findings offer insights into 
the potential for non-specific COX inhibitors to influence performance and 
neuromuscular fatigue development during different forms of exercise.     
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CHAPTER 1 
INTRODUCTION 
 
The development of fatigue during exercise (i.e., exercise-induced fatigue) is a 
complex phenomenon which arises from impairments in multiple physiological 
systems and compromises exercise performance. Exercise-induced fatigue can 
be defined as a condition in which there is a loss in the capacity for developing 
force and/or velocity in response to a load, regardless of whether or not the task 
can be sustained and which is reversible by rest (Enoka & Duchateau, 2008; 
Gandevia, 2001; Macklem, 1990).  The complexity of resolving the mechanisms 
that underpin exercise-induced fatigue is exemplified by the fact that fatigue 
development is influenced by various factors including, but not limited to, age, 
gender, exercise duration, intensity and mode of exercise as well as 
environmental conditions (Enoka & Duchateau, 2008). Moreover, research into 
the development and underpinning mechanisms of fatigue spans several 
disciplines, which often adopt different definitions of fatigue (Abbiss & Laursen, 
2005 for review). Although this multidisciplinary approach has been valuable in 
helping to generate multi-organ, integrative models of the putative mechanisms 
of exercise-induced fatigue (e.g., Amann & Calbet, 2008; Lambert et al. 2005; 
Noakes, 2005; St. Clair Gibson et al. 2018), there is currently no consensus on 
the causes of exercise-induced fatigue and no universal agreement on one 
model that fully explains its development. 
 
Controversy surrounding the mechanisms that underpin exercise-induced 
fatigue can also be attributed to variations in the testing procedures employed 
and the nomenclature adopted when assessing fatigue development. Indeed, 
the terms ‘fatigue’, ‘exhaustion’ and ‘task failure’ are often used 
interchangeably, despite describing different concepts and perhaps being 
underpinned by different mechanisms. Accordingly, research conducted within 
the field of exercise-induced fatigue should be interpreted with consideration of 
such inconsistencies. Moreover, the task-, intensity- and condition-dependence 
of exercise-induced fatigue further complicates the advancement of 
understanding. Therefore, for clarity and precision, it is important to define 
fatigue, exhaustion and task failure, as well as performance, at the outset of this 
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document so that the implications of, and mechanistic insights from, this work 
can be placed in the correct context. It is also pertinent to note that ‘exercise-
induced fatigue’ and ‘neuromuscular fatigue’ will be used interchangeably 
throughout this thesis.  
 
Exhaustion (or task failure) refers to the point where skeletal muscle force 
(power or velocity) production drops below the force required to continue the 
exercise task.  Time to exhaustion or task failure (Tlim) occurs due to a failure of 
the central nervous system (CNS) to activate the skeletal muscle and/or of the 
skeletal muscle to generate the required force to continue the exercise task 
despite sufficient central motor output (CMO).  Moreover, exhaustion/task 
failure might occur due to task disengagement, where the participant voluntarily 
ceases the exercise task despite having the potential to continue. To place 
these different concepts into context, if an individual was instructed to run at a 
set velocity until they were no longer able to run at this velocity and if regular 
measurements of the maximum capability of the lower limb muscles to produce 
force were performed, a decline in maximum force would be manifest due to a 
combination of central and peripheral factors (e.g., fatigue, discussed below) 
before exhaustion/task failure or task disengagement occurred (e.g., Tlim, figure 
1.1). Accordingly, exercise-induced fatigue, exhaustion/task failure and task 
disengagement, and the likely underpinning mechanisms, can be dissociated. 
Performance, on the other hand, refers to the accomplishment of a given task 
measured, typically, against pre-set known standards of time or distance. As 
such, tests to assess performance are often characterised by ‘closed-loop’ 
tests. Closed-loop tests are defined by the presence of a known endpoint (e.g., 
time or distance) such as a time-trial (TT) whereby individuals are able to 
regulate exercise intensity (e.g., self-pace). By direct contrast, open-loop tests 
are defined by the absence of a known endpoint such as a time-to-exhaustion 
test whereby individuals are required to maintain the required intensity for as 
long as possible before exhaustion/task failure or task disengagement occurs. 
Ultimately, the mechanisms that govern task failure (i.e., during open-loop tests) 
and work rare regulation (i.e., during self-paced closed-loop exercise) should be 
considered as different constructs. Whilst providing some use and benefit to 
improving understanding of exercise-induced fatigue, the difficulty with 
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assessing constant work rate (or open-loop) tests in the context of performance 
is that the mechanisms responsible for the final cessation of effort will be 
distinctly different from those responsible for the manipulation of work output 
during ‘self-paced’ exercise.  
 
 
Figure 1.1. Schematic illustrating the differences between exercise-induced 
fatigue and exhaustion. The y-axis represents a given intensity of exercise (% of 
maximum voluntary contractile force). Adapted from Millet (2016). 
 
Exercise-induced fatigue has been broadly categorised into two forms: 
peripheral fatigue, which occurs within the skeletal muscle, and central fatigue 
which is linked to the CNS. Historically, attainment of Tlim and the development 
of exercise-induced fatigue has often been attributed to predominantly one 
contributing mechanism such as perceptual, neurophysiological, cardiovascular 
or intra-myocyte bioenergetics and contractility. However, more recent evidence 
suggests that it is likely the sum and/or interaction of changes taking place 
throughout the body’s physiological and psychological systems which underpins 
the cessation of effort and exercise-induced fatigue (i.e., Barry & Enoka, 2007; 
Enoka & Duchateau, 2008; Lambert et al. 2005; St Clair Gibson & Noakes, 
2004; St. Clair Gibson et al. 2018).  
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For many years, work conducted by the pioneering exercise physiologist, A.V. 
Hill, was accepted to account for the mechanisms that underpinned exercise-
induced fatigue (Hill & Lupton, 1923). The series of experiments conducted by 
Hill reasoned that fatigue develops due to the oxygen requirements of the 
contracting muscles exceeding the capacity of the heart to supply oxygen 
(figure 1.2). Subsequently, the development of an ‘an anaerobic state’ within the 
working muscles and the resulting accumulation of lactic acid was argued to 
provoke peripheral failure and thus task cessation. From this seminal work, it 
was evident that exercise-induced fatigue had both central cardiovascular and 
peripheral components and that both contributed, to an extent, to fatigue 
development. Although this work laid the foundations for research to pursue the 
underling mechanisms of exercise-induced fatigue, recent research challenges 
some of the ideas championed in this model. In the years that followed, and on 
the basis of Hill’s postulate (Hill & Lupton, 1923) that metabolic changes within 
the contracting skeletal muscle were integral to exercise-induced fatigue, the 
majority of research investigating exercise-induced fatigue focused on 
peripheral components, without considering the potential contribution of central 
nervous system (CNS) limitations.  
 
Many disparate models of exercise-induced fatigue have since been developed 
and championed to explain how the integration of central and peripheral 
components conflate to dictate muscle fatigue development during exercise.  
For example, large parts of A.V Hill’s model have since been dismissed in the 
‘the central governor model’ (Noakes et al. 2001; 2005, Noakes, 2000; 2007; 
2012; St Clair Gibson et al. 2001; Ulmer, 1996) which proposes that efferent 
discharge from the central nervous system in response to metabolically 
triggered afferent feedback in the periphery, regulates exercise intensity in an 
anticipatory manner to prevent ‘catastrophic’ failure to homeostasis. Numerous 
other models have since been proposed including, but not limited to, the 
‘psychobiological’ model of fatigue (Marcora et al. 2009), the ‘Critical Peripheral 
Fatigue Threshold’ and/or a ‘sensory tolerance limit’ model (Amann & Calbet, 
2008; Hureau et al. 2018) and, more recently, the ‘Integrative Governor theory’ 
(St Clair Gibson et al. 2018). To further complicate the matter, such models are 
not consistently labelled within the literature. A number of comprehensive 
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reviews on fatigue and its candidate mechanisms, however, have been written 
(e.g., Allen et al. 2008; Amann, 2011; Ament & Verkerke, 2009; Bigland-Ritchie, 
1984; Boone et al. 2013; Enoka & Duchateau, 2008; Enoka & Stuart, 1992; 
Enoka et al. 2011; Ferreira & Reid, 2008; Fitts, 2008; Gandevia, 2001; Gibson & 
Edwards, 1985; Kent-Braun et al. 2012; Kirkendall, 1990; Morales-Alamo et al. 
2015; Sahlin, 1992; Taylor et al. 2016; Thomas et al. 2018; Van Cutsem et al. 
2017; Weir et al. 2006) and an overview of some of the literature harboured in 
support of these models of exercise-induced fatigue is provided in the review of 
literature (Chapter 2). Given that muscle contraction starts at the brain it is, 
perhaps, unsurprising that more recent attempts to explain fatigue have 
incorporated the brain in their model as oppose to previous ‘brainless’ models to 
explain endurance performance, for example (i.e., Joyner & Coyle, 2008). 
Indeed, it is generally accepted that peripheral muscle requires the CNS to 
function and the CNS requires afferent information from peripheral muscle to 
regulate work output. Ultimately, one (i.e., peripheral machinery) needs the 
other (i.e., CNS) to ‘function’ and to ‘function’ is to ‘fatigue’ appropriately, in 
order to conserve cellular integrity (see Chapter 2: Literature review).  
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Figure 1.2. Schematic of A.V Hill’s theoretical model of exercise performance 
(A.V Hill, 1923). Schematic adapted from Noakes (2012). 
 
Whilst it is well established that factors such as maximal oxygen uptake 
(V̇O2peak) and the lactate threshold are important determinants of endurance 
performance (Joyner & Coyle, 2008), work rate regulation is ultimately 
controlled by the brain (Ulmer, 1996). Consequently, measures of sensation 
during exercise have been suggested to play an important role (i.e., Marcora et 
al. 2009; Mauger, 2014; St Clair Gibson et al. 2003; Tucker, 2009). Specifically, 
another factor that might contribute to exercise-induced fatigue development but 
has received comparatively limited research attention in existing models, is pain 
sensation (Foster et al. 2014; Mauger et al. 2010). This is despite emerging 
evidence linking pain sensation (and the manipulation of pain) to fatigue and/or 
performance (e.g., Astokorki & Mauger, 2017; Foster et al. 2014; Mauger et al. 
2010). However, further research is needed to assess whether exercise-
induced pain can be included in models of fatigue and in which exercise 
contexts pain sensation has a greater (or a lesser) effect on fatigue 
development. Over-the-counter analgesics, such as acetaminophen (ACT) and 
the non-steroidal anti-inflammatory drug (NSAID), ibuprofen (IBP), are widely 
consumed by athletes to reduce pain sensation and inflammation. Both ACT 
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and IBP act primarily by inhibiting cyclooxygenase (COX) activity and thus 
prevent the synthesis of prostaglandins (PGs) following the release of 
arachidonic acid. PGs are known to sensitise group III/IV muscle afferents and 
thus are implicated in exercise-induced pain sensation (Hayes et al. 2006; Rueff 
et al. 1993; Schaible et al. 2011). There is emerging evidence to support the 
acute use of ACT in enhancing endurance performance, possibly by reducing 
pain sensation associated with intense exercise (Foster et al. 2014; Mauger et 
al. 2010; Mauger et al. 2014). In addition, ACT may favourably alter 
neuromuscular function to optimise performance by attenuating components of 
central fatigue development (Mauger, 2013; Mauger & Hopker, 2013). However, 
despite the prevalence of consumption of ACT and IBP amongst athletes, 
observations of an ergogenic effect of these drugs is limited. Therefore, the 
purpose of this thesis is to assess the efficacy of ACT and IBP to mitigate 
exercise-induced fatigue development and the mechanisms by which this 
potential ergogenic effect might be elicited in a range of exercise tasks.  
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CHAPTER 2 
LITERATURE REVIEW 
 
Exercise-induced fatigue is fundamentally important to the fields of sport and 
exercise physiology and exercise prescription and rehabilitation. Therefore, 
understanding the mechanisms of exercise-induced fatigue development has 
potential application in improving exercise performance in athletes and improving 
adherence to exercise training/rehabilitation programmes to improve health and 
wellbeing in the general public and patient populations. Moreover, from a basic 
science standpoint, resolving the mechanistic bases of fatigue is central to 
advancing our understanding of physiological control processes.  
 
The pioneering work of A.V Hill (Hill & Lupton, 1923) laid the foundations for 
understanding some of the mechanisms of fatigue, and suggested that fatigue 
develops due to the oxygen requirements of the exercising muscles exceeding 
the capacity of the heart to supply oxygen.  Subsequently, seminal work including 
that of Bergstrom and colleagues (1967) demonstrated that, during prolonged 
heavy-intensity, constant-load exercise, fatigue occurred concomitantly with 
muscle glycogen depletion. This provided a novel and important advancement in 
understanding the mechanisms of exercise-induced fatigue. Since then, a 
plethora of other intra- and extra-muscular factors have been implicated in the 
development of exercise-induced fatigue (see Finsterer, 2012 for brief review of 
the biomarkers of peripheral muscle fatigue during exercise).  Some of the 
components linked to peripheral fatigue include increased intramuscular 
metabolite accumulation, such as adenosine diphosphate (ADP) (e.g., McLester, 
1997), inorganic phosphate (Pi) (e.g., Allen & Trajanovska, 2012; McLester, 
1997; Westerblad et al. 2002), hydrogen ions (H+) (e.g., Sahlin, 1986; Westerblad 
et al. 2002; Wilkie, 1986) and thiol oxidation and reactive oxygen species (e.g., 
Juel, 2006; Reid, 2016); a reduction in the intramuscular substrates, 
phosphocreatine (e.g., Allen & Westerblad, 2001; Hirvonen et al. 1992) and 
glycogen (e.g., Ørtenblad et al. 2013); impairments in muscle calcium (Ca2+) 
regulation (e.g., Allen & Westerblad, 2001; Allen et al. 2002; 2007; 2008; Debold 
et al. 2016; Fitts, 2008), cross-bridge cycling (e.g., Fitts, 2007) and sodium-
potassium pump function (e.g., Lindinger & Sjøgaard, 1991; McKenna, 1992; 
McKenna et al. 2007; 2008); as well as metabolic acidification (e.g., Fitts, 2016) 
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and alterations in thermoregulation (e.g., González-Alonso et al. 1999; Tucker, 
2008; Westerblad et al. 1997), cardiovascular limitations, oxygen (O2) availability 
and respiratory function (e.g., Amann & Calbet, 2007; Romer & Polkey, 2007), 
endocrine function and hormonal regulation (e.g., Clausen et al. 1996; Cordeiro 
et al. 2017; Meeusen & De Meirleir, 1995; Meeusen et al. 2003). Additionally, 
regulation of excitability of the sarcolemma via interplay between muscle specific 
CLC-1 chloride channel regulation and extracellular potassium (K+) accumulation 
have been implicated in regulating muscle function (e.g., Bækgaard Nielsen et 
al. 2017).  
 
In addition, more recently, centrally-mediated mechanisms have also been linked 
to the fatigue process including impaired motor unit firing (e.g., Gandevia, 2001; 
Woods et al. 1987), decreased motoneuron excitability (e.g., Johnson et al. 2004; 
Taylor & Gandevia, 2008), reduced motor cortical drive and excitability (e.g., 
Klass et al. 2008; Macefield et al. 2001; Sogaard et al. 2006; Taylor & Gandevia, 
2008), cerebral blood flow (e.g., Secher et al. 2007) as well as a number of other 
supraspinal (cortical) and spinal mechanisms which are influenced by intrinsic 
changes within the CNS, including, for example, increases in the magnitude of 
inhibitory feedback from muscle afferents (Taylor et al. 2016 for review). This 
series of complex, multi-organ processes have recently been suggested to 
operate in an integrated and coordinated manner to regulate exercise-induced 
fatigue development (e.g., Amann & Calbet, 2008; Lambert et al. 2005; Noakes, 
2005). However, a criticism of models such as the central governor (CGM) is its 
lack of ability to consider the complex interplay between inhibitory and facilitatory 
physiological signals with inhibitory and facilitatory psychological drives to 
regulate work output (St. Clair Gibson et al. 2018). Indeed, exercise-induced 
fatigue should be considered to have both sensory/emotional and physiological 
(central and peripheral) components and not simply exclusively one or the other. 
In addition, the complex and individually-dependent nature of exercise-induced 
fatigue does not lend itself well to be explained by a simplistic model across a 
number of different scenarios. Figure 2.1 provides a brief summary of the 
complex chain of events involved in voluntary force production and thus the 
complexities inherent in investigating exercise-induced fatigue.  
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Figure 2.1. The complex chain of events involved in voluntary force production. 
Adapted from Gandevia (2001).  
 
This chapter will: 1) outline the methods used to assess exercise-induced fatigue 
development and its underpinning mechanisms; 2) review the mechanisms and 
task-dependence of exercise-induced fatigue; and 3) provide a summary of 
recent research linking exercise-induced pain sensation in the aetiology of 
exercise-induced fatigue and areas for further research to enhance 
understanding in this emerging topic within the field of exercise-induced fatigue. 
Finally, a brief review of some of the literature surrounding the effect of non-
specific COX-inhibitors on attenuating fatigue development is provided as an 
evidenced-based rationale for the experimental chapters that comprise this PhD 
thesis.  
 
2.1 Measuring exercise-induced fatigue  
To improve understanding of exercise-induced fatigue, a number of tools and 
methodologies have been used to isolate specific sites along the motor pathway 
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that contribute to the reduction in force production that accompanies exercise of 
a sufficient intensity and/or duration (Cairns et al. 2005; Vollestad, 1997 for 
review). Figure 2.2 provides a brief summary of the methodological apparatus 
that can be utilised at different anatomical locations throughout the motor 
pathway to investigate central and peripheral mechanisms of exercise-induced 
fatigue.  
 
Figure 2.2. The development of exercise-induced fatigue involves numerous 
complex mechanisms. Assessment of muscle fatigue can be segregated into 
peripheral and central components by motor nerve and muscle stimulation 
techniques. Supraspinal fatigue, a subset of central fatigue, can be assessed by 
motor cortex stimulation. Briefly, peripheral fatigue is assessed via changes to 
twitch force, excitability (i.e., M-wave) and contractility characteristics following 
supramaximal peripheral stimulation of a nerve or muscle. Whilst central fatigue 
can be assessed indirectly using similar techniques, stimulation of the spinal tract 
and/or the motor cortex allows for a more direct approach to assess changes in 
cortical voluntary activation (i.e., neural drive) and spinal and supraspinal 
excitability. Electromyography (EMG) is a technique used to record myoelectric 
signals formed by physiological variations in the muscle fibre membranes and 
Chapter 2: Literature review 
12 
 
can be used to infer changes to peripheral and central fatigue. More specifically, 
EMG can be used to assess changes in muscle activation as well as motor unit 
recruitment and firing frequency. EEG; electroencephalogram, TMS; transcranial 
magnetic stimulation, PNS; peripheral nerve stimulation, PMS; peripheral muscle 
stimulation, M1; primary motor cortex. Adapted from Goodall et al. (2010). 
 
2.1.1 Methods to assess neuromuscular fatigue 
The most common method of assessing the neuromuscular bases of exercise-
induced fatigue is via supramaximal stimulation of a peripheral nerve innervating 
the contracting musculature (or the muscle directly) by means of either electrical 
or magnetic methods to monitor changes in force production (e.g., potentiated; 
pTw and superimposed twitches; sTw described below), excitability parameters 
(e.g., M-wave response) and contractility characteristics (e.g., rates of force 
development and relaxation). Electromyography (EMG) can be used in 
combination with evoked stimulation techniques to assess muscle excitability and 
without evoked stimulation techniques to assess muscle activation as well as 
motor unit recruitment and firing frequency. These ‘pulses’ of stimulation can be 
administered as a single pulse (e.g., singlet), paired pulse (e.g., doublet) or 
continuous pulse (e.g., tetanus) and can be administered at different locations 
throughout the motor pathway to assess relative contributions of central (spinal 
and/or supraspinal) and peripheral fatigue mechanisms. In addition, these pulses 
can be manipulated (e.g., output/current and duration) to investigate a range of 
different fatigue mechanisms (i.e., high and low-frequency fatigue).  
 
The name given to the electrical signal evoked in the muscle fibres as a result of 
peripheral nerve stimulation is a compound muscle action potential or ‘M-wave’, 
whereas, a motor evoked potential or ‘MEP’ refers to the signal evoked from 
cortical stimulation. A ‘CMEP’ refers to a cervicomedullary motor-evoked 
potential following stimulation at the cervicomedullary junction (Gruet et al. 2013; 
Inghilleri et al. 1993; Taylor, 2004; 2006). The amplitude and/or area of the 
waveform are measured to characterise the M-wave (e.g., peripheral membrane 
excitability, figure 2.3), CMEP (e.g., spinal excitability) and/or MEP (e.g., 
supraspinal excitability). Therefore, decrements in these excitability parameters 
provide insight into peripheral and central fatigue development. Whilst changes 
to M-wave amplitude have been reported during fatiguing contractions (e.g., 
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Lepers et al. 2002), the maintenance of M-wave amplitude suggests no or little 
change to membrane/motoneuron excitability.  In this instance, the site of failure 
likely originates proximal to the sarcolemma.  On the other hand, MEPs can be 
used to examine the ability of the motor cortex to activate skeletal muscles e.g., 
changes in corticospinal excitability (Taylor & Gandevia, 2001). 
 
 
Figure 2.3. Compound muscle action potential (e.g., M-wave) evident within an 
EMG trace following supramaximal peripheral nerve stimulation. The M-wave 
amplitude is calculated via the peak-to-peak trace of the electrical potential 
(dotted arrow), whereas the M-wave area is calculated as the total integral of the 
curve (both positive and negative deflections).  
 
As well as monitoring changes in the M-wave response, peripheral fatigue can 
also be inferred via a reduction in the resting muscle twitch (e.g., pTw) following 
supramaximal peripheral nerve stimulation (Alway et al. 1987; Kufel et al. 2002). 
Alternatively, central fatigue can be identified via a decrease in voluntary 
activation (VA) using, for example, the interpolated twitch method (Merton, 1954) 
which is revealed as an increase in the twitch superimposed (e.g., sTw) onto a 
maximal voluntary contraction (MVC). The sTw typically increases during intense 
prolonged exercise, reflecting impaired VA (e.g., the participants’ inability to 
recruit sufficient muscle fibres, see below, figure 2.4). However, this method has 
received some criticism including providing a lack of sensitivity in the 
measurement of motoneuronal excitation at near-maximal forces (e.g., Herbert & 
Gandevia, 1999). A more direct approach of assessing the contribution from 
spinal and supraspinal structures is with the use of transcranial (TMS) and 
cervicomedullary magnetic stimulation. These techniques have been used to 
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further investigate the independent contributions of supraspinal and spinal fatigue 
(e.g., Gruet et al. 2013; Inghilleri et al. 1993; Taylor, 2004; 2006). 
 
For these methods, the subject is required to perform a maximal voluntary 
contraction (e.g., MVC). When the force produced by the subject reaches its 
peak, the investigator superimposes a supramaximal stimulation of the peripheral 
muscle (either by stimulating the muscle directly or the main nerve innervating 
the contracting musculature) and quantifies the change in force (figure 2.4). When 
a sTw is observed, this provides evidence that motor drive (conscious and/or sub-
conscious) was submaximal as the electrical or magnetic pulse was able to evoke 
additional force beyond that voluntarily produced (Merton, 1954). A ‘twitch’ is then 
produced again after the MVC with the same pulse to provide the investigator 
with a ‘reference value’ (e.g., pTw), which is used to infer peripheral fatigue 
development and peripheral muscle function (figure 2.4). However, contrary to 
peripheral stimulation methods, following a TMS evoked contraction of the target 
muscle group and production of a MEP, there is a silent period evident in the 
EMG trace. This period of EMG ‘inactivity’ is also referred to as the cortical silent 
period (CSP) and has been suggested to represent increased cortical inhibition 
(Inghilleri et al. 1993; Taylor et al. 1996; Taylor & Gandevia, 2001). 
 
Figure 2.4. Illustration of superimposed (sTw) and potentiated (resting, pTw) 
twitches, produced during and following a maximal voluntary contraction (MVC) 
for the determination of voluntary activation and peripheral function (edited from 
Merton, 1954). 
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2.1.2 Contraction characteristics 
For each pTw, contraction time, maximum rate of force development and one-
half relaxation time (RT0.5) can be obtained through analysis of the force trace. 
Changes to such characteristics are thought to represent alterations to Ca2+ 
release and uptake (Eleveld et al. 2004; Frank, 1982; Klitgaard & Clausen, 1989). 
In addition, a reduced rate of force development (or ‘MRFD’) is considered to 
reflect a decrease in the rate of cross-bridge formation (Fitts, 2008; Maffiuletti et 
al. 2016; Stein & Parmiggiani, 1981). Reductions in maximal relaxation rate and 
a prolonged RT0.5, however, are thought to reflect decreases in the maximal rate 
of weak-to-strong cross-bridge formation and decreases in the maximal rate of 
cross-bridge detachment, respectively (Westerblad, Bruton, & Lannergren, 1997; 
Westerblad, Lannergren, & Allen, 1997). 
 
2.1.3 Electromyography (EMG) 
EMG is a technique used in neuromuscular physiology which records myoelectric 
signals formed by physiological variations in the muscle fibre membranes and 
can be measured via surface electrodes placed on the skin superior to the muscle 
of interest, and more directly, via needles inserted into the muscle of interest 
(Enoka & Duchateau, 2008). For the purpose of this thesis, EMG amplitudes were 
rectified, since electrical activity appears positive as depolarization approaches 
the electrode and negative as it passes the recording electrode (which would 
cancel each other out). Reduced EMG amplitude during maximal contractions 
suggests reduced muscle activation, reduced motor unit recruitment and firing 
frequency and/or a change in muscle fibre-type recruitment (Sogaard et al. 2006). 
However, excitability of the sarcolemma can also be altered with fatigue (e.g., 
Lepers et al. 2002) and thus, the reduced EMG amplitude during maximal 
contractions may also be explained by changes in the maximal M-wave amplitude 
(Millet & Lepers, 2004). Thus, EMG can be normalised to the M-wave amplitude 
in order to exclude any changes to the trace due to changes in local membrane 
excitability. Although EMG has its limitations such as its inherent variability and a 
‘complex relationship with fatigue (see below) (Amann & Calbet, 2008; Enoka & 
Stuart, 1992; Martinez-Valdes et al. 2018; Taylor & Gandevia, 2008), it can also 
be used as a valid measure to estimate the development of both central and 
peripheral fatigue during exercise such that, for example, central fatigue from 
impaired alpha motor cord neuron firing will manifest as a reduced mean spectral 
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frequency (Bigland-Ritchie et al. 1978; 1981; 1983; 1986; Edwards, 1981; Enoka 
& Stuart, 1992; Gandevia, 2001; Stephens & Taylor, 1972). Reduced amplitude 
of EMG signals at task failure indicates either loss of recruitment or synergistic 
activation of multiple muscles (Gandevia et al. 1995; Taylor & Gandevia, 2008). 
However, surface EMG has recently been criticised in its use to indirectly infer 
changes to neural drive (Martinez-Valdes et al. 2018).  
 
The electromyographic response to exercise shares a highly complex 
relationship with fatigue. For example, during sustained maximal exercise, EMG 
declines as a function of time concomitant with decrements in force (e.g., Kent-
Braun, 1999). However, during sustained submaximal exercise, EMG typically 
increases until exercise is terminated as, at the onset of exercise, sub-maximal 
muscle activity does not induce maximal motor unit recruitment (Dimitrova & 
Dimitrov, 2003; Enoka & Stuart, 1992; Taylor & Gandevia, 2008). This is markedly 
different compared to maximal contractions where EMG activity (due to high firing 
rates) is at its highest at the start of exercise and continues to decline as a 
function of time (e.g., Burnley, 2009; St Clair Gibson et al. 2001).  However, 
during repeated submaximal contractions there is also a large inter-individual 
variability in the EMG response. As the relationship between EMG and fatigue 
can change dependent on the type of task being completed (i.e., an increase or 
decrease in the EMG trace doesn’t necessarily infer fatigue development), this 
does not necessarily mean that EMG is always a robust indicator of muscle 
fatigue (Enoka & Stuart, 1992; Taylor & Gandevia, 2008). In addition, the use of 
EMG during locomotion, particularly within field-based research, adds further 
complexity. For example, during cycling exercise, the terrain can have a direct 
impact on muscle activation at a given speed (i.e., Wang et al. 2013). In this 
instance, during self-paced exercise and independent of fatigue development, an 
individual may consciously decide to reduce muscle activation despite the lack of 
observation of significant central, peripheral and/or mental fatigue development. 
As a consequence, care should be taken when interpreting changes in the EMG 
signal during an exercise task. 
 
2.1.4 Voluntary activation (VA) 
VA is defined as ‘the level of neural drive to a muscle during exercise’ (Merton, 
1954) and reflects the ability to fully activate the target muscle group or the ability 
Chapter 2: Literature review 
17 
 
of the CNS to maximally drive a muscle during voluntary contraction. In a fatigued 
state, a larger twitch is evoked during an MVC (e.g., sTw) and VA is incomplete; 
that is, some motor units are not recruited or not firing fast enough to generate 
fused contractions (Gandevia et al. 1998; Todd et al. 2003). For the purpose of 
the investigations that comprise this thesis, VA was determined using the 
following equation: 
 
VA (%) = (1 - sTw/pTw) x 100             
 
Where pTw relates to the potentiated twitch produced by the quadriceps (i.e., for 
knee extension exercise). The presence of a sTw produced by TMS during the 
peak force production of an MVC suggests that the drive from the motor cortex is 
sub-optimal. Importantly, this conclusion cannot be made specific to the motor 
cortex from peripheral methods as the impairment may be located anywhere 
‘upstream’ from the peripheral nerve (Gandevia et al. 1998; Todd et al. 2003). 
Most healthy individuals can activate quadriceps muscle to near maximum 
(~95%; Kent-Braun, 1999). As the voluntary drive varies at different muscle 
groups, the degree of central fatigue will depend on the muscle tested. For 
example, maximal VA of the diaphragm is less than the biceps brachii as twitch 
force during maximum contraction has been shown to be relatively greater with 
the diaphragm than with the biceps (Gandevia et al. 1995). VA of a single muscle 
is also reduced when multiple muscles are simultaneously contracted (Howard & 
Enoka, 1991). VA is also reduced with pain, likely due to feedback inhibition to 
spinal alpha motor neurons via spinal oligosynaptic pathways (Gandevia, 2001; 
Martin et al. 2006; Taylor et al. 2000; Woods et al. 1987; Amann et al. 2008; 
Amann & Dempsey, 2008). In addition, whilst physical training has been shown 
to increase VA, immobilization is known to reduce it (Duchateau & Hainaut, 
1987). 
 
2.2 Multi-faceted, task-dependent nature of fatigue 
The aetiology of exercise-induced fatigue is recognised as being multi-factorial 
such that it can be caused by a number of different mechanisms that result in an 
acute reduction in the ability to perform an exercise task. However, exercise-
induced fatigue also appears to depend on the task characteristics, with 
variations in contraction intensity (or duration), speed of movement, or type of 
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muscle contraction influencing the relative contributions of central (spinal and 
supraspinal) and peripheral fatigue development (Enoka, 1995 for review). 
Specifically, the muscle mass engaged (single-limb vs. locomotor exercise; 
Amann et al. 2011; 2013, single vs. double limb exercise; Rossman et al. 2012; 
2014), nature of the task (e.g., intermittent vs sustained; Bigland-Ritchie et al. 
1986; Duchateau et al. 2002), duration and intensity (Thomas et al. 2014; 2016) 
of the task being performed (e.g., short vs prolonged; Bigland-Ritchie et al. 1986; 
Ross et al. 2010; Schillings et al. 2003; Smith et al. 2007; Sogaard et al. 2006) 
and even the target muscle group (e.g., elbow extensors vs knee extensors; 
Kawabata et al. 2000) or action (e.g., eccentric vs isometric; flexors vs extensors; 
(Smith & Newham, 2007) influence the bases of exercise-induced fatigue. This 
task-dependence of fatigue development makes resolving the mechanisms of 
exercise-induced fatigue highly complex. Therefore, caution should be applied 
when extrapolating findings on the mechanisms of exercise-induced fatigue to 
other exercise tasks.  Moreover, the task-dependent manner of exercise-induced 
fatigue complicates the pursuit of a unifying model of exercise fatigue. 
  
2.2.1 Peripheral and central fatigue mechanisms  
Peripheral fatigue is associated with an attenuation of muscle force production 
caused by processes distal to the neuromuscular junction (Ament & Verkerke, 
2009; Gandevia, 2001). As such, peripheral fatigue develops outside of the CNS 
consequent to changes in energy supply and/or metabolite accumulation and is 
manifest as impaired muscle membrane excitability, contractility and/or impaired 
neurotransmission. In peripheral skeletal muscle fatigue there are a number of 
sites where repeated contractions may cause impairment, either at the 
neuromuscular junction, muscle membrane, sarcoplasmic reticulum or within the 
sarcomeres (the proteins actin and myosin) of the working muscle. A brief 
summary of some of the main proposed mechanisms of peripheral fatigue is 
presented below: 
 Excitation-contraction uncoupling: Impaired Ca2+ release and active 
reuptake from sarcoplasmic reticulum, SR (e.g., excitation contraction 
uncoupling), as well as impaired interactions between myosin and actin 
during cross-bridge cycling and calcium sensitivity (e.g., lower force for a 
given intramyocyte [Ca2+]). 
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 Sodium (Na+) & potassium (K+) pump activity: Loss of electrical 
conduction from muscle membrane to t-tubule system. 
 Metabolite accumulation: accumulation of intramuscular lactic acid and 
H+ causes a reduction in the pH of the cell, while the accumulation of 
inorganic phosphate (Pi) and adenosine diphosphate (ADP) have also 
been implicated in peripheral fatigue development. 
 Impaired adenosine triphosphate (ATP) turnover via glycogen and/or 
phosphocreatine (PCr) depletion.  
 
Perhaps the most frequently contested discussion surrounding peripheral fatigue 
development and its contribution to Tlim and work output regulation, is the lack of 
observation of absolute depleted levels of substrates (i.e., whole muscle PCr, 
glycogen). In addition, when methods to manipulate central fatigue development 
are introduced (i.e., fentanyl administration, discussed below), further 
development of peripheral fatigue is observed, suggesting that peripheral fatigue 
(or more specifically, metabolite accumulation and/or substrate depletion) may 
be regulated by the CNS in order to prevent complete failure of the peripheral 
machinery. However, it is important to consider that localisation of [PCr] (i.e., 
Cannon et al. 2013; Sahlin et al. 2017) and glycogen (i.e., Nielsen et al. 2011; 
2012; 2014) depletion have been observed which can have profound effects on 
force production. In addition, it is pertinent to note that in the example of reduced 
glycogen levels, the rate of fat oxidation cannot meet the required ATP demand 
alone that is associated with high-intensity exercise and thus work output must 
reduce to allow exercise to continue (Baker et al. 2010). Although beyond the 
scope of this thesis, it is also worthy to note that factors of central (i.e., neural 
drive) and mental fatigue (i.e., effort perception, both discussed below), are also 
rarely observed at their ‘true’ zero/maximal, providing further support that a 
number of mechanisms likely coordinate to bring about fatigue development. For 
example, voluntary activation (a measure of neural drive) and RPE using the 6-
20 Borg scale (a measure of perceived effort) in healthy individuals are rarely 
observed <60% and at 20, respectively, during exhaustive exercise (i.e., Ross et 
al. 2010). A VA of >0% and RPE of <20 would, therefore, suggest a ‘reserve 
capacity’ located proximal to the neuromuscular junction within the CNS and/or 
that factors associated with mental fatigue (i.e., motivation) are sub-maximal at 
task-end, respectively.  
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In contrast, central fatigue encompasses mechanisms that originate within the 
CNS and manifests as a reduction in VA or neural drive to the target muscle due 
to, for example, decreases in the number of recruited motor units and/or their 
discharge rate from the primary motor cortex, M1 (Gandevia, 2001; Verin et al. 
2004). Such changes are likely due to alterations in cerebral metabolism and 
neurotransmitter responses (Gandevia, 2001; Verin et al. 2004 for review). As a 
consequence of central fatigue development, impairments upstream of the 
neuromuscular junction are observed such as alterations to spinal propagation, 
and corticospinal, intracortical and supracortical excitability changes (Gandevia, 
2001). In contrast to research on peripheral fatigue mechanisms, limited research 
has been conducted on the role of the CNS in human fatigue and thus less in 
known of the central regulation of human performance. This is likely because 
most research historically supported the theory of peripheral fatigue and that, 
comparatively, there were many limitations (and still are) in the ability to measure 
components of central fatigue. This is often because of a lack of objective 
measurement tools available to measure central fatigue.  However, the relatively 
recent introduction of TMS in underpinning a failure of central mechanisms during 
exercise now affords the researcher with the opportunity to explore exercise-
induced central fatigue development with relative ease (e.g., Taylor et al. 2006; 
Smith et al. 2007; Goodall et al. 2009; Sidhu et al. 2009; Goodall et al. 2012). The 
main proposed mechanisms of central fatigue include: 
 Loss of recruitment of high threshold motor units 
 Reduced central drive from increased inhibitory interneuron input to M1 
 Central conduction block from demyelination or motor neuron dropout 
 Increased inhibitory feedback from group III/IV muscle afferents 
 Loss of facilitatory feedback from muscle spindle group I sensory afferents 
 Deficit in brain serotonin 
 
The majority of research has demonstrated that peripheral fatigue mechanisms 
are the predominant contributors to fatigue development during the early stages 
of exercise (e.g., Bigland-Ritchie et al. 1983; 1986). Peripheral fatigue 
mechanisms also seem to dominate during higher-intensity exercise (e.g., 
Bigland-Ritchie et al. 1983; 1986; Thomas et al. 2014) as evidenced by a 
decreased pTw, decreased M-wave amplitude and changes to contraction 
characteristics such as an increase in relaxation rate (e.g., Bigland-Ritchie et al. 
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1986; Gandevia, 2001; Schillings et al. 2003; Smith et al. 2007; Sogaard et al. 
2006). Centrally mediated mechanisms have also been identified in a range of 
exercise tasks via significant reductions in VA, decreased MEP amplitude and 
extended CSP length (Taylor et al. 1996) indicative of a reduction or a cease in 
firing rates of some motoneurons (Bigland-Ritchie et al. 1983; 1986).  It appears 
that central fatigue mechanisms become increasingly important during extreme 
conditions (i.e., heat, hypoxia) and with increasing exercise duration where there 
is a concomitant decrease in exercise intensity (Froyd et al. 2016; Thomas et al. 
2014; Taylor et al. 2016 for review). The relative proportion of central fatigue 
development is also known to increase under extreme environmental conditions 
(e.g., hypoxia, extreme heat/cold) such that spinal and supraspinal contributions 
accelerate and interact with peripheral muscle to restrict exercise capacity (e.g., 
Amann et al. 2006; Goodall et al. 2010; Meeusen & Roelands, 2010; Nybo, 2010).  
 
Central fatigue can be further categorised into spinal and supraspinal fatigue. 
Supraspinal fatigue is defined as an exercise-induced decline in force caused by 
suboptimal output from the motor cortex demonstrated through a decreased 
descending drive or increased perceived exertion (or effort, RPE), whereas spinal 
fatigue relates to impairments within the spinal cord (Gandevia, 2001). From a 
technical perspective, central fatigue refers to any exercise-induced reduction in 
MVC force which is not accompanied by the same reduction in maximal evocable 
force (evoked by supramaximal stimulation of the target muscle group or nerve 
innervating the muscle group). For example, a decrease in VA of up to 10% has 
been observed after prolonged cycling (Lepers et al. 2002). After prolonged 
fatiguing muscle contractions, the amplitude of MEP in response to TMS has also 
been shown to be reduced, indicating a reduction in cortical excitability (Ross et 
al. 2007; Schillings et al. 2004). In addition, central fatigue has been identified 
during exercise tasks via impairments in the motor cortex (e.g., Gandevia et al. 
1996; Sidhu et al. 2009; 2013), impaired reflex responses at the spinal cord (e.g., 
Garland & McComas, 1990; Klass et al. 2008) and alterations to intrinsic 
properties of motoneurons (e.g., McNeil et al. 2011a; 2011b). Central fatigue 
development has also been attributed to a reduced drive from motor neurons via 
reflex effects from muscle afferents. Specifically, stimulation of group III/IV 
afferent nerves (chemo- and nociceptive afferents) induces a decrease in motor 
neuron firing frequency and an inhibition of the motor cortical output (e.g., Amann 
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et al. 2013). Greater discussion on the role of group III/IV afferents in the 
development of central fatigue is provided in section 2.3. The M1 behaviour has 
been found to be altered in a complex manner during exercise as the excitability 
of cells within the cerebral cortex is known to increase as a result of physical 
activity (e.g., Wrightson et al. 2016). However, as fatigues ensues as a function 
of increased duration and intensity of exercise, the excitability of cortical cells 
decreases, leading to impaired exercise performance (e.g., Sharples et al. 2016). 
 
Mental fatigue, which has been defined as a psychobiological state caused by 
prolonged periods of demanding cognitive activity and is characterised by 
subjective feelings of “tiredness” and “lack of energy” (Boksem & Tops, 2008), 
was once considered a strand of central fatigue. However, most research now 
describes mental fatigue as a ‘sensation’ and its contribution to central fatigue 
development is unclear. Specifically, whilst some studies have demonstrated a 
decrease in endurance performance and earlier attainment of task 
disengagement (i.e., Tlim) (e.g., Bray et al. 2008; Marcora et al. 2009; Pageaux et 
al. 2013), others have shown no effect (e.g., Martin et al. 2015; Pageaux et al. 
2015), following a mentally fatiguing task. Nevertheless, it would seem that 
perceived exertion (i.e., Bayne et al. 2008; Crewe et al. 2008; Pires et al. 2011; 
Romer et al. 2007) and exercise-induced pain (discussed below) may have the 
potential to influence exercise performance irrespective of their underpinning 
mechanisms. For example, studies attempting to attenuate the negative effects 
of mental fatigue have shown improvements in Tlim and exercise performance by 
way of providing an external motivation to participants (i.e., self-talk, Blanchfield 
et al. 2014; monetary reward, Zedelius et al. 2014; competition, Corbett et al. 
2012). In addition, some studies have also observed beneficial effects on 
performance using methods of deception (Mauger et al. 2009; Stone et al. 2012; 
Williamson et al. 2011). However, it is possible that such effects of mental fatigue 
and interventions aimed at reducing the perceived demands of the task may be 
limited in trained subjects (i.e., Corbett et al. 2012; Hulleman et al. 2007; Skorski 
et al. 2017).  It is also possible that the effect of mental fatigue is specific to the 
task and the type of ‘mentally fatiguing’ intervention (Van Cutsem et al. 2017 for 
review). In addition, during exercise it is likely that mechanisms of mental fatigue 
and the psychological demands of exercise interact with multiple physiological 
systems to bring about the final cessation of effort and exercise-induced fatigue 
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development (Inzlicht, & Marcora, 2016; McCormick et al. 2015; Van Cutsem et 
al. 2017 for review).  
 
There is also ongoing debate as to whether sensory input (i.e., group III/IV muscle 
afferents) contribute to the perception of effort (de Morree et al. 2012; Khan et al. 
2011; Kjaer et al. 1989) and/or whether perception of effort can be disassociated 
from perceived exertion (Peñailillo et al. 2018) and the perception of exercise-
induced pain (i.e., Pageaux, 2016). Instead, group III/IV muscle afferent feedback 
may simply act as a means to inform pain and numerous other sensations during 
exercise and thus not provide sensory signals for generating perception of effort 
(de Morree et al. 2012; Khan et al. 2011; Kjaer et al. 1989; Marcora, 2008). 
However, it is pertinent to note that the generation and interpretation of effort is 
likely multi-factorial (i.e., sensory and emotional) and that central command does 
not always increase linearly with the perception of effort during exercise (Abbiss 
et al. 2015; Nybo & Nielsen, 2001; Pageaux, 2016). 
 
It has also been suggested that RPE may be set at the beginning of the exercise 
task in ‘teleoanticipation’ as part of a feedforward control mechanism (i.e., O2 
levels of ambient air, skin temperature, glycogen levels), comparing a ‘template’ 
of previous experiences as well as knowledge of distance/duration, the level of 
motivation and competition, to the instantaneous actual power (or velocity) and 
pacing profile to prevent a threat to homeostasis (i.e., Central Governor Model, 
Noakes & St. Clair Gibson, 2004; Crew et al. 2008; Tucker, 2009). In this case, 
the RPE will rise to reach maximum levels at exercise completion, irrespective of 
the exercise task (i.e., time to exhaustion vs. time-trial) (Noakes & St. Clair 
Gibson, 2004 for review; Tucker et al. 2004). In support of this notion, Swart et 
al. (2008) found that RPE was strongly correlated with the duration of exercise 
when participants had prior knowledge of the ‘end-point’.  Indeed, this model of 
fatigue is of interest for self-paced exercise as work output is typically reduced 
much before any whole muscle ‘limiting environment’ is attained (Noakes & St. 
Clair Gibson, 2004 for review; Tucker et al. 2004). However, originally thought to 
be solely a sub-conscious mechanism, it is now generally accepted that work 
output during self-paced exercise is likely regulated by a combination of 
conscious and sub-conscious mechanisms and that different regions of the brain 
as an ‘integrative controller’ acts as a complex system to regulate output (i.e., 
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Crewe et al. 2008; St Clair Gibson et al. 2018). Interestingly, Crewe et al. (2008) 
found that the rate of rise in RPE accurately predicted Tlim almost from the onset 
of exercise. Ultimately, whilst beyond the scope of this thesis, there is evidence 
to suggest that many factors contribute to the sensation of effort (i.e., Marcora, 
2008; Pageaux, 2016; Smirmaul, 2012; St Clair Gibson et al. 2003). Furthermore, 
given that corollary discharge represents the efferent output to increase activation 
of skeletal muscle (and work output), it is perhaps unsurprising of its association 
with RPE (Marcora, 2008). However, it is important to note that the CNS must 
receive information from periphery muscle in order to determine corollary 
discharge to inform the exercising human of when and to what extent to increase 
and/or decrease effort to drive skeletal muscle (i.e., Smirmaul, 2012). However, 
an extensive review on the role of mental fatigue and perceived effort (and/or 
exertion) in determining Tlim and performance during a range of tasks is beyond 
the scope of this thesis.  
 
2.2.2 Sustained maximal exercise 
During sustained maximal exercise, force declines as fatigue ensues. During the 
initial stages of sustained maximal exercise, this decline has been attributed 
almost exclusively to peripheral factors (e.g., Bigland-Ritchie et al. 1978; 
Schillings et al. 2003) and manifests as a reduction in twitch force and slowed 
twitch dynamics (e.g., rate of force development, RT0.5), with no change in M-
wave parameters, suggesting that the contractile machinery, and not impulse 
propagation, is impaired (Bigland-Ritchie et al. 1978). By contrast, central fatigue 
manifests as a reduction in voluntary force that is faster than the force decrement 
elicited via peripheral nerve or muscle stimulation and its relative contribution 
increases with duration (e.g., Kent-Braun, 1999; Froyd et al. 2016; Thomas et al. 
1989; Schillings et al. 2003). The development of supraspinal fatigue during an 
MVC is accompanied by an increase in the sTw evoked by TMS, the development 
of which increases as a function of time (Todd et al. 2005). In addition to changes 
in the sTw twitch, MEP size decreases during sustained MVCs with time, 
revealing rapid reductions in motoneuron excitability that are compensated for by 
sufficient on-going voluntary drive (McNeil et al. 2009; Taylor et al. 1996). During 
sustained maximal exercise tasks, EMG is at its highest on initiation of the task 
and continues to decline until task cessation reflecting a gradual decrease in input 
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from the motor cortex, development of peripheral fatigue and thus reduced 
muscle activation.  
 
In a recent study, neuromuscular fatigue development was assessed during the 
completion of a 60 MVC protocol over a period of 5 min (60 repetitions of 3 s 
MVCs, and 2 s passive recovery) (Burnley, 2009). During the MVCs, force 
declined to approximately 30% of baseline values, which was shown to be not 
different from the critical torque (CT), the asymptote of the torque-duration 
relationship (figure 2.5). VA declined from ~91% to 67% and pTw declined to 
~48% of resting levels, indicating the development of central and peripheral 
fatigue, respectively. During prolonged maximal exercise, alongside the 
development of central and peripheral fatigue, distinct changes to the muscle 
metabolic milieu (e.g., Pi, PCr and H+ accumulation) and muscle activation (EMG) 
are also evident (e.g., Burnley, 2009; Fulford et al. 2013). At the onset of exercise, 
there is a rapid decline in muscle [PCr] and pH coupled with a rapid rise in [Pi], 
[ADP] and [AMP] before reaching a peak that coincides with task cessation, the 
achievement of CT and a plateau in the decline of muscle activation to 
approximately 70% of maximal baseline levels (as measured via EMG) (Burnley, 
2009; Fulford et al. 2013).  
 
Figure 2.5. Mean torque ± SD during the 60 maximal contractions that comprised 
the 5-min all-out test. Edited from Burnley (2009). 
2.2.3 Exercise intensity domains 
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Submaximal constant work rate exercise can be categorised into three distinct 
intensity domains based on kinetics of oxygen consumption (V̇O2) and the blood 
[lactate] response: moderate, heavy and severe (Black et al. 2017; Whipp & 
Ward, 1992). The upper limit of the moderate-intensity exercise domain is 
indicated by the lactate (LT) and/or gas exchange threshold (GET), which 
comprises work rates for which there is no change (or only a transient increase) 
in blood [lactate] and a steady state in O2 uptake is attained (Burnley & Jones, 
2007; Wilkerson et al. 2004). The boundary between the heavy and severe 
exercise intensity domains is demarcated by critical power (CP, or critical torque, 
CT, as an exercise modality equivalent), which reflects the asymptote of the 
power (or torque)-duration relationship. In addition, the CP represents a threshold 
for neuromuscular fatigue development (Burnley, 2009; Burnley et al. 2012; 
Moritani et al. 1993). During heavy-intensity exercise, a V̇O2 slow component is 
evident, causing a delayed and elevated steady state in V̇O2 and blood [lactate] 
(Poole et al. 1988). Whereas, the severe-intensity domain encompasses work 
rates above CP in which maximal oxygen uptake (V̇O2max) can be elicited (~2-15 
min in duration) and is associated with a progressive increase in muscle 
metabolic perturbation (Jones et al. 2008; Poole et al. 1988, figure 2.6). 
 
2.2.4 Submaximal exercise 
During submaximal exercise, the extent of neuromuscular fatigue and thus the 
relative contributions of central and peripheral mechanisms are highly dependent 
on the intensity of exercise or contractions. For example, during sustained lower 
intensities (e.g., <30% MVC) the contribution of central fatigue is substantially 
higher than that observed during sustained higher intensity submaximal 
contractions (e.g., >30% MVC) where peripheral fatigue dominates and central 
fatigue is modest or even absent (Bigland-Ritchie et al. 1986; Eichelberger & 
Bilodeau, 2007; Yoon et al. 2007). Indeed, the CT has been identified as a distinct 
point at which the rate of peripheral fatigue development precipitously 
accelerates, whereas, below CT, central fatigue gradually increases (Burnley et 
al. 2012). At intensities below CT, exercise tolerance is typically >20 min, 
whereas, peripheral fatigue continues to increase above the CT until exhaustion 
ensues within ~20 min. The EMG response to submaximal exercise is also 
distinctly different to maximal exercise tasks. Unlike maximal activity, submaximal 
muscle activity does not induce maximal motor unit recruitment from 
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exercise/contraction onset.  Instead, a progressive rise in EMG, reflecting an 
increase in motor unit recruitment and/or motor unit firing rate, is evident 
(Dimitrova & Dimitrov, 2003). The size of the MEP, CSP length and sTw evoked 
by TMS has also been shown to increase during submaximal exercise as a 
function of time (particularly during lower intensity contractions), reflecting a 
decrease in corticospinal excitability and increases in cortical inhibition and 
supraspinal fatigue (Sogaard et al. 2006; Smith et al. 2007; Taylor et al. 1996). 
However, when volitional drive is reduced and/or absent, MEP and CMEP size 
are reduced and thus excitability is impaired (McNeil et al. 2011). 
 
Similar to sustained maximal exercise, during submaximal exercise within the 
severe-intensity domain, distinct changes in muscle metabolism are evident (e.g., 
Black et al. 2017; Chidnok, et al. 2013a; 2013b; Jones et al. 2008).  During 
exercise in the severe-intensity domain, the termination of exercise is believed to 
coincide with the depletion of the finite anaerobic reserves and an accumulation 
of metabolites (e.g., H+, Pi, ADP), which have been linked to exercise-induced 
fatigue (Jones et al. 2008; Vanhatalo et al. 2010). Recent research has implicated 
a critical threshold of accumulation of these by-products in the fatigue process, 
suggesting that the development of metabolic perturbation and peripheral fatigue 
development may be restricted by the attainment of a ‘sensory tolerance limit’ 
which limits CMD and expedites central fatigue development (Amann & Calbet, 
2008; Gandevia, 2001 for review). The sensory tolerance limit is a hypothetical 
construct thought to relate to a specific, individually determined tolerable level of 
peripheral fatigue development to protect homeostasis (Amann & Calbet, 2008; 
Gandevia, 2001; Hureau et al. 2018). Section 2.3 and 2.4 below discusses in 
further detail how metabolites activate group III/IV afferent firing in contributing to 
the fatigue process due the attainment of the sensory tolerance limit. 
 
During exercise below CP, PCr, Pi and muscle pH are able to achieve steady 
state values within minutes of initiation of an exercise task (Black et al. 2017; 
Jones et al. 2008; Newham & Cady, 1990; Vanderthommen et al. 2003). 
However, during severe-intensity exercise there is a progressive loss of muscle 
homeostasis (Black et al. 2017; Burnley & Jones, 2010; Burnley, et al. 2010; 
Hogan et al. 1999; Jones et al. 2008; Sogaard et al. 2006). A rapid decline in pH 
coupled with an increase in Pi and a steady fall in PCr are evident, with 
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exhaustion soon occurring perhaps to an individually determined ‘critical level’ of 
muscle metabolic perturbation (Black et al. 2017; Chidnok et al. 2013a; 2013b; 
Jones et al. 2008; Vanhatalo et al. 2010). However, whilst there is evidence to 
suggest that inhibiting group III/IV muscle afferent feedback during severe-
intensity exercise, via lumbar intrathecal administration of fentanyl, lowers central 
fatigue development and facilitates increased skeletal muscle metabolic 
perturbation via greater increases in muscle [Pi], other markers of muscle 
metabolic perturbation (pH, [PCr] and [ADP]) are not different (i.e., Amann et al. 
2009, 2011; Blain et al. 2016; Broxterman et al. 2017a, 2017b; 2018; Sidhu et al. 
2014, 2017, 2018). Further research, therefore, is needed to provide clarity on 
the direct role of group III/IV afferents on muscle metabolic perturbation in light of 
these discrepancies.  
 
   
Figure 2.6. Muscle metabolic response during constant work rate exercise just 
above and just below critical torque. A – Phosphocreatine [PCr] B – Inorganic 
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phosphate [Pi]. A steady fall in PCr (B) and a rapid increase in Pi (B) are evident 
when exercising above (open circles), compared to below (filled circles), the 
critical torque (From Jones et al. 2008).  
 
In addition to the muscle metabolic responses to severe-intensity exercise, 
Moritani and colleagues (1993) showed that the EMG response could be 
stabilised at a given work rate, but continued to gradually increase once CP was 
exceeded. Furthermore, Burnley et al. (2012) found that the rate at which fatigue 
developed, and the site of neuromuscular fatigue (e.g., central or peripheral 
fatigue) differed above and below CT. The rate of change in the MVC torque and 
the pTw torque were disproportionately larger during exercise above, compared 
to below the CT (figure 2.7). At exercise intensities just above CT, exercise 
duration was ~18 min and was accompanied by a 24% drop in VA. Conversely, 
at the highest exercise intensity, (~3 min), the drop in VA was only 6%. The drop 
in pTw, on the other hand, was not different between trials, providing evidence 
for the existence of a threshold for peripheral fatigue during exercise to 
exhaustion above CT (Burnley et al. 2012). It was concluded that exercise above 
the CT is limited by the development of peripheral failure, whereas central fatigue 
likely plays a greater role during exercise below the CT.  
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Figure 2.7. Maximal voluntary contraction torque [A], electromyograhy (EMG) 
[B], potentiated twitch torque [C] and voluntary activation (VA) [D] responses to 
contractions performed 20% below (filled circles), 10% below (open circles) and 
five works rates of increasing intensity above critical torque (CT) (filled triangles, 
open triangles, filled squares, open squares and filled diamonds, respectively) 
(Burnley et al. 2012). During exercise below CT, there is an initial decrease in 
torque, EMG, twitch torque and VA before plateauing. Note increases in the 
relative contribution from centrally-mediated mechanisms as a function of time 
(i.e. VA). During exercise above CT, there is a rapid decline in torque, twitch 
torque and VA and continued rise in EMG before task cessation. Note peripheral 
mechanisms dominate during severe-intensity exercise (i.e. twitch torque) 
perhaps to individually specific levels of peripheral fatigue development. Taken 
from Burnley et al. (2012).  
 
2.2.5 Locomotor exercise 
The cause of fatigue during locomotion is highly sensitive to the type, intensity 
and duration of exercise, even more so during smaller, isolated exercise tasks 
(Enoka & Stuart, 1992; Barry & Enoka, 2007). Many studies that have attempted 
to characterise the neuromuscular fatigue response during locomotor exercise 
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have been constrained by methodological issues and the fact that fatigue 
assessment is also highly sensitive to the type of task. Much of the available 
literature has been based on the assessment of neuromuscular fatigue 
immediately post-exercise on a separate apparatus, which is confounded by a 
significant recovery of neuromuscular function when transferring between the 
different experimental set ups (Carroll et al. 2017). However, recent studies have 
employed novel approaches to assess neuromuscular fatigue during ergometry 
(e.g., Black et al. 2017; Doyle-Baker et al. 2017; Sidhu et al. 2012). As with 
maximal contractions, short duration high-intensity locomotor exercise appears 
to be primarily limited by mechanisms of peripheral fatigue (as evidenced by 
reduced pTw and impaired contraction characteristics), whilst central fatigue 
becomes increasingly prevalent as exercise duration is prolonged (as evidenced 
by decreases in maximal VA, e.g., Decorte et al. 2012; Lepers et al. 2000; 2002; 
Millet et al. 2003; Place et al. 2004; Ross et al. 2010; Sidhu et al. 2009; Thomas 
et al. 2014; 2015). There is less clear evidence of neurotransmission failure 
contributing to fatigue, with some authors reporting reductions (e.g., Millet et al. 
2003) and others observing no change (e.g., Ross et al. 2010) in M-wave 
responses. A limited number of studies have adopted the use of TMS during 
locomotion and demonstrated the presence of supraspinal (Goodall et al. 2012; 
Ross et al. 2007; Sidhu et al. 2009; 2012; 2013) and corticospinal fatigue (Sidhu 
et al. 2012; Sidhu et al. 2013). However, more research is required to reveal a 
more comprehensive understanding of the central regulation of fatigue during 
locomotion.  
 
2.3 Group III/IV muscle afferents and fatigue  
Muscle afferents have been implicated in the development of exercise-induced 
fatigue. The nervous system has different types of neurons that can be sub-
categorised into afferent and efferent neurons. Afferent neurons receive 
information from sensory organs and communicate this to the CNS via ascending 
tracts, whereas, efferent neurons send impulses from the CNS to peripheral limbs 
and organs via descending tracts (figure 2.8). In the peripheral nervous system, 
an afferent nerve fibre is the axon of an afferent sensory neuron. There are many 
types of afferent and efferent fibres, each of which have different functions. In 
particular, group III (myelinated) and IV (unmyelinated) afferent fibres monitor 
changes in contraction-induced mechanical and chemical stimuli within skeletal 
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muscle and have respective conduction velocities of 4-20 and 0.2-3 m/sec (Boyd 
& Davey, 1968).  
 
 
Figure 2.8. Afferent neurons receive information from sensory organs and 
communicate this back to the CNS via ascending tracts, whereas, efferent 
neurons send impulses from the CNS to peripheral limbs and organs via 
descending tracts (adapted from https://www.studyblue.com/).  
 
At the onset of exercise, changes in contraction-induced mechanical stimuli and 
noxious chemicals activate molecular receptors which are located on the terminal 
end of both group III/IV muscle nerve fibres. The exercise-induced activation of 
these receptors increases the discharge of the thin fibre muscle afferents that 
project to various sites within the CNS at both spinal and supraspinal levels, many 
of which are currently unknown, via the lumbar dorsal horn of the spinal cord 
(Adreani et al. 1997; Brooks et al. 2005; Katayama et al. 2007; Light et al. 2008; 
Wilson et al. 2002; Wilson & Hand, 1997). These noxious chemicals either 
sensitise (e.g., reduce the threshold of these nociceptors to fire) or cause the 
discharge of nociceptors with the resulting response subsequently perceived as 
pain (along with many other sensations) by the exercising human (Dubin & 
Patapoutian, 2010; Mense, 2008; Miles & Clarkson, 1994; O’Connor & Cook 
1999; McCord & Kaufmann 2010; Pollak et al. 2014). During exercise, group III/IV 
muscle afferents play a major role in regulating the cardiovascular and ventilatory 
responses (Amann et al. 2010; 2011; 2015 for review), CMD (the output of spinal 
motoneurons) (Amann et al. 2009; 2011; 2012; Blain et al. 2016; Laurin et al. 
2015; Hilty et al. 2011; Sidhu et al. 2017) and efficiency of skeletal muscle 
contractile function (Broxterman et al. 2017a; 2017b; 2018). Specifically, 
continuous afferent feedback from working locomotor muscle is essential for 
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evoking appropriate ventilatory and circulatory responses during exercise in order 
to prevent premature peripheral fatigue by allowing sufficient blood flow and thus 
oxygen delivery to the working muscle (Amann & Calbet, 2008 for review). 
However, group III/IV muscle afferents are also known to provide a regulatory 
role by limiting CMD and the development of peripheral fatigue to a ‘critical 
threshold’, likely to protect the organism from excessive exhaustion and 
potentially harm (Amann et al. 2009; 2010; 2015 for review, figure 2.9).   
 
As such, group III/IV muscle afferent feedback has been suggested to contribute 
to the attainment of the ‘sensory tolerance limit’ (Gandevia, 2001; Hureau et al. 
2016), a hypothetical construct relating to a specific critical level of peripheral 
fatigue prior to the withdrawal of CMD. Indeed, with intact feedback from muscle 
afferents, numerous studies have revealed that the inability to continue high-
intensity, constant-load endurance exercise coincides with the attainment of a 
specific critical level of peripheral fatigue and/or metabolic perturbation (e.g., 
Amann & Dempsey, 2008; 2016; Amann, et al. 2006; 2007; Black et al. 2017; 
Chidnok et al. 2013a; 2013b; Duffield et al. 2010; Gagnon et al. 2009; Romer et 
al. 2007; Saey et al. 2005; Vanhatalo et al. 2010; 2016). However, other studies 
have also refuted such claims (e.g., Froyd et al. 2016; Thomas et al. 2018 for 
review) suggesting that performance and fatigue are not regulated to a peripheral 
critical threshold and that, instead, fatigue is determined by the mode and 
intensity of the task which dictate the active muscle mass and demand on other 
physiological systems. Together, these systems interact to determine fatigue 
development and exercise tolerance (Thomas et al. 2018 for review). 
Nevertheless, such studies support the notion that the absolute magnitude (or 
ensemble) of muscle afferent feedback from intense exercise regulates 
performance.  
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Figure 2.9. Schematic illustration of the afferent-feedback model of fatigue 
proposed by Amann & Dempsey (2008). Briefly, afferent neurons, and the 
associated inhibitory feedback that projects towards cortical regions of the central 
nervous system, have been suggested to regulate the magnitude of central motor 
drive which, in turn, determines the sustainable intensity of the peripheral 
muscles. Adapted from Amann & Dempsey (2008).    
 
Whilst muscle afferent feedback appears to be of critical importance during 
whole-body exercise (i.e., Amann & Calbet, 2008; Amann & Dempsey, 2008; 
Amann et al. 2008; 2009; 2010; 2011; Blain et al. 2016; Gandevia, 1996; 
Rossman et al. 2014; Sidhu et al. 2014; Taylor et al. 1996; Weavil et al. 2015; 
2016), it should be acknowledged that muscle afferent feedback is only one of 
several potential factors that may account for the inability to continue high-
intensity, constant load endurance exercise and a reduction of CMD (see figure 
2.1).  Moreover, two different subtypes of chemosensitive group III/IV muscle 
afferents have been characterised. The so-called ‘metaboreceptors’, only 
respond to levels of intramuscular metabolites (e.g., lactate, ATP, protons) 
associated with ‘normal’ (e.g., freely perfused) exercise (Amann et al. 2015; 
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Bangsbo et al. 1993; Hellsten et al. 1998). In contrast, the other subtype, 
metabonociceptors, only respond to higher (noxious) levels of metabolites 
present in muscle during ischaemic contractions or following hypertonic saline 
infusions, but not to non-noxious metabolite concentrations associated with 
‘normal’ exercise (Jankowski et al. 2013; Light et al. 2008; Pollak et al. 2014). 
This suggests, perhaps, that methodologies such as the use of occlusion 
techniques or hypertonic saline infusions may no longer be considered optimal 
techniques for investigating the role of group III/IV muscle afferents in exercise-
induced fatigue.  Consequently, further research is required to elucidate the 
importance of afferent feedback as a candidate mechanism for exercise-induced 
fatigue.  
 
To assess the importance of afferent feedback as a candidate mechanism for 
exercise-induced fatigue, a number of recent studies have attempted to 
experimentally manipulate group III/IV muscle afferent feedback during exercise 
(e.g., Amann, et al. 2006; 2007; 2008; 2009; 2010; 2011; 2013; Amann & 
Dempsey, 2008; Blain et al. 2016; Broxtermnn et al. 2017; 2018; Dempsey et al. 
2008; 2014; Hilty et al. 2011; Katayama et al. 2007; Romer et al. 2007; Rossman 
et al. 2012; 2014; Sidhu et al. 2014; 2017; Weavil et al. 2015; 2016). The same 
level of peripheral fatigue has been observed despite manipulating oxygen 
availability (e.g., hypoxia, hyperoxia, Amann et al. 2006; 2007; Vanhatalo et al. 
2010) and pre-existing muscle fatigue (e.g., Amann & Dempsey, 2008), factors 
which would be expected to increase type III/IV muscle afferent feedback. 
However, the administration of fentanyl, a pharmacological agent that abolishes 
pain sensation and type III/IV afferent feedback  in the lower limbs (e.g., Amann 
et al. 2009, figure 2.10; Amann et al. 2010; 2011; Blain et al. 2016; Broxterman 
et al. 2018; Sidhu et al. 2017), permitted a greater development of peripheral 
fatigue. Specifically, Amann et al. (2011) suggested that participants were able 
to delay the attainment of the sensory tolerance limit which permitted further 
development of peripheral muscle fatigue beyond their “critical threshold” with 
intact afferent feedback. In further support of the role of group III/IV afferent 
feedback regulating central function, abolishing neural input via fentanyl 
attenuates intracortical inhibition, via a reduced cortical silent period during a 
single leg exercise task (Hilty et al. 2011). This supports the notion that central 
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effects of muscle afferents might accelerate intracortical inhibition and thus the 
development of central fatigue. 
 
Although there is robust experimental evidence to support a role for fentanyl 
administration to modulate the bases of exercise-induced fatigue, the effects of 
fentanyl administration on exercise performance and/or Tlim is unclear (e.g., 
Amann et al. 2009; 2010; 2011; Blain et al. 2016; Broxterman et al. 2017b; 2018; 
Hilty et al. 2011; Sidhu et al. 2017). Therefore, further research is needed to 
assess the role of afferent feedback in exercise performance/fatigue 
development. In support of the notion that group III/IV muscle afferent feedback 
impairs exercise performance by accelerating central fatigue, Sidhu et al. (2014) 
demonstrated that the decline in VA observed post-exercise could be abolished 
with impaired feedback (via fentanyl blockade) during severe-intensity cycling. 
Indeed, the use of fentanyl has also been shown to reduce the CSP, thought to 
reflect attenuation in inhibitory intercortical interneuron activity that is a likely 
contributor to central fatigue as well as enhance spinal excitability (Sidhu et al. 
2017). However, during non-fatiguing contractions, the facilitatory effects of 
muscle afferents was also abolished, highlighting a complex role of muscle 
afferents on exercise performance (Sidhu et al. 2017).  
 
Whilst studies administering fentanyl provide evidence for an inhibitory effect of 
afferent feedback on output from spinal motoneurones and peripheral muscle 
fatigue, a limitation of this approach is that it has been shown that the blocking of 
group III/IV muscle afferents impairs the cardiopulmonary responses during 
exercise, particularly as fatigue ensues (Amann et al. 2009; 2010; 2011; Blain et 
al. 2016), which can compromise exercise performance in certain experimental 
conditions (Amann et al. 2009; 2010; 2011; Blain et al. 2016). An alternative 
approach to investigate the influence of group III/IV muscle afferents is to 
increase the inhibitory feedback. For example, when peripheral locomotor muscle 
fatigue has been induced prior to a cycling test (Amann & Dempsey; 2008; 
Gagnon et al. 2009) (which would be expected to provoke higher afferent 
feedback) a lower output of spinal motoneurones (estimated via EMG) and an 
impaired cycling performance during a subsequent trial has been reported 
(Amann & Dempsey, 2008; Gagnon et al. 2009).  
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Figure 2.10. Effect of reduced afferent feedback on central motor drive and 
power output during a 5-km cycling time trial; (A) Effects of intrathecal fentanyl 
on EMG and; (B) Power output during the 5 km time trial with and without neural 
feedback blockade. Mean EMG during the time-trial (TT) was significantly 
increased following intrathecal fentanyl administration as the CNS permitted a 
higher degree of central motor drive, enhancing exercise performance. However, 
the administration of fentanyl allowed a higher degree of peripheral fatigue 
development which impaired performance in the second half of the trial, with no 
overall net effect of 5-km TT performance. From Amann et al. (2009).  
 
Interestingly, as found with impaired feedback, a greater degree of peripheral 
fatigue development has also been found during small compared to large muscle 
mass exercise (i.e., single leg vs. whole body cycling; single vs. double leg 
exercise) (Rossman, et al. 2012; 2014). This has been attributed to confining 
group III/IV muscle afferent feedback to a small muscle mass, enabling the CNS 
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to ‘tolerate’ a greater degree of peripheral fatigue.  Specifically, trials performed 
with single-leg knee-extension resulted in significantly greater peripheral 
quadriceps fatigue than double-leg knee-extension, as evidenced by changes in 
the EMG signal (147 and 85%), MVC (-25 and -12%), and pTw (-44 and -33%), 
for single-leg and double-leg knee-extension, respectively (Rossman et al. 2014). 
It is, therefore, likely that the magnitude of ‘ensemble’ afferent feedback is more 
important in determining the magnitude of CMD during fatiguing exercise. This is 
in agreement with recent reviews (i.e., Thomas et al. 2018) criticising the 
existence of a critical peripheral threshold and that, instead, the critical 
development of peripheral fatigue is specific to the task characteristics. However, 
it would have been of interest in this line of studies to normalise iEMG to a 
presentative M-wave amplitude to provide more conclusive evidence of the effect 
of abolishing afferent feedback to neural drive.  
 
It would also seem that group III/IV afferent feedback associated with exhaustive 
exercise has the ability to compromise performance of remote non-exercised 
muscle groups during locomotion (e.g., Sidhu et al. 2014). Indeed, Sidhu and 
colleagues (2014), found that following exhaustive leg cycling, maximal voluntary 
muscle activation (during and after exercise) of a non-local muscle group e.g., 
elbow flexors (not directly involved in the task) was reduced (Sidhu et al. 2014). 
Specifically, Sidhu et al. (2014) completed constant-load leg fatiguing (i.e., to 
exhaustion) and non-fatiguing (30 s of sub-maximal exercise) cycling exercise 
both under control conditions and with lumbar intrathecal fentanyl to impair 
feedback from μ-opioid receptor-sensitive lower limb muscle afferents. 
Interestingly, central fatigue was manifest during control fatiguing conditions in 
the, rested, elbow flexors (i.e., reduced MVC, VA and MEP). However, when the 
central projection of afferent feedback was attenuated, these effects were 
abolished. Interestingly, despite the non-fatiguing bout enhancing corticospinal 
excitability (increased MEP) fentanyl administration attenuated this blockade, 
resulting in a 14% lower corticospinal responsiveness during this bout (thus 
abolishing the facilitatory effects of muscle afferents) and highlighting the 
complex role of group II/IV muscle afferents during exercise. Taken together, 
these observations suggest that in the absence of muscle fatigue (i.e., during 
non-fatiguing contractions), group III/IV muscle afferent facilitate responsiveness 
of the motor pathway to non-local muscle. However, by direct contrast, in the 
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presence of locomotor muscle fatigue (i.e., during fatiguing contractions), group 
III/IV afferents exacerbate supraspinal fatigue and inhibit the responsiveness of 
corticospinal projections in remote muscle non-exercised muscle groups (Sidhu 
et al. 2014).  
 
2.4 Contralateral limb fatigue  
Cross-over (or non-local muscle fatigue; NLMF) is characterised by performance 
impairments in remote non-exercised muscles following a fatiguing protocol of a 
contralateral or ipsilateral muscle group (Halperin et al. 2015, for review; e.g., 
Doix et al. 2013; 2014; Halperin et al. 2014; Halperin et al. 2014; Kennedy et al. 
2014; Martin & Rattey, 2007; Sidhu et al. 2014). The mechanisms of NLMF are 
poorly understood but are thought to be due to a number of complex neurological, 
biochemical, biomechanical and psychological factors (Halperin et al. 2015, for 
review). The topic of contralateral (or ipsilateral) limb fatigue is of interest as it 
offers insights into the potential determinants of exercise-induced fatigue. 
Growing evidence suggests that humans voluntarily terminate high-intensity, 
constant-load endurance exercise once their ‘sensory tolerance limit’ is reached 
(Gandevia, 2001 for review) by inhibiting CMD (Gandevia, 1996; Taylor et al. 
1996; Todd et al. 2003; 2005). However, whilst many studies have attempted to 
isolate the inhibitory effect of muscle afferents via pharmacological inhibition (i.e., 
fentanyl), these studies are confounded or complicated by impeding the 
cardiopulmonary response to exercise and/or inhibiting different afferent fibres to 
those emanating from the exercising skeletal muscles (e.g., Amann et al. 2009; 
2010; 2011; Blain et al. 2016; Amann & Calbet, 2008 for review). Previous studies 
have also been confounded by issues such as changes in peripheral muscle 
function (pre-fatigue studies e.g., Amann & Dempsey, 2008) and to the external 
environment (hypoxia studies e.g., Amann, et al. 2006; 2007).  
 
To bypass these issues, Amann and colleagues (2013) conducted a study that 
sought to determine whether muscle afferent feedback associated with peripheral 
muscle fatigue inhibits CMD via a single leg model where subjects were asked to 
perform single leg knee-extensor exercise to exhaustion in one leg immediately 
followed by the identical task in the other, rested, leg (e.g., leg2).  Specifically, 
participants performed constant-load, single-leg knee extensor exercise to 
exhaustion at 85% of peak work rate with each leg. In addition, the test was 
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repeated but with the contralateral limb performed immediately at the cessation 
of the first leg task (Amann et al. 2013). Tlim (e.g., exercise tolerance, time-to-
exhaustion) of the consecutively exercising contralateral leg was 49% shorter 
when compared to its single leg control (without prior contralateral fatigue). 
Additionally, pTw following the contralateral limb protocol was 19% less in leg2 
(33 vs 52%). End-exercise EMG amplitude was also 26% lower and perceived 
exertion was consistently 28% higher, all providing evidence that peripheral 
fatigue and associated afferent feedback limits the development of further 
peripheral fatigue and compromises endurance exercise performance by 
inhibiting CMD. Therefore, it is possible that, during contralateral limb exercise 
(via a feedback loop), group III/IV muscle afferents have an inhibitory impact on 
the CNS, leading to decrements in CMD to both the working and non-exercised 
muscles (e.g., Amann et al. 2013; Sidhu et al. 2014). It could, therefore, be likely 
that the termination of exercise during this constant load task was due to 
participants reaching their ‘sensory tolerance limit’ (Amann et al. 2013; Gandevia, 
2001; Hureau et al. 2018). Importantly, any possible humoral cross-over effect 
was excluded as neither handgrip MVC nor quadriceps muscle function of the 
rested contralateral leg were altered by exhaustive single-leg knee-extension 
(Amann et al. 2013). Figure 2.11 summarises the proposed mechanisms for the 
existence of contralateral limb fatigue and the interactions between afferent 
feedback, peripheral fatigue, CMD and endurance exercise performance. 
Importantly, further research is necessary to understand whether Tlim is linked to 
the sensory tolerance limit (i.e., via an increased magnitude of group III/IV muscle 
afferent feedback) and/or to direct local effects of changes to muscle metabolic 
milieu (i.e., high [H+], low [PCr]) on muscle contraction (i.e., not reliant on group 
III/IV muscle afferent feedback or changes in CMD). 
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Figure 2.11. Theory proposed by Amann et al. (2013) for the interactions 
between afferent feedback, peripheral fatigue, central motor drive (CMD) and 
endurance exercise performance. Specifically, task disengagement of the prior 
limb exercise (i.e., leg1) coincides with the attainment of the sensory tolerance 
limit [A], a hypothetical construct that coincides with a certain level of peripheral 
fatigue and associated intramuscular metabolic milieu. Upon task cessation of 
leg1, the contralateral limb (i.e., leg2) completes the identical exercise task. 
However, whilst there is some recovery from afferent firing, afferent feedback 
remains elevated from leg1 exercise [B], and the sensory tolerance limit is 
reached at an earlier time point during leg2 exercise [C], contributing to 49% 
impairment in single-limb knee-extension exercise performance when compared 
to the identical exercise task without pre-existing fatigue in the opposing limb.  
 
Several other studies have also documented a significant reduction in CMD to 
the contralateral rested muscle (e.g., Rattey et al. 2006; Todd et al. 2003; 
Zijdewind et al. 1998). However, the effect of contralateral limb fatigue was quite 
pronounced in the Amann et al. (2013) study, with a 49% impairment in leg2. This 
observation is consistent with some (e.g., Amann et al. 2013; Doix et al. 2013; 
Halperin et al. 2014; Kennedy et al. 2013; Rattey et al. 2006; Takahashi et al. 
2011), but not all (e.g., Elmer et al. 2013; Grabiner & Owings, 1999; Regueme et 
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al. 2007; Todd et al. 2003; Zijdewind et al. 1998), previous studies reporting 
increased fatigue development after prior contralateral or non-local muscle 
fatigue. Some studies have also reported reductions in the output of spinal 
motoneurons to the contralateral rested muscle, but with no performance 
impairment (e.g., Rattey et al. 2006; Todd et al. 2003; Zijdewind et al. 1998). This 
inter-study discrepancy in the potential ergolytic effect of contralateral fatigue 
(and NLMF) has been attributed to differences in sex, exercise modality, utilised 
muscle mass (and thus the total magnitude of group III/IV muscle afferent 
feedback), and/or the use of flexor vs. extensor muscles (Amann et al. 2013).  
However, this ‘task-dependency’ requires further investigation (Halperin et al. 
2015 for review). 
 
These discrepancies might be also explained, in part, by the possibility that sub-
maximal non-local muscle exercise can potentiate contractility of resting muscles 
(Sidhu et al. 2014). A recent study provides further controversy on contralateral 
limb fatigue and the significance of the role of afferent feedback during exercise 
(Kennedy et al. 2015). In this study, participants completed a series of MVCs with 
the contralateral knee extensors after completing a two minute continuous 
unilateral MVC of the knee extensors with and without lower limb occlusion to 
maintain or increase firing frequency of group III/IV muscle afferents. However, 
no differences in MVC torque was observed with blood flow occlusion. Thus, 
further investigation is required to confirm the contribution of group III/IV muscle 
afferents to contralateral limb impairments, particularly in light of recent research 
that has criticised techniques such as occlusion to alter the magnitude of afferent 
feedback (Bangsbo et al. 1993; Hellsten et al. 1998; Jankowski et al. 2013; Light 
et al. 2008; Pollak et al. 2014). 
 
2.5 COX-inhibitors and exercise performance 
Emerging evidence shows that blunting afferent feedback (via the use of mild 
analgesics), but not completely abolishing sensory input (via fentanyl 
administration), can improve exercise performance (Foster et al. 2014; Mauger 
et al. 2010; 2014). In addition to their known role in regulating the exercise 
pressor reflex (Amann et al. 2012; Secher & Amann, 2012 for review), the 
discharge of group III/IV muscle afferents in response to mechanical and 
metabolic stimuli also contributes to the sensation of muscle pain during exercise 
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(O’Connor & Cook 1999; McCord & Kaufmann 2010; Pollak et al. 2014). Over-
the-counter pharmacological agents, such as anti-inflammatory drugs (NSAIDs) 
and paracetamol (or acetaminophen, ACT) which act primarily by inhibiting the 
activity of COX enzymes (isoforms: COX-1, COX-2, COX-3), are known to reduce 
the sensation of pain. Consumption of an acute dose of ACT may improve 
exercise performance (Foster et al. 2014; Mauger et al. 2010; 2014) but the 
potential mechanism(s) of action is/are unclear. Therefore, further studies are 
required to better understand the physiological mechanisms by which analgesic 
drugs might enhance exercise performance. The following sections will focus on 
the literature that has assessed the effects of consuming non-specific COX-
inhibitors (e.g., ACT and IBP) on exercise performance and its underpinning 
mechanisms to help generate the rationale for the current thesis and justify the 
experimental hypotheses. 
 
2.5.1 ACT mechanism of action and pharmacokinetics 
ACT and IBP (a non-steroidal anti-inflammatory drug, NSAID) are competitive 
inhibitors of the enzyme, COX, which mediates the bioconversion of arachidonic 
acid to PGs, endogenous algesic exokines (and its derivatives i.e., TXA2, PGD2, 
PGE2, PGF2). It is believed that NSAIDs act centrally and peripherally to reduce 
the sensation of pain and tissue inflammation, respectively (Fridén & Lieber, 
1992). ACT is a commonly used non-prescription pain reliever (e.g., an analgesic) 
and antipyretic (e.g., able to reduce fever) and is considered one of the safest 
non-opioid analgesics at therapeutic doses (1 g, Toussaint et al. 2010). Following 
oral ingestion, ACT is rapidly absorbed from the gastrointestinal tract and then 
metabolized by the liver into toxic and non-toxic compounds (Hodgman & 
Garrard, 2012) with a resultant bioavailability of 70 to 90% (Forrest et 
al. 1982). However, whilst gastric emptying can be slowed by the intake of food, 
the absorption of ACT is not affected (Prescott, 1980). Research has 
demonstrated peak plasma [ACT] to be attained at ~60 min (e.g., Anderson et al. 
2008; Forrest et al. 1982) and up to 120 min (1.5 g dose, Foster et al. 2016) 
following oral ingestion. The plasma half-life of acute ACT ingestion at the 
therapeutic doses ranges between 1.5 and 4 h in humans (Forrest et al. 1979; 
1982; Prescott et al. 1971; Prescott, 1980). Whilst the mechanisms that underlie 
the analgesic effect of ACT are not completely understood in vivo, the analgesic 
effect is considered to be predominantly mediated by central factors (Anderson 
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2008; Graham et al. 2013; Smith 2009; Toussaint et al. 2010). Conventionally, 
the analgesic effect of ACT has been attributed to the inhibition of COX enzymes, 
which stimulate nociceptor discharge through the synthesis of PGs (Graham et 
al. 2013; Jóźwiak-Bębenista & Nowak 2014, figure 2.12). There is also evidence 
that the analgesic effect of ACT is linked to potentiation of descending 
serotoninergic pathways (Andersson et al. 2011Pickering et al. 2006; 2008), and 
modulating opioid and cannabinoid receptors (Graham et al. 2013; Ottani et al. 
2006). These mechanisms likely interact to lower pain sensation (as well as 
inflammation and body temperature) following acute ACT ingestion by increasing 
the nociceptive stimuli required to evoke a given pain sensation.  
 
Figure 2.12. Mechanism of action of non-specific COX-inhibitors (e.g., 
acetaminophen, ACT, ibuprofen, IBP) on cyclooxygenase (COX) and 
prostaglandin (PG) synthesis. Pain is considered the body’s ‘early warning 
system’ as its primary purpose is to protect the body from further harm. 
Nociceptors, which are specialised nerve cells that stretch from the spinal cord to 
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areas including skeletal muscle, skin, bones and internal organs, relay 
information back to the brain to inform the central nervous system of a painful 
stimulus. Nociceptors, in contrast to other nerve cells, have a threshold to fire and 
thus are only stimulated on exceeding this threshold. Following the delivery of a 
painful stimulus [1] and the subsequent damage to cells, PGs (or PGH2) are 
produced following the bioconversion of arachidonic acid (released following 
painful stimuli [2]) by cyclooxygenase enzymes (e.g., COX-1, COX-2) [3]. PGs 
sensitise nociceptors, thus lowering the threshold to fire. Following the 
conversion of arachidonic acid, PGs are then converted to a number of different 
chemicals (e.g., TXA2, PGD2, PGE2, PGF2) [4] and subsequently have a number 
of effects on the body including raising the body temperature, causing 
inflammation and lowering the pain threshold [5]. Non-specific COX-inhibitors 
(e.g., ACT and IBP) provide analgesic, antipyretic and inflammatory effects 
through (non-selectively) binding to the active sites of COX [e.g., 3], blocking the 
metabolism of arachidonic acid and thus preventing PG synthesis. 
 
2.5.2 ACT and neuromuscular function  
PGs are lipid autacoids that are derived from arachidonic acid by the action of 
COX isoenzymes and contribute to the sensation of pain and to the desensitizing 
of group III/IV muscle afferent fibres. Indeed, as PGs biosynthesis is blocked by 
non-specific COX-inhibitors, manipulating PG synthesis in this way may act as a 
less invasive means to assess the potential contribution of group III/IV muscle 
afferent feedback to exercise performance in a more applied and ‘real-world’ 
setting when compared to the invasive nature of spinal fentanyl administration 
that has previously been discussed. In addition, acute pain has been observed to 
increase corticospinal inhibition which likely inhibits optimal motor cortex 
activation during voluntary movement and thus impairs voluntary muscle 
activation and, ultimately, muscle function (Dubé & Mercier, 2011). In direct 
contrast, ACT ingestion is known to reduce pain and has been reported to 
increase resting corticospinal excitability, as inferred from an increased MEP 
amplitude (Mauger & Hopker 2013). This increased resting corticospinal 
excitability would be expected to manifest during exercise if inhibitory feedback 
from group III/IV muscle afferents was attenuated with ACT ingestion and could 
explain its ergogenic capabilities. In support of these observations, it has 
previously been demonstrated in mice that ACT increases the activity of TRPA1 
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at the spinal level and increases the activity of endocannabinoid CB1 receptors 
within the brain (Andersson et al. 2011; Ottani et al. 2006).  Together, these 
factors might contribute to the enhanced excitability of the corticospinal tract in 
resting conditions. Indeed, as suggested by Mauger & Hopker (2013), it would 
perhaps be unsurprising if this effect would translate to improvements in exercise 
performance and/or the tolerable duration of exercise, as exercise-induced 
fatigue has been linked with decreased cortical excitability (e.g., Ross et al. 
2010). However, despite these observations, the extent to which these 
neuromuscular alterations at rest relate to improved exercise performance during 
and following intense exercise is currently untested. In addition, a prior 
investigation performed by Mauger & Hopker (2013) of a subset of the subjects 
in the same study revealed that ACT had no effect on compound muscle action 
potentials at rest (e.g., M-wave) in further support that its effect is likely located 
distal to the neuromuscular junction. In agreement, there is currently no evidence 
to support the ingestion of ACT evoking a systemic physiological response during 
exercise or affecting skeletal muscle peripheral fatigue development. Further 
research is, therefore, required to investigate the effect of non-specific COX-
inhibitors on neuromuscular function as relatively little is known of its potential to 
favourably enhance neuromuscular parameters during exercise.  
 
2.5.3 ACT effect on performance and exercise capacity 
ACT is widely consumed by athletes and recreational sports men and women 
alike (e.g., Brewer et al. 2014; Feucht & Patel, 2010; Garcin et al. 2005; Tscholl 
& Dvorak, 2012; Warden, 2010). Indeed, in support of its ingestion, emerging 
evidence suggests that ACT can improve exercise performance (Mauger et al. 
2010; 2014; Mauger & Hopker, 2013; Foster et al. 2014). Specifically, Mauger et 
al. (2010) identified a 2% improvement in power output across a 10-mile cycling 
TT following the ingestion of 1.5 g of ACT in trained male cyclists (figure 2.13). 
The ergogenic potential of acute ACT ingestion (at 20 mg·kg−1 lean body mass) 
has also been reported during cycling in the heat (30°C, 50% relative humidity) 
by improving exercise tolerance by ~17% in recreationally active, untrained, 
males (Mauger et al. 2014). This was accompanied by significantly lower core (-
0.15°C) and skin (-0.47°C) temperature as well as lower reported ratings of 
thermal sensation (subjective perception of thermal comfort). However, whilst 
thermoregulatory adjustments following ACT consumption have been linked to 
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improved performance in the heat (Mauger et al. 2014), the tests we will use in 
this thesis will be conducted in temperate conditions and will be short in duration 
and thus not limited by the tolerance of heat.   
 
 
Figure 2.13. Acetaminophen (black line) reduced the extent to which power 
output declined towards the middle section of the time-trial, resulting in a 2% 
improvement on performance time compared to placebo (red line). From Mauger 
et al. (2010). 
 
Foster et al. (2014) have also demonstrated a significant increase in mean power 
output (391 ± 74 vs. 372 ± 90 W) during a repeated sprint cycling protocol 
(Wingate anaerobic tests: 8 × 30 s sprints, 2 min active rest intervals) following 
the ingestion of a 1.5 g dose of ACT in nine recreationally active male 
participants. The observed improvement in repeated sprint ability was the result 
of an attenuated decline of power output in the latter stages of the protocol (e.g., 
sprints 6, 7 and 8). In direct contrast, more recently, data has also been presented 
to suggest ACT does not influence sprint interval treadmill running despite 
reducing pain sensation (Park et al. 2016), 
 
2.5.4 Pain as a determinant of endurance performance 
Pain is a sensory and emotional experience associated with performing intense 
activity (International Association for the Study of Pain, 2018; Treede, 2018). This 
suggests that pain is a subjective experience and influenced by previous history 
of pain. As a consequence, pain is not always proportionally dependent on the 
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nociceptive signal. Exercise-induced pain is processed by the brain following 
feedback from group III/IV muscle afferent fibres, which are activated or 
sensitised by mechanical pressure, heat, cold and algesic substances, relaying 
information to the CNS regarding tissue damage (O’Connor & Cook, 1999). 
These chemicals (e.g., metabolites) are released when there is a disturbance to 
homeostasis.  As increases in relative work rate are associated with increased 
metabolic perturbation (e.g., Vanhatalo et al. 2011) and therefore stimuli for group 
III/IV muscle afferent feedback, it is unsurprising that exercise-induced pain 
increases as a function of work rate (e.g., Astokorki & Mauger, 2017a; Cook et 
al. 1997; Sgherza et al. 2002). However, different types of pain are sensed and 
processed by the body differently (i.e., thermal pain, chemical pain, pressure pain 
etc.) and the same ‘signal’ does not always result in the same level of pain 
sensation (or ‘perception’), complicating understanding of the potential role of 
exercise-induced pain sensation in the aetiology of exercise-induced fatigue 
(Astokorki & Mauger, 2017a).  
 
Although previous research has reported no relationship between pain and 
exercise performance, a limitation of these studies is that they are confounded 
by pain being induced through interventions (i.e. pain pressure tests) that differ 
markedly from exercise-induce pain (e.g., Astokorki & Mauger, 2017a), 
questioning the validity of some of these early studies on exercise-induced pain. 
This is pertinent to note as different causes of pain (i.e., mechanical, chemical, 
thermal) activate different pain pathways (Olesen et al. 2012). Therefore, despite 
other techniques that have been adopted to assess exercise-induced pain (i.e., 
cold pressor test, algometry) having excellent validity and reliability in studies of 
clinical pain, the processing and subsequent response to exercise-induced pain 
is likely fundamentally different as each may arise from different stimuli (i.e., 
neuropathic, inflammatory, and nociceptive) as well as be perceived differently, 
and so exert a different ‘response‘ (Olesen et al., 2012). 
 
More recent evidence using valid measures of exercise-induced pain suggests 
that the sensation of pain during exercise exhibits an inverse relationship with 
endurance performance (e.g., Astokorki & Mauger, 2017a). Indeed, Astokorki & 
Mauger (2017a) found exercise-induced pain, using a pain perception score, 
predicted performance by 7.5% (P<0.05), stronger than other traditional 
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endurance parameters such as V̇O2peak and GET. Indeed, it is also attractive to 
consider that the typical day-to-day variability in exercise performance regularly 
observed amongst elite performers (i.e., Hickey et al. 1992) may be explained, at 
least in part, to differences in the sensations associated with intense activity. This 
is particularly pertinent within homogenous groups of elite athletes with similar 
physiological qualities. In further support of the significance of pain to exercise 
performance, athletes generally report higher levels of pain tolerance during 
exercise when compared to recreationally active individuals (Janal et al. 1994; 
O’Leary et al. 2017; Tesarz et al. 2013) and, consequently, the willingness to 
tolerate pain during exercise has been identified as an important predictor of 
endurance performance (e.g., Astokorki & Mauger, 2017a; 2017b; Mauger, 2014; 
Mauger et al. 2010).  
 
Whilst studies have been able to demonstrate that exercise-induced pain shares 
a strong relationship with exercise intensity (i.e., Cook et al., 1997), and that 
interventions (i.e., paracetamol, caffeine, amphetamines) aimed at reducing pain 
can enhance exercise performance (i.e., Astorino et al., 2011, 2012; Felippe et 
al. 2018; Foster et al., 2014; Gonglach et al. 2016; Hudson et al., 2008; Jenkins 
et al., 2008; Mauger et al., 2010, 2014; Swart et al. 2009), other studies have 
questioned the role of pain in regulating work output and performance (i.e., 
aspirin, Cook et al., 1997; ginger, Black & O’Connor, 2008; Black et al., 2010; 
paracetamol, Park et al. 2016; ibuprofen, Da Silva et al. 2015). However, whilst 
other factors may contribute to its ergolytic effect, it is important to note than when 
pain is increased during exercise through muscle damage (i.e., Black & Dobson, 
2013) and intramuscular saline injections (i.e., Graven-Nielsen et al., 2002; Khan 
et al., 2011), exercise performance is impaired. This may suggest that the 
aforementioned analgesics (i.e., paracetamol, caffeine, amphetamines) may 
enhance exercise performance by altering pain as well as other aspects that 
contribute to exercise performance and/or that the effect of analgesics are 
specific to the task and/or population. For example, caffeine, which binds to 
adenosine receptors involved in nociceptive signalling, is also known to provide 
analgesia via a similar mechanism to paracetamol (discussed below) via 
inhibition of COX-enzymes (i.e., Fiebich et al. 2000). However, caffeine may also 
act to increase fat oxidation and motor unit recruitment as well as alter dopamine 
and serotonin release (Baratloo et al. 2016; Felippe et al. 2018; Gonglach et al. 
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2016; Jenkins et al. 2008; Walton et al. 2003). Similar to caffeine, amphetamines 
(i.e., methylphenidate), whilst also reduce pain sensation, also act as a central 
stimulant and favourably alter the ratio of dopamine/serotonin, permitting a higher 
metabolic stress (i.e., Swart et al. 2009).  
 
2.5.5 ACT effect on pain sensation during exercise 
Research suggests that interventions, such as ACT, aimed at reducing pain 
sensation during exercise (may have the potential to enhance performance 
(Foster et al. 2014; Mauger et al. 2010; 2014). However, whilst acute ACT 
ingestion may improve exercise performance independent of its effect on pain 
(and effort and/or exertion) sensation by alleviating the development of central 
fatigue (Mauger & Hopkins, 2013), ACT may also help to maintain cortical 
excitability, enhance muscle activation and/or reduce cortical inhibition by 
modulating pain sensation (e.g., Dubé & Mercier 2011). In addition, ACT may 
enhance corticospinal excitability in the absence of acute pain (Mauger & Hopker, 
2013) which may enhance exercise performance and attenuate exercise-induced 
fatigue development (e.g., Ross et al. 2010). There is also evidence to suggest 
that, in athletes, ACT ingestion reduces RPE at the lactate threshold (Garcin et 
al. 2005) and can reduce exercise-induced pain during the latter stages of sprint 
interval running (Park et al. 2016). However, pain at the lactate threshold is, 
typically, very low if present at all (Garcin et al. 2005). In addition, as 
aforementioned, caffeine, a widely accepted ergogenic aid, also provides mild 
analgesia which can reduce muscle pain at a given intensity (e.g., Cotl et al. 
2003) providing further support for interventions aimed at reducing pain sensation 
in enhancing exercise performance.  However, further research is required to 
assess the effects of ACT ingestion on exercise performance and the 
mechanisms underpinning any ergogenic effect, particularly as Park et al. (2016) 
recently demonstrated an acute dose of ACT to reduce exercise-induced pain 
during the latter stages of sprint interval treadmill running but without influencing 
performance. This, possibly, highlights a task specific effect of ACT on 
performance and/or that the effects of ACT ingestion on performance and pain 
sensation can be dissociated.  
 
Despite this, Mauger et al. (2010) demonstrated a significant improvement in 
cycling TT performance via increasing power output at a given sensation of pain 
Chapter 2: Literature review 
51 
 
and effort (and thus likely lowering pain and effort sensation for a given power 
output). Specifically, although Mauger et al. (2010) demonstrated no difference 
in RPE or perceived pain following acute ACT ingestion, participants cycled at a 
higher mean power output, with an increased heart rate and blood [lactate] 
response, for the same RPE and pain rating. These findings, therefore, support 
the notion that performance can be influenced by pain perception, and that an 
increased pain tolerance can improve exercise capacity possibly by permitting 
further development of peripheral fatigue into a ‘metabolic reserve’ (Mauger, 
2014 for brief review). This is also supported by data from Mauger et al. (2014) 
who demonstrated a 17% improvement in time-to-exhaustion during cycling in 
the heat (30°C) after ingestion 20 mg·kg lean body mass−1 ACT and by Foster et 
al (2014) who found improved performance during a repeated sprint protocol 
following ACT ingestion to be associated with a reduction of pain for a given work 
rate. Collectively these findings highlight the potential for pain sensation to 
mediate the effect of ACT ingestion on enhancing exercise performance (Foster 
et al. 2014; Mauger et al. 2010; 2014).  
 
Whilst improving pain tolerance or reducing exercise-induced pain sensation can 
be crucial to athletic performance (e.g., Astokorki & Mauger, 2017a; 2017b; 
Mauger et al. 2010), the manipulation of pain by modulating type III/IV muscle 
afferent feedback has marked effects on the exercise pressor reflex (i.e., Amann 
et al. 2009; 2011; 2012; 2015; Blain et al. 2016; Secher & Amann, 2012 for 
review). Indeed, muscle afferents are not only responsible for communicating the 
‘pain signal’ to the brain, but also regulate the cardiopulmonary response to 
exercise, which can have implications for exercise performance. This might 
account for observations of impaired performance in the second half of a 5 km 
cycling TT when all feedback from group III/IV muscle afferents is removed via 
intrathecal fentanyl administration despite an elevated CMD and performance in 
the first half of the 5 km TT (Amann et al. 2009; Blain et al. 2016). ACT 
administration, on the other hand, which seemingly acts predominantly through 
central processes to blunt, but not completely abolish, pain sensation and afferent 
feedback (Anderson, 2008; Graham et al. 2013; Smith, 2009; Toussaint et al. 
2010) may act as a ‘real-world’ and less invasive means to enhance CMD and 
permit further development of peripheral fatigue without impairing the 
cardiopulmonary response to whole-body exercise. However, the potential 
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mechanisms by which analgesics that can modulate type III/IV muscle afferent 
feedback might improve exercise performance are unclear and will be addressed 
in this thesis.  
 
2.5.6 Ibuprofen and exercise performance  
IBP also contains analgesic properties and is predominantly used to treat pain 
and reduce inflammation and fever. IBP is considered safe for oral ingestion 
within healthy populations at the standard therapeutic dose (Albert & Gernaat, 
1984; García-Martín et al. 2004). Consequently, utilisation of analgesic and anti-
inflammatory medication, such as IBP, has also emerged as a popular pre-
competition strategy in elite athletes attempting to enhance athletic performance 
(Alaranta et al. 2008; Corrigan & Kazlauskas, 2003; Da Silva et al. 2015; Gorski 
et al. 2011; Huang et al. 2006). It is believed that NSAIDs act centrally and 
peripherally to respectively reduce pain perception and tissue inflammation 
(Fridén & Lieber, 1992) by inhibiting COX and the subsequent synthesis of PG 
(e.g., PGE2, Albert & Gernaat, 1984; Fridén & Lieber, 1992). However, in contrast 
to the effects of ACT consumption on exercise performance, there is currently 
very limited published research on NSAID and NSAID-like compounds during 
exercise when muscle damage is not present during whole body exercise in 
humans (e.g., Cleak, & Eston. 1992; Da Silva et al. 2015; Nosaka & Clarkson, 
1996; Tokmakdis et al. 2003). Despite the prevalence of its use amongst athletic 
populations, it is unclear whether IBP provides an ergogenic benefit to 
performance in a ‘fresh’ state. Nonetheless, while there is some evidence to 
suggest that the increases in muscle soreness, pain, damage and contractile 
dysfunction after contraction-induced muscle damage can be attenuated 
following NSAID administration (Ebbeling & Clarkson, 1989; Hasson et al. 1993; 
Pizza et al. 1999; Tokmakdis et al. 2003), there is also evidence that NSAID 
administration does not impact these variables after muscle damage is induced 
(Da Silva et al. 2015; Donnelly et al. 1990; Grossman et al. 1995; Tokmakdis et 
al. 2003; VanHeest et al. 2002). Taken together, these observations suggest that 
the ergogenic potential of administering IBP, a purported analgesic and anti-
inflammatory agent (Fridén & Lieber, 1992), is limited without prior induction of 
muscle damage, and even when muscle damage is induced, and inflammation 
and pain sensation are correspondingly increased, the effect of IBP ingestion on 
exercise performance is equivocal.  Further research is therefore required to 
Chapter 2: Literature review 
53 
 
assess the potential of IBP to enhance performance and the mechanisms that 
might underpin any ergogenic effect of IBP ingestion.  
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2.6 Study aims and hypotheses 
The overall aim of the thesis was to assess the efficacy of acute oral consumption 
of non-specific cox-inhibitors (e.g., ACT and IBP) to improve exercise 
performance and the potential underlying neurophysiological mechanisms for any 
ergogenic effects of ACT and IBP ingestion.  
 
Study 1: The effect of acute acetaminophen ingestion on performance 
during maximal intermittent knee extensor exercise.  
 
Aims: Acute consumption of acetaminophen has been shown to improve 
exercise performance by increasing pain tolerance/lowering pain sensation. 
However, the neurophysiological bases of this effect and how it impacts the 
parameters of the torque-time relationship, critical torque and W′, had yet to be 
established. The purpose of this initial study was to test the efficacy of acute 
acetaminophen consumption to improve total work, critical torque, muscle 
activation and the rate of neuromuscular fatigue development, including markers 
of central and peripheral fatigue development, using a controlled experimental 
model. Specifically, this study sought to assess the ergogenic potential of 1 g 
acetaminophen ingestion prior to completion of a 5 min single-leg maximal 
intermittent knee-extension test as this afforded the opportunity to robustly 
assess performance, and neuromuscular, peripheral and central fatigue 
development.  
 
Study 2: The effect of acute acetaminophen ingestion on muscle activation 
and performance during a 3-min all-out cycling test. 
 
Aims: The subsequent study sought to assess whether the effect of 
acetaminophen on performance in a small muscle mass model was transferable 
to a larger muscle mass model.  Therefore, a standard therapeutic dose of 
acetaminophen (1 g) was administered prior to assessing performance in an 
experimental model with improved translation to whole body exercise 
performance by conducting cycling exercise. This is important since the exercise 
modality employed, and volume of skeletal muscle mass engaged, is known to 
influence the extent, and underpinning mechanisms, of neuromuscular fatigue 
development.  
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Study 3: The neuromuscular and muscle metabolic responses to 
contralateral limb fatigue following acute acetaminophen ingestion.  
 
Aims: The existence of non-local muscle fatigue is thought to be predominantly 
centrally mediated. Since the mechanisms for the purported ergogenic effect of 
acetaminophen ingestion are also thought to be predominantly centrally 
mediated, this study sought to test the potential for acetaminophen ingestion to 
attenuate contralateral limb fatigue and whether this effect was greater compared 
to short-duration unilateral severe-intensity exercise in which fatigue 
development is predominantly peripherally mediated.  This study also used 31P-
MRS to assess whether acute acetaminophen ingestion (1 g) permitted the 
attainment of a greater degree of perturbation to intramuscular phosphorous 
substrates and metabolites during exercise to provide novel insight into the 
mechanisms by which acute acetaminophen ingestion might be ergogenic.  
 
Study 4: The effect of acute ibuprofen ingestion on performance and fatigue 
development during maximal intermittent knee extensor exercise and an 
all-out cycling test.  
 
Aims: Whilst research suggests that acute consumption of pharmacological 
analgesics can improve exercise performance, the ergogenic potential of 
ibuprofen administration is poorly understood, particularly when muscle damage 
is not present or inflammation is not elevated above baseline levels. This is an 
important research question as ibuprofen is regularly consumed by athletes to 
enhance performance. In addition, as ibuprofen is known to act both centrally and 
peripherally to respectively reduce the sensation of pain and tissue inflammation, 
this study tested the efficacy of oral ibuprofen ingestion to improve performance 
using the same protocols as administered in studies 1 and 2 and how this 
compared to the effects observed following acetaminophen ingestion. This may 
yield important information on the relative ergogenic efficacy of COX inhibitors 
after acute ingestion of the recommended therapeutic dose (400 mg). 
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CHAPTER 3 
GENERAL METHODS 
 
The general methods that have been applied throughout this thesis will be 
explained in this chapter. The specific methods in each experimental chapter 
will be fully described in the methods section of the respective chapters. The 
experimental studies included in this thesis entailed 524 exercise tests. All 
exercise tests in the following experimental chapters took place in an air 
conditioned exercise physiology laboratory or MRI suite at sea level with an 
ambient temperature of 18-22ºC.  
 
3.1 Pre-test procedures 
3.1.1 Ethical approval 
Prior to the commencement of data collection, ethical approval for each study 
(chapters 4-7) was obtained from the University of Exeter Research Ethics 
Committee (Sport and Health Sciences). For each study, participants were 
provided with an information sheet providing an explanation of the potential 
risks and benefits of participation, and information regarding data storage 
safety, publication and anonymity. After reading this information sheet, 
participants were afforded the opportunity to ask any questions they had about 
the study and the participation requirements. Subsequently, participants 
provided their written, informed consent to take part if they were happy to 
participate. In addition, participants completed a health questionnaire prior to 
data collection for each study.  This health questionnaire incorporated specific 
questions for each study relating to the safety of the electrical and magnetic 
stimulation protocols, exercise protocols and, where appropriate, the ingestion 
of pain relief medication prior to performing intense exercise (appendix 9.1). 
Participants were made aware that they were free to withdraw from study 
participation at any point with no disadvantages to themselves. 
 
3.1.2 Health and Safety 
All procedures and protocols utilised in the studies that comprise this PhD 
thesis conformed to the health and safety guidelines and risk assessments of 
the Department of Sport and Health Sciences at the University of Exeter. 
Exercise physiology laboratories and other experimental testing areas were 
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clean, safe and suitable for conducting human exercise physiology experiments. 
Routine safety checks on all testing areas and equipment used were also 
conducted by members of the technical staff.  
 
3.1.3 Participants  
A range of active male volunteers, aged 18-45 yrs, were recruited across the 
experimental chapters including participants from the University student and 
staff population and from the local community. All volunteers were screened 
prior to recruitment to ensure suitability for participation. Participants were 
excluded when the prior completion of the health questionnaire revealed any 
health concerns that might have put them at risk during the experimental 
conditions.  For example, any history of motor or neurological disorders or any 
complications relating to the ingestion of paracetamol and/or non-steroidal anti-
inflammatory medication. In each study, participants were familiarised with the 
experimental protocols and procedures (i.e., measurements of neuromuscular 
function) until the coefficient of variation (CV %) between trials was considered 
acceptable. Subjects were instructed to arrive at the laboratory on each 
occasion in a rested and fully hydrated state, at least 3 h post-prandial, to avoid 
strenuous exercise in the 24 h preceding each testing session and to refrain 
from consuming caffeine and alcohol in the 12 h preceding each visit. All tests 
were performed at a similar time of day (± 2 h) to account for daily variations in 
neuromuscular excitability (Küüsmaa et al. 2015; Tamm et al. 2009). 
Participants were also required to refrain from analgesics and any form of anti-
inflammatory medication during the testing period. Following the first 
experimental visit, participants were instructed to replicate their usual diet and 
exercise regime as closely as possible for each subsequent trial.  
 
3.1.4 Anthropometry 
All experimental testing procedures (excluding tests within MRI scanner) were 
conducted in the Sport and Health Sciences department at the University of 
Exeter. Prior to the commencement of data collection, participants’ height, body 
mass, age and, where appropriate, leg dominance were recorded. Height (m) 
and body mass (kg) were measured using a stadiometer (Seca 220, Seca 
Limited, Birmingham, UK) and calibrated electronic scales (Seca 220, Seca 
Limited, Birmingham, UK), respectively, using the standard procedures for 
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height and weight measurement. Upon returning to the laboratory for each 
experimental test, participants had their body mass determined before 
performing exercise tests. 
 
3.1.5 Supplementation 
For Chapters 4-6, 1 g of maltodextrin (placebo, PL) or 1 g of ACT were ingested 
orally, 60 min prior to the exercise bout such that the start of the exercise trial 
was expected to coincide with attainment of peak plasma [ACT] (Anderson et al. 
2008; Forrest et al. 1982). Following oral ingestion, ACT is rapidly absorbed 
from the gastrointestinal tract and its bioavailability ranges from 70 to 90% 
(Forrest et al. 1982). Both 0.5 g and 1.0 g doses of ACT have been shown to 
have an analgesic effect superior to that of placebo from 1 and up to 5 h after 
administration, with peak analgesia effects achieved between 1 and 2 h 
following oral ingestion (Nielsen et al. 1992). For chapter 7, 400 mg IBP was 
ingested prior to the exercise bout (s). Following oral administration, IBP is 
rapidly absorbed but both peak plasma concentrations and maximal analgesic 
onset are achieved within 1.5-2 hours of oral administration (Albert & Gernaat, 
1984). However, there has been shown to be a significant correlation between 
plasma IBP levels and the resultant degree of pain relief, particularly ~1 hour 
after administration (Laska et al., 1986). The absolute bioavailability of IBP 
indicates a complete absorption when administered (Martin et al. 1990).  
 
3.2 Apparatus, procedures & measurements  
To investigate exercise-induced fatigue and its underlying mechanisms, a 
number of experimental apparatus and a range of methodologies were used. 
Techniques such as magnetic resonance spectroscopy (MRS), femoral nerve 
stimulation and EMG were employed to provide insight into the specific site of 
failure and mechanistic basis for the reduction in force production. The following 
sections will outline the main procedures used in this thesis. More specific 
information is provided in each experimental chapter.  
 
Exercise testing procedures 
Subjects completed (a) preliminary trial(s) for familiarisation to the 
measurement techniques and experimental protocol for all chapters. For all 
experimental chapters, trials started with a standardised warm-up routine and 
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testing of the optimal EMG electrode, anode, and cathode placement and 
intensity required for peripheral nerve stimulation. 
 
3.2.1 Cycle ergometry and ramp incremental test 
All cycling exercise tests in Chapters 4 and 7 were performed on an 
electronically braked cycle ergometer (Lode Excalibur Sport, Groningen, 
Netherlands, figure 3.1). During the initial visits to the laboratory, ramp 
incremental tests to volitional exhaustion were performed in order to acquire 
individual metrics including peak work rate and V̇O2peak and the gas exchange 
threshold (GET). A linear factor was used to determine the work rates during a 
3-min maximal cycling test (described in chapters 4 and 7). The work rate 
imposed by the linear function is cadence-dependent and is given by the 
following equation: Linear factor = Power output ÷ Cadence2. The ramp 
incremental tests used in chapters 4 and 7 commenced with the completion of a 
3 min period of pedalling at 20 W (baseline period) at a self-selected cadence 
(80-100 rpm). Upon completion of baseline cycling, the work rate was linearly 
increased at a rate of 30 W∙min-1 until the limit of tolerance (Tlim), using the 
cadence-independent power-time function. The test was terminated when the 
pedal rate fell by >10 rpm below the self-selected cadence despite strong verbal 
encouragement. The self-selected cadence, as well as the position of the 
handle bars and saddle, were recorded during the initial visit and repeated for 
all subsequent visits. During all cycle tests, pulmonary gas exchange and 
ventilation were measured breath by breath. 
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Figure 3.1. Participant performing a 3-min all-out cycling test on an 
electronically braked cycle ergometer. Note neuromuscular function is also 
being assessed via peripheral nerve stimulation and electromyography of the 
quadriceps.  
 
3.2.2 Isokinetic dynamometry  
An isokinetic dynamometer (Biodex System 3 Medical Systems 830-200, 
Shirley, N.Y. 11967 USA) was used in chapters 4 and 7 for assessment of 
torque and fatigue of the knee extensors and adjusted so that the axis of 
rotation of the lever arm was in line with the lateral epicondyle of the right femur. 
Subjects were seated with the hip and knee joints at relative angles of 155° and 
90°, respectively (figure 3.2). The remainder of the chair settings were recorded 
and replicated in all subsequent trials to ensure an identical body position was 
assumed throughout the experimental trials. The semi-supine position was 
employed as it permitted better access to the superficial femoral nerve for 
peripheral nerve stimulation as verified during pilot testing. Inelastic padded 
Velcro straps were fastened at the ankle, quadriceps, hip and shoulders to 
maintain a stable body position.  
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Figure 3.2. A participant preparing to undertake a maximal voluntary 
contraction of the quadriceps muscles. 
 
3.3 Measurements 
3.3.1 Reliability 
To assess the reliability of the mean maximal voluntary contraction (MVC) 
performance and EMG amplitude during the 60 MVC test used in chapters 4 
and 7, 12 individuals completed two 60 MVC tests on separate days yielding a 
coefficient of variation of 2.9% and 4.8% for mean MVC torque and EMG 
amplitude, respectively. The cycling ergometer used in chapters 5 and 7 has 
been shown to be highly reproducible, making it a reliable method for 
monitoring cycling performance (CV 1.0-5.0%; Driller, 2012; Earnest et al. 
2005). For chapters 5 and 7, participants completed a 3 min all-out cycling test. 
End power-output has been demonstrated to yield a coefficient of variation 
within <2% (Vanhatalo et al. 2007, Wright et al. 2017). The coefficient of 
variation for severe-intensity knee-extension exercise performed within the MRI 
for chapter 6 for time to task failure in our laboratory is 5–7% (Bailey et al. 
2010). To assess the within and between-day reliability of all remaining 
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neuromuscular measures used throughout this thesis in chapters 4, 5 and 7, a 
variety of evoked and voluntary contractions were administered and/or 
performed at rest with 12 individuals yielding respective coefficients of variation 
of 4.7%, 6.2% and 4.5% for voluntary activation (VA), M-wave amplitude and 
quadriceps potentiated twitch (pTw), respectively.  
 
3.3.2 Determination of GET and V̇O2peak 
The GET was determined as: 1) the first disproportionate increase in V̇CO2 
versus V̇O2; 2) an increase in minute ventilation (V̇E) relative to V̇O2 with no 
increase in V̇E/ V̇CO2 and; 3) the first increase in end-tidal O2 tension with no 
fall in end-tidal CO2 tension. The GET was estimated independently by three 
experienced assessors using code labelled data files such that the assessors 
were blind to the subject being assessed and others estimations. V̇O2peak was 
determined as the highest 30-s mean value attained during ramp incremental 
tests. Oxygen uptake and other ventilatory and gas exchange responses (e.g., 
V̇E, V̇CO2 and RER) were measured using a Cortex MetaLyzer (Cortex, Leipzig, 
Germany). Briefly, subjects wore a mask connected to an impeller turbine 
transducer assembly. Expired gas volume and concentration signals were 
continuously sampled at 100 Hz. These analysers were calibrated before each 
test with gases of known concentration, and the turbine volume transducer was 
calibrated using a 3-L syringe (Hans Rudolph, KS).  
 
3.3.3 Torque 
Knee extensor torque during voluntary and evoked contractions was measured 
via the use of isokinetic dynamometry (Biodex System 3 Medical Systems 830-
200, Shirley, N.Y. 11967 USA). Knee-extensor torque from the Biodex® was 
sampled at 1,000 Hz and low-pass filtered at 40 Hz, before being displayed on 
a wide screen monitor using Spike2 (CED, Cambridge, UK). Voluntary torque 
was expressed as a percentage (%) of pre-exercise MVC.  
 
Assessment of neuromuscular function 
Throughout this thesis, neuromuscular function was assessed before, during 
and after the exercise tests. This included the characteristics of the M-wave 
response to supra-maximal femoral nerve stimulation, contractility of the muscle 
(e.g., maximal rate of force development, contraction time and rate), voluntary 
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activation (VA) and potentiated twitch (pTw). Data were analysed using a 
custom written script developed in Spike2 software (Cambridge Electronic 
Design, Cambridge, UK). Responses from peripheral nerve stimulation were 
recorded as described below in order to assess changes in membrane 
excitability (via M-wave changes), muscle activation and neural drive drive (via 
changes in EMG and VA) and peripheral muscle function (via changes in pTw).  
 
3.3.4 Electromyography  
Electromyography refers to the technique used in neuromuscular physiology to 
record myoelectric signals formed by physiological variations in the state of 
muscle fibre membranes.  In this thesis, EMG was measured via surface 
electrodes placed on the skin superior to the muscle of interest. Electrodes 
placed on the surface of the skin record the sum of all action potentials 
propagated along the sarcolemma to the muscle fibres at that point in time. For 
all experimental chapters, surface EMG activity was recorded from m.vastus 
lateralis, m.vastus medialis and m.rectus femoris of the quadriceps and lateral 
head of the m.biceps femoris of the hamstring of the right leg using active 
bipolar bar electrodes single differential configuration (DE2.1, DelSys Inc, 
Boston, MA, USA, figure 3.3). It was necessary to measure activity from the 
biceps femoris as inadvertent co-activation of antagonist muscles can affect the 
measurement of voluntary activation when using twitch interpolation (Allen et al. 
1995). Surface EMG activity of both the right and left leg were recorded for 
chapter 6. The two electrodes, which were housed into one unit, were placed 
over the respective muscle bellies parallel to the longitudinal axis of each 
muscle in parallel with the Surface Electromyography for the non-invasive 
assessment of muscles (SENIAM) guidelines. Final electrode positions were 
recorded and marked with indelible ink to ensure consistent placement between 
experimental sessions. The skin area underneath each EMG electrode was 
shaved, then exfoliated and cleaned with alcohol to minimise the skin 
impedance. Double-sided adhesive tape and a hypoallergenic medical tape 
were used to ensure the EMG sensor stability during exercise.  
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Figure 3.3. Experimental set up of surface EMG electrodes superficial to the 
quadriceps muscles. Surface EMG activity was recorded from vastus lateralis, 
vastus medialis and rectus femoris of the quadriceps and biceps femoris of the 
hamstring of the right leg using active bipolar bar electrodes single differential 
configuration. The ground electrode was placed over the patella of the right leg. 
 
The EMG signal was pre-amplified (1,000 x), band-pass filtered (20–450 Hz, 
Bagnoli-8, DelSys Inc, Boston, MA, USA), and then transferred to a computer 
with a sampling frequency of 2 kHz. EMG data were recorded continuously and 
digitised synchronously with 16 bit resolution via an A/D converter (±5 V range, 
CED 1401 power, Cambridge, UK). Throughout, a digital smoothing algorithm 
was used to provide a mean EMG value over time as bursts of raw EMG during 
voluntary activity are not consistently formed. We used the root mean square 
method (EMGRMS), which reflects the mean power of the signal and is 
recommended for measuring muscle activation during contractions of constant 
force (De Luca, 1997). The RMS is calculated by squaring each data point, 
summing the squares, dividing the sum by the number of data points and then 
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taking the square root over a given time frame (Konrad, 2005). EMGRMS was 
normalised to the pre-exercise maximum (or maximal EMG signal) and the local 
M-wave amplitude (closest measure of the M-wave to the MVC) to exclude any 
changes to the EMG trace as a result of changes in local excitability (Millet & 
Lepers, 2004). The ground electrode was placed over the patella of the right leg 
so that the electrical potential could be compared to that of a ‘reference’ 
electrode located in an environment that is electrically quiet (Basmajian & De 
Luca, 1985). Throughout this thesis, the signal from the m.vastus lateralis was 
used as the primary measure of EMG activity. It has been shown that, during 
exercise, EMG activity from the m.vastus lateralis can be considered as a 
surrogate measure of EMG activity of the knee-extensors as a whole (Alkner et 
al. 2000; Amann et al. 2006; Lepers et al. 2001; Millet et al. 2002; Place et al. 
2007; Romer et al. 2006). 
 
3.3.5 Peripheral Nerve Stimulation 
Single electrical stimuli were delivered to the femoral nerve applied by a 
constant current stimulator (Digitimer Stimulator DS7, Digitimer, Welwyn 
Garden City, Hertfordshire, UK). Specific protocols to assess changes in 
peripheral and central function are outlined in each experimental chapter. The 
electrical current is passed to the body tissues by means of two stimulating 
pads placed on the surface of the skin. Frequency, duration and intensity can 
be used to describe single pulses delivered by electrical stimulation. The 
frequency of stimulation refers to how many pulses are delivered per second; 
this can be from 1 Hz upwards. The duration of each pulse is referred to in 
microseconds (μs) and the intensity of current is described in milliamps (mA) or 
voltage (V) (Low & Reed, 1994). The stimulation current was identified by 
constructing a stimulus-response curve for each individual. Single stimuli (1 Hz, 
200 µs duration) were delivered in 20 mA step-wise increments from 100 mA 
until plateaus were evident in the potentiated twitch force and Mmax, indicating 
maximum depolarisation of the femoral nerve. The positive electrode (cathode) 
was placed over the femoral nerve approximately 3–5 cm below the inguinal 
ligament in the femoral triangle, and the negative electrode (anode) was placed 
midway between the iliac crest and the greater trochanter (Sidhu et al. 2009b). 
The cathode was systematically moved vertically and horizontally and the 
amplitude of the muscle action potential (M-wave) was monitored to identify the 
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optimal position of the cathode for attaining maximal peak-to-peak Mmax. Once 
the M-wave was elicited, the maximum amplitude (peak-to-peak) of the M-wave 
was determined (Mmax) for the m.vastus lateralis and m.vastus medialis.  
 
To account for activity dependent changes in axonal excitability (Burke, 2002), it 
was necessary to use a supramaximal level of stimulation. To ensure a 
supramaximal response, the current was increased by an additional 30% 
(Goodall et al. 2010; Neyroud et al. 2014; Sidhu et al. 2017). The mean Mmax 
was obtained from 3 stimuli, with ~30 s separating each pulse at rest to 
minimise the effect of potentiation (Hodgson et al. 2005). Maximal rate of force 
development, maximal relaxation rate, contraction time and contraction rate 
were analysed for all pTw. For chapters 5 and 7, during cycling exercise, the 
crank angle at which peripheral nerve stimulation was to be delivered during the 
trials, was determined for each subject as described by Black et al. (2017) and 
Sidhu et al. (2012). Briefly, stimulations were delivered at the identified crank 
angle for all subsequent trials for that participant to align with maximal muscle 
activation. A custom written sequencer script triggered 3 stimulations, with at 
least 1 and up to 10 pedal revolutions between each stimulus.  
 
3.3.6 Excitability parameters 
Voluntary muscular activity results in a quantifiable EMG response that can be 
measured on the surface of the skin. The name given to the electrical signal 
manifest in the muscle fibres leading to the activation and contraction of the 
muscle fibres is a compound muscle action potential (or M-wave). When 
responses were evoked by electrical stimulation of the femoral nerve, the M-
wave was used to assess changes in membrane excitability. The properties of 
the waveforms produced following stimulation included the peak-to-peak 
amplitude and area. The peak-to-peak amplitude was manually identified post-
experiment and defined as the absolute difference between the maximum and 
the minimum points of the waveform (negative and positive deflections). The 
area was calculated as the integral of the reflected value of the entire waveform 
(Fowles et al. 2002).  
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3.3.7 Twitch parameters 
In addition to M-waves evoked in skeletal muscle, changes in the resting 
potentiated muscle twitch and twitches superimposed onto an MVC were 
measured. A reduction in the potentiated twitch, for example, is indicative of 
peripheral failure. It has previously been demonstrated that the potentiated 
twitch is more sensitive to the changes that occur in fatigued muscle when 
compared to the ‘unpotentiated’ twitch (Kufel et al. 2002). One proposed 
mechanism of the potentiated twitch is the phosphorylation of myosin regulatory 
light chains via myosin light chain kinase, rendering actin-myosin interaction 
more sensitive to Ca2+ released from the sarcoplasmic reticulum (Hodgson et 
al. 2005). An increased sensitivity of Ca2+ increases the rate by which myosin 
cross-bridges move from a non-force producing state to a force producing state, 
thus increasing the size of a resting muscle twitch for a given intramyocyte 
[Ca2+] (Szubski et al. 2007). 
 
Contraction time, maximum rate of force development, maximum relaxation rate 
and one half relaxation time (RT0.5) were analysed by Spike2 for each pTw 
whereby changes to such characteristics may represent alterations to Ca2+ 
release and uptake (Klitgaard et al. 1989). Contraction time was defined as the 
time between the stimulus and peak twitch force in response to peripheral nerve 
stimulation. RT0.5 was defined as the time taken for twitch force to decay to half 
of the peak twitch amplitude. Maximal rate of force development occurs during 
the initial linear incline of the force response and was calculated as the slope of 
the tangent drawn to the steepest portion of the curve. Maximal relaxation rate 
occurs during the initial decline in the force response and was calculated as the 
slope of the tangent drawn to the steepest portion of the curve. A reduced 
MRFD is considered to reflect a decrease in the rate of cross-bridge formation 
(Stein & Parmiggiani, 1981). Reductions in relaxation rate and a prolonged 
RT0.5, are thought to reflect decreases in the maximal rate of weak-to-strong 
cross-bridge formation and decreases in the maximal rate of cross-bridge 
detachment, respectively (Westerblad et al. 1997).  
 
3.3.8 ‘Peripheral’ voluntary activation 
The sTw can be used to infer changes to VA. VA is defined as the level of 
neural drive to a muscle during exercise and reflects the ability to fully activate 
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the target muscle group or the ability of the central nervous system to maximally 
drive a muscle during voluntary contraction (Merton, 1954) and can be 
estimated from peripheral, cortical and spinal methods. Briefly, when peak force 
(approximately 0.5-1-s into a 3-s contraction) was attained during an MVC, a 
single stimulus was delivered to the femoral nerve to evoke an increment in 
force. The superimposed twitch torque was calculated as the increment in 
torque immediately following the pulse during MVCs. The amplitude of the 
twitch evoked by the peripheral stimulus was compared with the amplitude of 
the resting potentiated twitch delivered immediately after (1-2 s post) the MVC 
(figure 2.4) and VA was determined using the following equation:  
 
Voluntary Activation (%) = (1 - sTw/pTw) x 100 
 
In a fatigued state, a larger twitch is evoked during an MVC and voluntary 
activation is incomplete.  This indicates that that some motor units are not 
recruited or not firing fast enough to generate fused contractions e.g., the drive 
from the motor cortex is sub-optimal. This conclusion cannot be made specific 
to the motor cortex from peripheral methods as the impairment may be located 
anywhere upstream from the peripheral nerve.  
 
3.4 Statistical analyses 
Statistical analyses in all experimental chapters were performed using the 
Statistical Package for Social Sciences (SPSS v.23 (Chapter 4 and 7) and 
SPSS v.24 (Chapters 5-6)). The statistical procedures specific to each chapter 
are outlined in the Statistical analyses sections of Chapters 4-7. For calculation 
of effect size, partial eta squared (η2) was used for omnibus tests. Cohen's d 
was used to calculate the effect size for paired t-tests and post-hoc 
comparisons. In all chapters, data are presented as mean ± SD unless 
otherwise stated and statistical significance was accepted at P<0.05.  
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ABSTRACT 
Aim: Acetaminophen is a commonly used medicine for pain relief and emerging 
evidence suggests that it may improve endurance exercise performance. This 
study investigated some of the physiological mechanisms by which acute 
acetaminophen ingestion might blunt muscle fatigue development. Methods: 
Thirteen active males completed 60 × 3 s maximum voluntary contractions 
(MVC) of the knee extensors with each contraction separated by a 2 s passive 
recovery period.  This protocol was completed 60 min after ingesting 1 g of 
maltodextrin (placebo) or 1 g of acetaminophen on two separate visits.  
Peripheral nerve stimulation was administered every 6th contraction for 
assessment of neuromuscular fatigue development, with the critical torque (CT), 
which reflects the maximal sustainable rate of oxidative metabolism, taken as 
the mean torque over the last 12 contractions. Surface electromyography was 
recorded continuously as a measure of muscle activation.  Results: Mean 
torque (61 ± 11 vs. 58 ± 14 % pre-exercise MVC) and CT (44 ± 13 vs. 40 ± 15 
% pre-exercise MVC) were greater in the acetaminophen trial compared to 
placebo (both P<0.05) , respectively. Voluntary activation and potentiated twitch 
declined at a similar rate in both conditions (P>0.05). However, the decline in 
electromyography amplitude was attenuated in the acetaminophen trial, with 
electromyography amplitude being greater compared to placebo from 210 s 
onwards (P<0.05). Conclusion: These findings indicate that acute 
acetaminophen ingestion might be ergogenic by increasing CT and preserving 
muscle activation during high-intensity exercise.  
 
Key words: Analgesic; critical torque; electromyography; neuromuscular 
fatigue; single leg exercise  
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INTRODUCTION 
Neuromuscular fatigue is defined as a decrease in skeletal muscle force 
production capacity (Gandevia, 2001). This neuromuscular fatigue development 
can arise from physiological perturbations within the central nervous system, 
termed central fatigue, or within, or distal to, the neuromuscular junction, termed 
peripheral fatigue (Gandevia, 2001). Exercise-induced fatigue is a complex, 
multi-factorial process, the physiological bases of which are still widely debated 
(Enoka & Duchateau, 2008; Gandevia, 2001; Hureau et al. 2016; Place et al. 
2010; Taylor et al. 2016).  Indeed, recent research suggests that peripheral 
fatigue and central fatigue develop inter-dependently and are likely to interact in 
a coordinated manner to determine neuromuscular fatigue development 
(Hureau et al. 2016).  
 
Following the onset of muscle contractions, group III and IV afferents discharge 
in response to mechanical and metabolic stimuli, contributing to the sensation of 
muscle pain during exercise (McCord and Kaufman, 2010; O’Connor & Cook, 
1999; Pollak et al. 2014). Group III/IV muscle afferent feedback, and the 
associated sensation of pain, appears to play a role in neuromuscular fatigue 
development through modulating both central and peripheral fatigue. Indeed, 
when the ascending projection of group III and IV muscle afferents is attenuated 
via intrathecal fentanyl administration, central motor drive is increased (as 
inferred via electromyography, EMG, and peripheral fatigue development is 
expedited (Amann et al. 2009, 2011; Blain et al. 2016). Therefore, interventions 
that can modulate skeletal muscle pain sensation have the potential to impact 
muscle activation and exercise-induced fatigue development. 
 
Acetaminophen (ACT; or paracetamol) is a commonly used non-prescription 
pain reliever which is considered one of the safest non-opioid analgesics at 
therapeutic doses (Toussaint et al. 2010). Acute ACT consumption has been 
shown to improve exercise performance concomitant with a lower pain 
sensation (Foster et al. 2014; Mauger et al. 2010). The mechanisms that 
underlie the analgesic effect of ACT are not completely understood but are 
considered to be predominantly mediated by central factors (Anderson, 2008; 
Graham et al. 2013; Smith, 2009; Toussaint et al. 2010). Conventionally, the 
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analgesic effect of ACT has been attributed to the inhibition of cyclooxygenase 
enzymes, which stimulate nociceptor discharge through the synthesis of 
prostaglandins (Graham et al. 2013; Jóźwiak-Bębenista and Nowak, 2014). 
There is also evidence that the analgesic effect of ACT is linked to potentiation 
of descending serotoninergic pathways (Andersson et al. 2011; Pickering et al. 
2006, 2008), and to modulation of opioid and cannabinoid receptors (Graham et 
al. 2013; Ottani et al. 2006). These mechanisms likely interact to lower pain 
sensation after acute ACT ingestion by increasing the nocioceptive stimuli 
required to evoke a given pain sensation. Although ACT ingestion has been 
reported to increase resting cortico-spinal excitability, as inferred from an 
increased motor evoked potential amplitude (Mauger & Hopker, 2013), the 
neuromuscular bases for blunted exercise-induced fatigue development 
following ACT ingestion have yet to be investigated.   
 
In addition to altering pain sensation and neuromuscular function, ACT 
ingestion might attenuate fatigue development and enhance performance by 
modulating aspects of the power or torque-duration relationship. The asymptote 
of the hyperbolic torque-duration relationship is termed the critical torque (CT) 
and can be estimated from the mean torque produced over the last 12 
maximum voluntary contractions (MVC) of a 60 MVC knee extension protocol 
(Burnley, 2009). The CT reflects the maximal sustainable rate of oxidative 
metabolism (Jones et al. 2008 for review) and represents a critical threshold for 
neuromuscular fatigue development (Burnley et al. 2012).  The curvature 
constant of the torque-duration hyperbola is termed the W′ and represents a 
fixed amount of torque-impulse (surrogate measure of ‘total work’) that can be 
completed above CT (Burnley and Jones, 2016; Jones et al. 2008; Poole et al. 
1988). Together, CT (or critical power, critical speed for other forms of exercise) 
and W′ (or its equivalent) can be used to accurately predict exercise 
performance (Black et al. 2014, Burnley et al. 2012).  An intervention that 
enhances high-intensity exercise tolerance or performance, or attenuates 
fatigue development, would be expected to enhance CT or W′ (or their exercise-
modality-specific equivalents). For example, critical power, but not W′, is 
increased following endurance training concomitant with improved endurance 
exercise performance (Vanhatalo et al. 2008). Therefore, the reported 
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improvement in exercise performance with acute ACT ingestion (Foster et al. 
2014; Mauger et al. 2010, 2014) would be expected to be linked to 
improvements in CT and/or W′, but this has yet to be investigated.   
 
The purpose of this study was to test the hypotheses that, compared to 
placebo, acute consumption of 1 g ACT would reduce the rate of neuromuscular 
fatigue development, and increase total impulse (torque-time integral), CT and 
muscle activation during a 5-min single-leg intermittent MVC test. 
 
METHODS 
Participants 
Thirteen healthy male volunteers (mean ± SD: age 31 ± 7 years, height 1.76 ± 
0.08 m, body mass 75 ± 11 kg) provided written, informed consent to participate 
in the present study, which was approved by the Ethics Committee of Sport and 
Health Sciences (University of Exeter). After being informed of the experimental 
procedures and associated risks, all participants completed a medical health 
questionnaire to ensure it was safe to consume ACT prior to performing 
exhaustive exercise. Subjects were not consumers of any ‘pain relief’ 
medication (prescription or non-prescription) over the course of the study. None 
of the subjects had a history of motor or neurological disorders.  
 
Experimental Design 
Subjects visited the laboratory on three occasions over a 3- to 4-week period 
with all tests separated by at least 1 week and conducted at a similar time of 
day (± 90 min) to limit changes in quadriceps strength and to account for diurnal 
variations in neuromuscular excitability. The first laboratory visit was used to 
familiarise subjects to the measurements and experimental protocol described 
below. During these sessions, the settings and placement of the dynamometer 
and electromyography (EMG) and peripheral nerve stimulation electrodes were 
recorded for each subject. Subsequently, subjects performed the fatiguing 
protocol under two conditions (see ‘Experimental Protocol’): placebo (PL) and 
ACT.  
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Experimental Protocol  
Subjects completed a preliminary trial for familiarisation to the measurement 
techniques and experimental protocol. An isokinetic dynamometer (Biodex 
System 3, Shirley, NY, USA) was used in all tests and adjusted so that the axis 
of rotation of the lever arm was in line with the lateral epicondyle of the right 
femur. Subjects were seated with the hip and knee joints at relative angles of 
155° and 90°, respectively. The remainder of the chair settings were recorded 
and replicated in all subsequent trials to ensure an identical body position was 
assumed throughout the experimental trials. The semi-supine position was 
employed as it permitted better access to the superficial femoral nerve for 
peripheral nerve stimulation as verified during pilot testing. Inelastic padded 
Velcro straps were fastened at the ankle, quadriceps, hip and shoulders to 
maintain a stable body position. The procedures adopted during the 
familiarisation trial were replicated in all experimental trials.  
 
The trials on visits 2 and 3 were completed in a double-blind, randomised 
fashion using a counter-balanced cross-over experimental design. Prior to each 
visit, subjects were required to refrain from caffeine (for at least 12 h), strenuous 
exercise and alcohol (for at least 24 h), analgesics and any form of anti-
inflammatory drug (for the duration of the experimental trial) and to arrive in a 
fully rested, hydrated state. Subjects were instructed to maintain their usual diet 
and exercise regime during the study. 1 g of maltodextrin (placebo) or 1 g of 
acetaminophen was ingested orally, 60 mins prior to the exercise bout such that 
the start of the exercise trial was expected to coincide with attainment of the 
peak plasma [acetaminophen] (Anderson et al. 2008; Forrest et al. 1982). 
Following oral ingestion, ACT is rapidly absorbed from the gastrointestinal tract 
and its bioavailability ranges from 70 to 90% (Forrest et al. 1982). The trials 
started with a standardised isometric warm-up routine (10 isometric contractions 
for 3 s at 50% of pre-exercise MVC as determined during familiarisation testing) 
and testing of the optimal EMG electrode, anode, and cathode placement and 
stimulation intensity for peripheral nerve stimulation. Neuromuscular function 
was assessed pre-trial, during and (<10 s) post-trial.  Single peripheral nerve 
stimulation pulses were manually triggered at rest to determine pre-exercise 
neuromuscular function, namely the characteristics of the M-wave response (M-
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wave amplitude; Mmax) to supra-maximal nerve stimulation, contractility of the 
muscle (e.g., maximal rate of force development, half relaxation time and 
contraction time), voluntary activation (VA) and potentiated twitch force (pTw). 
During maximal voluntary contractions (MVCs), peripheral nerve stimulation 
pulses were triggered to occur as soon as a peak torque was achieved (typically 
1.5 s into a 3 s contraction), each separated by a 45 s rest. The stimuli were 
also delivered 1-2 s after the cessation of the contraction to provide a resting 
pTw. Identical measurements were repeated as soon as possible (<10 s) after 
the fatiguing exercise to determine post-exercise neuromuscular function (see 
figure 4.1).  
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Figure 4.1. Graphic overview of the procedures used in the current study. A 
and C: Procedures employed pre and post (<10 s) high-intensity exercise, 
respectively. 10 s separated each single pulse stimulation administered at rest 
(small dashed arrows). A 45 s rest period separated maximal efforts (MVCs). 
Single pulse stimuli were administered during peak force production of MVCs 
(large solid arrow) and immediately (1-2 s post; small grey arrows). B: 60 MVC 
protocol of the knee extensors. The figure presents a period of 30 s which is 
repeated sequentially for 5 min. Each MVC was held for 3 s and interspersed by 
a 2 s passive recovery period. Every 6th MVC was accompanied by single 
pulse stimuli administered during peak force production (Large solid arrow) and 
immediately following (<2 s post; small grey arrows). This cycle was repeated 
10 times such that the protocol spanned 5 minutes requiring the completion of 
60 MVCs. MVC, maximal voluntary isometric contraction. Surface 
electromyography (EMG) was measured throughout. 
 
The intermittent isometric contraction protocol used in this study had a similar 
design to that presented by Burnley (2009). The protocol consisted of repeated 
brief MVCs (3 s contraction, 2 s rest), timed via a visual prompt to ‘go’ and 
‘relax’ (separate to the torque output screen), accompanied by the same verbal 
instructions from the experimenter. The protocol was terminated when the 
subjects completed the 60th MVC. Every 6th contraction was accompanied by 
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peripheral nerve stimulation during and post MVC (as described for pre- and 
post-trial measurements). Subjects were not given a visual representation of the 
torque produced during each MVC or made aware of the number of MVCs 
elapsed during the protocol. Subjects were instructed to continue to perform 
maximal contractions throughout. The coefficient of variation for MVC 
performance (mean torque through 60 MVCs) and electromyography root mean 
square (EMGRMS) amplitude using this experimental set up was 2.9% and 4.8%, 
respectively as calculated during pilot testing. 
 
Measurements 
Torque 
Knee-extensor torque from the Biodex dynamometer was sampled at 1,000 Hz 
and low-pass filtered at 40 Hz, before being displayed on a wide screen monitor 
using Spike2 (CED, Cambridge, UK).  Torque was expressed throughout as a 
percentage (%) of pre-exercise MVC.  
 
Electromyography  
Surface EMG activity was recorded from vastus lateralis, vastus medialis and 
rectus femoris of the quadriceps and biceps femoris of the hamstring of the right 
leg using active bipolar bar electrodes single differential configuration (DE2.1, 
DelSys Inc, Boston, MA, USA). The electrodes were placed over the respective 
muscle bellies (SENIAM guidelines). Double-sided adhesive tape and a 
hypoallergenic medical tape were used to ensure the EMG sensor stability for 
recording electrodes. The skin area underneath each EMG electrode was 
shaved, then exfoliated and cleaned with alcohol to minimise the skin 
impedance. The EMG and torque signals were pre-amplified (1,000 x), band-
pass filtered (20–450 Hz, Bagnoli-8, DelSys Inc, Boston, MA, USA), and then 
transferred to a computer with a sampling frequency of 2 kHz. EMG and torque 
data were recorded continuously and digitised synchronously with 16 bit 
resolution via an A/D converter (±5 V range, CED 1401 power, Cambridge, UK). 
The electrodes were used to record: 1) evoked muscle action potentials (peak-
to-peak amplitude of the M-wave); and 2) EMG to estimate muscle activity and 
the output of spinal motoneurons (motor unit recruitment and firing frequency). 
EMG was average rectified using the root mean square method (EMGRMS). 
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EMGRMS was then normalised to the pre-exercise maximum (or maximal EMG 
signal) and the local M-wave amplitude (closest measure of the M-wave to the 
MVC) in order to exclude any changes to the EMG trace to changes in local 
membrane excitability. The ground electrode was placed over the patella of the 
right leg.  
 
Peripheral Nerve Stimulation 
Electrical stimulation was applied by a constant current stimulator (Digitimer 
Stimulator DS7, Digitimer, UK). M-waves were elicited by supramaximal 
percutaneous electrical stimulation of the femoral nerve (200 µs duration). The 
cathode was placed over the femoral nerve in the inguinal fossa, approximately 
3–5 cm below the inguinal ligament in the femoral triangle. Once the M-wave 
was elicited, the maximum amplitude (peak-to-peak) of the M-wave was 
determined (Mmax) for the vastus lateralis and vastus medialis. To determine the 
stimulation intensity (current), single stimuli were delivered in 20 mA step-wise 
increments from 100 mA until a plateau in quadriceps pTw and M-wave were 
observed. To ensure a supramaximal response, the current was increased by 
an additional 30% (mean ± SD current = 194 ± 81 mA; Burke, 2002; Goodall et 
al. 2010; Neyroud et al. 2014). The average Mmax was obtained from 3 stimuli, 
with ~8-10 s separating each pulse at rest. Peak torque, maximal rate of force 
development, half relaxation time and contraction time were analysed for all 
pTw.  
 
Data Analyses 
Data were analysed using a custom written script developed in Spike2 software 
(CED, Cambridge, UK). Mean torque for each 3 s contraction was determined 
for all tests as the mean value over a 1 s period which approximated the plateau 
level of the highest torque (e.g., 500 ms before and after the peak torque). The 
pTw was calculated as the peak torque achieved following the single pulse 
delivered 1 s post-MVC. The twitch torque superimposed onto the peak force 
production of the MVC (sTw) was calculated as the increment in torque 
immediately following the pulse during MVCs. The torque impulse was 
calculated as the area under the torque-time curve by accumulating the time 
integral of each MVC (3 s) by the difference in torque between MVCs. The end-
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test torque (e.g., CT) during the 60 MVC test was defined as the mean of the 
last 12 contractions (e.g., the last 60 s; Burnley, 2009). The Wʹ was calculated 
as the area above the CT from the torque-time curve (e.g., impulse above CT). 
Central fatigue was assessed as the maximal voluntary activation of the 
motoneuron pool (VA, %), calculated using the interpolated twitch method from 
peripheral nerve stimulation (Merton, 1954). Specifically, the increment in 
torque evoked during the MVCs was expressed as a fraction of the amplitude of 
the potentiated twitch produced with the same stimulus in the relaxed muscle 
post MVC. The level of voluntary drive was then quantified as a percentage: [1 
− evoked torque (superimposed on voluntary torque, sTw)/ (mean control 
evoked response, pTw) × 100] (e.g., Allen at al. 1998).  
 
The changes in maximal voluntary torque, pTw, VA and EMGRMS, were used to 
quantify peripheral fatigue and central fatigue. The maximal EMG was taken 
from the first MVC during the 60 MVC task and compared to the last MVC at 
task end. The neuromuscular parameters extracted from the three sets of 
maximal contractions completed post-exercise were tested for statistical 
differences between sets of contractions and then compared to the first set of 
MVCs completed pre-exercise (Froyd et al. 2013; Pageaux et al. 2015; Doyle-
Baker et al. 2017). Neuromuscular function was also measured for each of the 
stimulated contractions during the exercise and normalised to the 
corresponding pre-exercise values at 100% MVC. All neuromuscular 
parameters and torque were averaged across the protocol using 10 (30 s) bin 
averages.  
 
Statistics 
Paired-samples t-tests were used to compare the mean torque, total impulse, 
CT and Wʹ (e.g., impulse above CT) between ACT and PL conditions. In 
addition, paired samples t-tests were used to assess parameters of 
neuromuscular function at task end between trials including pTw, maximal rate 
of force development, half relaxation time and contraction time. The profiles of 
torque, VA, pTw and m-wave amplitude were analysed using two-way ANOVAs 
with repeated measures (using 12 contraction averages; e.g., 6 time points). 
Normalised EMGRMS were analysed using two-way ANOVAs with repeated 
Chapter 4: Acute acetaminophen ingestion improves performance and 
muscle activation during maximal intermittent knee extensor exercise 
 
80 
 
measures using 30 s mean values (e.g., 10 time points). Where the ANOVA 
revealed a significant interaction effect, post-hoc tests were completed using a 
Bonferroni correction. For calculation of effect size, partial eta squared (η2) was 
used for omnibus tests. Cohen's d was used to calculate the effect size for 
paired t-tests and post-hoc comparisons. A t-test was also conducted on the 
differences in EMG and force production (torque) from task end (e.g., 300 s) to 
150 s (mid-point) to assess the rate of change as the protocol progressed. All 
statistical tests were performed both on % change and raw data. Where 
sphericity was violated, a greenhouse-geisser correction factor was used. For 
all tests, results were considered statistically significant when P<0.05. Data are 
presented as means ± SD unless otherwise indicated. All statistical analyses 
were conducted using IBM SPSS Statistics version 23. 
 
RESULTS 
The mean MVC torque achieved prior to the 60 MVC protocol was 232 ± 47 and 
228 ± 48 N·m for PL and ACT, respectively.  Voluntary activation of the knee 
extensors achieved during the preliminary MVCs was 88 ± 7% and 87 ± 5 for 
PL and ACT, respectively. Baseline MVC and VA were not different between 
conditions (P>0.05).  
 
60 MVC Performance 
The profile for mean torque across all subjects and a representative individual 
plot during each contraction for the 60 MVC protocol is shown in figure 4.2. 
During the PL trial, torque declined from a peak of 99 ± 3% MVC (relative to 
pre-exercise MVC) during the first contraction to 40 ± 15% MVC during the last 
12 contractions (P<0.0001, η2=0.908; table 4.1, figure 4.2). The mean torque 
(relative to pre-exercise MVC) achieved across the 60 MVCs was greater with 
ACT (61 ± 11%, 97.1 ± 23.2 N·m) compared to PL (58 ± 14%, 83.8 ± 22.7 N·m; 
P=0.030, d=0.656) and there was a significant interaction effect (time × 
condition; P=0.036, η2=0.260). Post-hoc tests revealed significant differences in 
torque between conditions at task end (P=0.044, d =0.656) but at no other time-
points (all P>0.084 and d<0.548). CT was higher with ACT compared to 
placebo (ACT: 44 ± 13 % vs. PL: 40 ± 15%, P=0.011, d=0.691), with no 
between-condition differences in Wʹ (PL: 6.97 ± 2.43, ACT: 6.91 ± 2.54 N·m·s; 
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P=0.879, d=0.026). Total impulse in the 60 MVC protocol was higher with ACT 
(24386 ± 3793 N·m·s) compared to PL (22055 ± 3885 N·m·s; P=0.006, 
d=0.973). As time progressed, the difference in force production between 
conditions increased as evidenced by a significant difference in rates of change 
between conditions (e.g., difference between 300 and 150 s time points; 
P=0.035, d=0.696). The individual responses following ACT supplementation to 
the torque-impulse can be seen in figure 4.3. Table 4.2 illustrates the 
parameters of the 60 MVC test for PL and ACT for individual subjects.  
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Figure 4.2. Torque profile during the 60 maximal contractions for placebo (clear 
circles) and acetaminophen (filled circles) trials. All contractions were 
normalized to a control maximal voluntary contraction (MVC) performed before 
the test commenced. Mean ± SE torque responses are presented in panel A 
with the torque response from a representative individual presented in panel B 
for the 6th and 54th contractions, respectively, for PL (grey line) and ACT (black 
line).  Note that torque falls over the first ~150 s before reaching stable values 
between 240 and 300 s (the end-test torque; last 12 MVCs). For panel B, black 
arrows indicate point of peripheral nerve stimulation.  
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Figure 4.3 Individual responses to ACT supplementation on 60 MVC 
performance (torque-impulse). *Significantly different from placebo (P<0.05). 
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Table 4.1: Performance and neuromuscular function parameters of the 60 MVC test 
following placebo and acetaminophen ingestion 
 
 
 
Placebo 
 
Acetaminophen 
 
Performance 
  
Peak MVC (N·m) 221 ± 49 230 ± 38 
Mean torque (% MVC) 58 ± 14 61 ± 11* 
Total torque-impulse (N·m·s) 22,055 ± 3,885 24,386 ± 3,792* 
CT (% MVC) 40 ± 15 44 ± 12* 
Wʹ (N·m·s) 6,971 ± 2,432 6,906 ± 2,537 
   
Neuromuscular function   
End-exercise pTw (N·m) 30 ± 20 31 ± 23 
End-exercise:    
Contraction time (ms) 83.2 ± 10.9 81.3 ± 14.0 
Half relaxation time (ms) 72.5 ± 17.2 75.5 ± 17.5 
MRFD (N·m·s) 1330 ± 471 1230 ± 433 
End-exercise VA (%) 59 ± 19 62 ± 16 
End-exercise M-wave amplitude (%) 96 ± 14 95 ± 18 
End-exercise M-wave amplitude (mV) 5.64 ± 2.59 5.44 ± 2.72 
End-exercise EMG amplitude (%) 59 ± 17 87 ± 28* 
 
 
MVC, maximal voluntary contraction; CT, critical torque measured in the last 6 
contractions; mean torque measured as to average torque across the 60 MVC test; 
pTw, potentiated twitch force; MRFD, maximal rate of force development; VA, 
voluntary activation measured using the interpolated twitch method technique; 
EMG, electromyography; N·m, newton metres; N·m·s, newton metres per second; 
ms, milliseconds. *Significantly different from placebo (P<0.05). 
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Neuromuscular Function 
There was a main effect for time on pTw (figure 4a, P<0.001, η2=0.754), 
voluntary activation (figure 4b, P<0.001, η2=0.647) and M-wave amplitude figure 
(4c, P=0.005, η2=0.281), which all declined as the protocol progressed. VA 
declined from 89 ± 8% to 59 ± 19% and from 88 ± 5% to 62 ± 16% in the PL 
and ACT conditions (P<0.0001, figure 4.3), respectively. However, there were 
no main condition effect on M-wave amplitude (P=0.733, η2=0.012), pTw 
(P=0.783, η2=0.032) or VA (P=0.841, η2=0.004) between the PL and ACT 
conditions (figure 4.4c). Likewise, there was no significant interaction effect 
(e.g., time × condition) on M-wave amplitude (P=0.993, η2=0.009) or VA 
(P=0.387, η2=0.097). In addition, pTw declined from 68 ± 8 to 30 ± 20 N·m and 
from 71 ± 12 to 31 ± 23 N·m (both P<0.0001) for PL and ACT, respectively, but 
there was no significant difference in end-exercise pTw between conditions 
(P=0.763, d=0.047). There was also no significant difference in end-exercise 
maximal rate of force development (P=0.181, d=0.383), half relaxation time 
(P=0.234, d=0.341) or contraction time (P=0.595, d=0.232) between conditions. 
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Figure 4.4. Mean ± SE potentiated twitch (A), voluntary activation (B), and M-
wave amplitude (C) responses during the 60 maximal voluntary contraction 
(MVC) test for placebo (clear circles) and acetaminophen (filled circles) trials. 
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Using 6 contraction (30-s) bin means, EMGRMS decreased from 99 ± 4% to 59 ± 
17% in the PL trial (from first 6 to last 6 contractions; P<0.0001, η2=0.502; figure 
4.5). This decline in EMGRMS was attenuated following ACT ingestion (100 ± 5 
to 87 ± 28%), demonstrating a significant main effect of condition (P=0.033, 
η2=0.381) and an interaction effect (P=0.043, η2=0.229). The EMGRMS was 
elevated at 60 s (P=0.036, d=0.730), 90 s (P=0.020, d=0.835), 210 s (P=0.070), 
240 s (P=0.015, d=0.886), 270 s (P=0.019, d=0.844) and 300 s (P=0.001, 
d=1.306) in ACT compared to PL (figure 4.5). As time progressed, the 
difference in EMG amplitude between conditions increased as evidenced by a 
significant difference in rates of change between conditions (e.g., difference 
between 300 and 150 s time points; P=0.024, d=0.804).  
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Figure 4.5. Surface electromyography (EMG) responses (expressed relative to 
M-wave amplitude) during the 60 MVC test for placebo (clear circles) and 
acetaminophen (filled circles) trials.  Mean ± SE EMG responses are presented 
in panel A with the EMG response from a representative individual presented in 
panel B, for the 5th and 55th contractions, respectively, for PL (grey line) and 
ACT (black line). Individual representative data for m-wave can be seen in 
panel C 6th and 54th contractions, respectively, for PL (grey line) and ACT (black 
line). *Significantly different from placebo (P<0.05). 
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DISCUSSION 
Consistent with our experimental hypotheses, the principal findings of this study 
were that acute ACT ingestion increased mean MVC torque, and increased CT 
and EMG amplitude during the latter stages of the 60 MVC protocol. These 
observations offer insights into the mechanisms by which ACT blunts fatigue 
development and suggest that the ergogenic effect of ACT ingestion may be 
linked to increases in CT and muscle activation during fatiguing skeletal muscle 
contractions.      
 
In the present study, fatigue development and some of its underpinning 
mechanisms were assessed during the completion of 60 MVCs of the knee-
extensors using the protocol described by Burnley (2009). Consistent with 
Burnley (2009), torque and pTw declined by 60% and ~55%, respectively, and 
VA declined to 59%, reflecting peripheral and central fatigue development. 
However, although neuromuscular fatigue was also manifest during the ACT 
trial, the acute ingestion of ACT increased the mean torque during the fatiguing 
60 MVC protocol by ~4% compared to the PL condition. This finding is in line 
with previous observations that acute ACT ingestion can improve performance 
during whole body exercise in humans (Foster et al. 2014; Mauger et al. 
2010a).   
 
The attenuation of neuromuscular fatigue development following ACT ingestion 
was not accompanied by specific alterations in central fatigue (voluntary 
activation), peripheral fatigue (potentiated twitch, pTw) or peripheral 
neuromuscular excitability (M-wave) between the ACT and placebo trials.  
However, while EMG declined across the 60 MVC protocol in both conditions, it 
declined to a lesser extent with ACT (declined to ~87 %) compared to PL 
(declined to ~59%).  This observation suggests that improved muscle activation 
might have contributed to the ergogenic effect of ACT ingestion. This 
interpretation is strengthened by our observation of a positive correlation 
between the inter-trial changes in EMG and torque (r = 0.85). Although ACT 
ingestion has previously been reported to increase cortico-spinal excitability at 
rest (Mauger & Hopker, 2013), the neuromuscular mechanisms for improved 
performance during exercise had not been explored in previous studies 
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reporting an ergogenic effect of ACT ingestion (Foster et al. 2014; Mauger et al. 
2010, 2014).  Therefore, by suggesting that ACT can improve muscle activation 
during repeated fatiguing skeletal muscle contractions, our findings extend 
previous observations by providing insight into the potential neuromuscular 
bases for the ergogenic effect of ACT ingestion.     
 
It is possible that the effect of ACT may be linked to a sub-conscious 
neuromuscular alteration during exercise via a reduction in the magnitude of 
muscle afferent feedback. During exercise, ascending group III and IV muscle 
afferents discharge in response to noxious, metabolic and mechanical stimuli 
within the contracting skeletal muscles to regulate the sensation of pain, muscle 
activation and peripheral fatigue development (Amann et al. 2009, 2011; Blain 
et al. 2016; Hureau et al. 2016; McCord and Kaufman, 2010; Pollak et al. 2014). 
When the magnitude of group III and IV muscle afferent feedback is reduced, 
performance is compromised and pacing strategy is adversely impacted 
(Amann et al. 2009, 2011; Blain et al. 2016), despite enhanced muscle 
activation, as peripheral fatigue development is exacerbated. ACT 
administration, on the other hand, which seemingly acts predominantly through 
central processes to blunt pain sensation (Anderson, 2008; Graham et al. 2013; 
Smith, 2009; Toussaint et al. 2010), appears to have attenuated the decline in 
muscle activation without impacting peripheral fatigue development, culminating 
in blunted neuromuscular fatigue development in the current study. Taken 
together, these observations suggest that reducing, but not abolishing, pain 
sensation can attenuate neuromuscular fatigue development during exercise 
and/or that a higher magnitude of afferent feedback is needed to trigger a given 
pain sensation. However, the findings, whilst suggesting that improved 
maintenance of muscle activation might have contributed to the ergogenic effect 
of ACT ingestion, cannot differentiate between a sub-conscious alternation in 
neuromuscular control or a conscious ability to increase muscle recruitment via 
a reduction in pain sensation.  
 
The increased muscle activation in the latter stages of the ACT trial compared 
to the placebo trial was accompanied by a higher mean torque over the final 12 
MVCs, and therefore a higher CT (Burnley, 2009). The CT is an important 
Chapter 4: Acute acetaminophen ingestion improves performance and 
muscle activation during maximal intermittent knee extensor exercise 
 
91 
 
physiological threshold that is linked to neuromuscular fatigue development 
through influencing muscle metabolic homeostasis (Jones et al. 2008; 
Vanhatalo et al. 2016), systemic respiratory and acid-base profiles (Poole et al. 
1988) and neuromuscular fatigue development (Burnley et al. 2012). During the 
60 MVC protocol employed in the current study, there is a precipitous 
perturbation to skeletal muscle homeostasis, central and peripheral fatigue 
development, a decline in muscle activation and a hyperbolic reduction in 
torque that asymptotes at CT (Burnley, 2009; Burnley et al. 2010). By lowering 
pain sensation (Foster et al. 2014; Mauger et al. 2010), ACT might have 
permitted the attainment of a greater degree of intramuscular metabolic 
perturbation, thereby leading to improved exercise tolerance. However, since 
potentiated twitch force was not different between the ACT and PL trials, it 
appears that ACT ingestion did not result in greater peripheral fatigue 
development in this study. Instead, ACT ingestion enhanced muscle activation 
and increased CT over the latter stages of the 60 MVC protocol. Therefore, it is 
also possible that ACT ingestion lowered fatigue development through 
permitting greater muscle activation for a given degree of intramuscular 
metabolic perturbation.  
 
The blunted neuromuscular fatigue development in this study occurred in 
association with increased muscle activation.  However, it is surprising that the 
attenuation in neuromuscular fatigue development was not accompanied by 
changes in central (e.g., voluntary activation) or peripheral (e.g., potentiated 
twitch force) fatigue in this study. Indeed, since muscle activation and torque 
were increased, this might be expected to result in greater intramuscular 
metabolic perturbation and, by extension, greater peripheral fatigue 
development.  Although we cannot exclude the possibility that ACT enhanced 
systemic physiological responses or skeletal muscle efficiency to mitigate this 
potential for greater peripheral fatigue development, we are not aware of any 
published evidence to support such effects. 
 
Experimental Considerations  
It is acknowledged that a limitation of the current study was that pain sensation 
were not directly assessed. Pain was not assessed due to the protocol requiring 
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the completion of 60 MVCs with a short (2 s) recovery period; asking subjects to 
rate pain sensation in this setting may have compromised their ability to focus 
on the exercise task and provide a true maximal effort during the experimental 
protocol. Previous studies have observed a higher power output for the same 
pain sensation, suggestive of a reduction in the sensation of pain during cycle 
ergometry exercise (Foster et al. 2014; Mauger et al. 2010). However, these 
studies used a higher ACT dose (~1.5 g) and a different exercise modality 
(cycling) compared to the current study. Therefore, we are unable to draw 
conclusions regarding pain sensation with ACT in the current study. It should 
also be acknowledged that in the face of a relatively small (~4%) improvement 
in torque, it is possible that the central and peripheral fatigue measurements in 
our study were not sensitive enough to detect small defects in central nervous 
system and peripheral muscle function. Moreover, while ACT increased EMG 
during the latter stages of the 60 MVC protocol compared to PL, which might be 
linked, in part, to increased muscle activation and central motor drive, VA was 
not impacted by ACT. This might have been a function of the continuous 
assessment of the EMG response and torque throughout the 60 MVC protocol, 
compared to every 6th MVC for VA, such that EMG might have provided a more 
complete picture of central fatigue development across the protocol. Recent 
research has also challenged the validity of VA estimated using the interpolated 
twitch technique as a measure of central fatigue (Neyroud et al. 2016), which 
might contribute to the disparity between the EMG-inferred central motor drive 
and the VA results. Accordingly, further research is required to resolve the 
underlying mechanisms for the ergogenic effect of ACT ingestion. In addition, 
although the current study is consistent with previous studies reporting an 
ergogenic effect of acute ACT consumption (Foster et al. 2014; Mauger et al. 
2010, 2014), we do not advocate regular ACT use or exceeding a single dose of 
1 g given the potent hepatotoxicity of ACT ingestion (Graham et al. 2013). 
Therefore, individuals wishing to explore the use of ACT to enhance exercise 
performance should do so infrequently, and with caution.  
 
In conclusion, acute ACT ingestion increased the mean torque across 60 MVCs 
of the knee-extensors in agreement with earlier reports that ACT can attenuate 
neuromuscular fatigue development and improve exercise performance. Our 
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results extend these previous observations by providing novel insights into the 
mechanisms for the potential ergogenic effect of ACT ingestion.  Specifically, 
the improved mean torque was accompanied by an increase in CT and greater 
muscle activation during the latter stages of the 60 MVC protocol. Therefore, 
ACT ingestion appears to attenuate fatigue development during repeated 
skeletal muscle MVCs by enabling a better preservation of muscle activation 
during exercise.  
Chapter 4: Acute acetaminophen ingestion improves performance and 
muscle activation during maximal intermittent knee extensor exercise 
 
94 
 
 
 
Table 4.2. Parameters of the 60 MVC test for placebo and acetaminophen 
Placebo  Acetaminophen 
  
Total 
impulse 
 
Mean  
Torque 
 
End-test  
torque (CT) 
 
Curvature 
constant (Wʹ) 
  
Total 
impulse 
 
Mean 
torque 
 
End-test  
torque (CT) 
 
Curvature 
constant (Wʹ) 
Subject (N·m·s) (N·m) (% MVC) (N·m) (% MVC) (N·m·s)  (N·m·s) (N·m) (% MVC) (N·m) (% MVC) (N·m·s) 
1 19072 106.0 56.9 82.8 44.5 4162  25185 139.9 56.7 114.4 46.3 4589 
2 26481 147.1 46.0 97.1 30.4 9008  28304 157.2 51.2 92.9 30.2 11591 
3 17854 99.2 47.9 69.0 33.3 5427  23308 129.5 51.0 87.2 34.3 7617 
4 28802 160.0 83.3 131.5 68.4 5124  28389 157.7 78.1 140.4 69.5 3123 
5 21691 120.5 66.7 85.0 47.0 6385  23676 131.5 60.5 103.5 47.6 5044 
6 24102 133.9 68.9 92.3 47.5 7495  25334 140.7 75.5 96.9 52.0 7899 
7 23494 130.5 70.5 103.3 55.8 4894  25020 139.0 69.9 110.9 55.8 5063 
8 26437 146.9 61.9 90.4 38.1 10166  29108 161.7 69.2 109.7 46.9 9353 
9 19481 108.2 37.8 48.3 16.9 10794  18946 105.3 41.4 54.1 21.3 9205 
10 21095 117.2 49.9 69.1 29.4 8662  22141 123.0 61.5 76.6 38.3 8356 
11 20256 112.5 45.9 67.1 27.4 8186  26654 148.1 59.0 110.0 43.8 6849 
12 15893 88.3 58.3 69.7 46.0 3349  16568 92.0 57.0 68.8 43.1 4178 
 
Mean 22,055 122.5 57.8 83.8 40.4 6,971 
   
24,386* 
   
135.5*      61.0* 
   
97.1*      44.1* 6,906 
SD 3,885 22.0 13.7 22.7 14.7 2,432  3,792 21.1 10.7 23.2 12.5 2,537 
Mean torque, average torque achieved during the test; MVC, maximal voluntary contraction, End-test torque (e.g., CT), mean torque measured in 
the last 12 contractions of the 60 MVC test. *Significantly different from placebo (P<0.05).  
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ABSTRACT 
Purpose: Acute acetaminophen (ACT) ingestion has been shown to enhance 
cycling time-trial performance.  The purpose of this study was to assess 
whether ACT ingestion enhances muscle activation and critical power (CP) 
during maximal cycling exercise. Methods: Sixteen active male participants 
completed two 3-min all-out tests against a fixed resistance on an electronically-
braked cycle ergometer 60 min after ingestion of 1 g of ACT or placebo 
(maltodextrin, PL). CP was estimated as the mean power output over the final 
30 s of the test and W′ (the curvature constant of the power-duration 
relationship) was estimated as the work done above CP. The femoral nerve was 
stimulated every 30 s to measure membrane excitability (M-wave) and surface 
electromyography (EMGRMS) was recorded continuously to infer muscle 
activation. Results: Compared to PL, ACT ingestion increased CP (ACT: 297 ± 
32 vs PL: 288 ± 31 W, P<0.001) and total work done (ACT: 66.4 ± 6.5 vs PL: 
65.4 ± 6.4 kJ, P=0.03) without impacting Wˈ (ACT: 13.1 ± 2.9 vs PL: 13.6 ± 2.4 
kJ, P=0.19) or the M-wave amplitude (P=0.66) during the 3-min all-out cycling 
test. Normalized EMGRMS amplitude declined throughout the 3-min protocol in 
both PL and ACT conditions; however, the decline in EMGRMS was attenuated in 
the ACT condition, such thats the EMGRMS amplitude was greater in ACT 
compared to PL over the last 60 s of the test (P=0.04). Conclusion: These 
findings indicate that acute ACT ingestion might increase performance and CP 
during maximal cycling exercise by enhancing muscle activation. 
 
Key words: Analgesic; critical power; electromyography; exercise performance; 
muscle activation; neuromuscular fatigue  
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INTRODUCTION 
Fatigue is a complex, multi-factorial process that is linked to perturbations within 
the central nervous system and the contracting skeletal muscles (Enoka & 
Duchateau, 2008; Hureau et al. 2018). Recent studies suggest that fatigue 
development may be related, at least in part, to pain sensation (Astokorki & 
Mauger 2017a; s2017b; O’Leary et al. 2017). Acetaminophen (ACT) is a 
commonly used medicine for general pain relief.  Ingestion of ACT lowers pain 
sensation by inhibiting the cyclooxygenase enzymes, which stimulate 
nociceptor discharge through the synthesis of prostaglandins (Graham et al. 
2013; Jóźwiak-Bębenista & Nowak, 2014), and modulating serotoninergic, 
opioid and cannabinoid pathways that may contribute to the responsiveness of 
the corticospinal tract (Andersson et al. 2011; Graham et al. 2013; Ottani et al. 
2006; Pickering et al. 2006, 2008). Acute ACT ingestion has been shown to 
enhance endurance exercise performance consistent with the notion that 
interventions that can modulate pain sensation have the potential to influence 
exercise performance (Foster et al. 2014; Mauger et al. 2010, Morgan et al. 
2018). Indeed, similar to the effects of caffeine (O’Connor et al. 2004), Mauger 
et al. (2010) and Foster et al. (2014) have both previously reported enhanced 
exercise performance and/or work output at a given level of muscle pain 
following acute ACT ingestion. These results suggest that ACT reduces pain at 
a given absolute work rate and/or permits a higher work rate for an equivalent 
pain sensation.  
 
In a recent study conducted within our lab, Morgan et al. (2018) reported an 
attenuated decline in skeletal muscle electromyography (EMG) amplitude, 
reflective of an increase in muscle activation, and an increased critical torque 
during a maximal intermittent single-leg knee extensor test following ACT 
ingestion. During cycling exercise, the power equivalent of the critical torque, 
the critical power (CP), represents an important threshold for oxidative 
metabolic control and exercise tolerance (Jones et al. 2010; Vanhatalo et al. 
2011). Indeed, CP, which is the asymptote of the hyperbolic relationship 
between power output and time to exhaustion, reflects the highest work rate 
that can be sustained without a progressive loss of intramuscular and systemic 
homeostasis (Black et al. 2017; Poole et al. 1988; 2016; Vanhatalo et al. 2016), 
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and interacts with the curvature constant of this relationship, W′, to define 
exercise tolerance within the severe exercise intensity domain (Jones et al. 
2010; Vanhatalo et al. 2011). Since CP is linked to muscle activation and 
neuromuscular fatigue development during exercise, as inferred from EMG 
responses (Burnley et al. 2012), and since ACT ingestion can concomitantly 
influence EMG responses and the critical torque (Morgan et al. 2018), ACT 
might also enhance CP by modulating aspects of central fatigue development 
during large muscle mass exercise. This potential blunting of central fatigue 
development could be mediated by inhibition of nociceptor sensitising 
prostaglandins (Graham et al. 2013; Jóźwiak-Bębenista & Nowak, 2014), 
enhanced efferent pathways (Andersson et al. 2011; Ottani et al. 2006) and/or 
enhanced corticospinal excitability (Mauger & Hopker, 2013), permitting an 
increased CP and thus improved endurance exercise performance.      
 
Although the improvement in cycling performance that has been reported 
following ACT ingestion (Foster et al. 2014; Mauger et al. 2010) may also be 
linked to enhanced neuromuscular function and a higher CP, as observed 
during single leg exercise (Morgan et al. 2018), the exercise modality and the 
volume of skeletal muscle mass engaged are known to influence the degree of 
neuromuscular and peripheral fatigue development. Specifically, greater 
peripheral fatigue development has been observed at the same relative 
intensity during knee-extensor exercise compared to cycling and single vs. 
double leg exercise (Rossman et al. 2012, 2014).  Therefore, further research is 
required to resolve the .mechanisms underpinning the potential ergogenic effect 
of ACT on larger muscle mass exercise such as cycling, which is more relevant 
for sports performance, requires further research.  
 
The purpose of the present study was, therefore, to assess the effect of acute 
ACT ingestion on neuromuscular fatigue development and its potential 
underlying mechanisms during large muscle mass exercise. We tested the 
hypotheses that, compared to placebo (PL), acute consumption of 1 g of ACT 
would increase total work done, CP and muscle activation during a 3-min all-out 
cycling test. 
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METHODS 
Participants 
Sixteen trained male cyclists (mean ± SD: age 29 ± 9 y, height 1.79 ± 0.07 m, 
body mass 77 ± 8 kg, V̇O2peak 60.8 ± 6.0 ml·kg-1·min-1, range: 52-77 ml·kg-1·min-
1) provided written informed consent to participate in the present study, which 
was approved by the local Ethics Committee (Sport and Health Sciences, 
University of Exeter). All subjects participated in local cycling competitions. 
Trained individuals were selected as it has been shown that endurance training 
influences pain tolerance (O’Leary et al. 2017). After being informed of the 
experimental procedures and associated risks, all participants completed a 
medical health questionnaire, which was checked by a medical doctor, to 
ensure it was safe to consume ACT prior to performing exhaustive exercise. 
The questionnaire incorporated questions pertaining to: known allergies to 
medications, current intake of medication and prior use of ACT as well as any 
history of illnesses, cigarette use, alcohol consumption, illegal drug intake and 
chronic illnesses (personal and family history). None of the participants had a 
history of motor and/or neurological disorders or frequent chronic ingestion of 
pain relief medication (e.g., ACT, non-steroidal anti-inflammatory medication 
etc.). Participants were also advised to avoid ingestion of pain relief medication 
over the duration of the study and were provided with a list of prohibited 
medication(s). Participants were instructed to arrive at the laboratory in a rested 
and fully hydrated state, at least 3 h post-prandial, and to avoid strenuous 
exercise, and consumption of caffeine and alcohol in the 24 h prior to each 
testing session. 
 
Experimental Design 
Participants visited the laboratory on 5 occasions over a 5- to 6-week period 
with all tests conducted at a similar time of day (± 90 min). All tests were 
conducted on an electronically braked cycle ergometer (Lode Excalibur Sport, 
Groningen, Netherlands). On the first laboratory visit, participants performed a 
incremental ramp cycling test for the determination of the linear factor (as 
described below), gas exchange threshold (GET), peak aerobic power output 
and the peak oxygen uptake (V̇O2peak). During this initial laboratory visit, the 
seat and handlebar positions were adjusted for comfort and replicated for all 
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tests. The second and third laboratory visits were used to familiarise 
participants to the measurements and experimental protocol (as described 
below). During these visits (e.g., visits 2 and 3), participants completed a 3-min 
all-out cycling test to ensure the coefficient of variation for work done and CP 
between visits was <1% and that the criteria to ensure a valid test were fulfilled 
(Jones et al. 2010). For each 3-min test, achievement of V̇O2peak (>95%), as 
verified by the V̇O2peak achieved during the ramp incremental ramp tests, was 
an obligatory criterion for a valid test. In the one instance where these criteria 
were not fulfilled, the participant completed a further familiarisation trial prior to 
commencing the experimental trials. During these sessions, the settings and 
placement of EMG and peripheral nerve stimulation electrodes were recorded 
for each subject as a reference for electrode placement in subsequent 
experimental trials (see below for further details). These trials were not included 
in the subsequent data analysis. Participants then performed the fatiguing 
protocol under two experimental conditions: placebo (PL) and ACT. 
Experimental sessions were separated by 3-7 days.  
 
Experimental protocol 
All trials (visits 1-5) started with a standardised warm-up routine (10 min at 100-
150 W, corresponding to <90% GET, followed by 5 min of passive rest) and 
testing of the optimal EMG electrode (for recording muscle activation), anode 
and cathode placement and stimulation intensity (for peripheral nerve 
stimulation). Single peripheral nerve stimulation pulses were manually triggered 
to determine the characteristics of the M-wave response to supra-maximal 
nerve stimulation. Neuromuscular function was assessed pre-, during- and post-
trial (<10 s) as described below.   
 
The experimental protocol comprised a 3-min period of unloaded pedalling at 
the participant’s preferred cadence, followed by a 3-min all-out sprint, 60 min 
following ingestion of either PL (1 g maltodextrin) or 1 g ACT (visits 4-5). This 
timing was selected to coincide with the approximate attainment of the peak 
plasma [ACT] concentration (Anderson et al. 2008). The placebo was made 
from dextrose powder inserted into gelatine capsules designed to have an 
identical appearance and weight to ACT capsules but without the analgesic and 
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antipyretic effects. The order of trials for visits 4 and 5 were administered in a 
double-blind, randomised fashion using a counter-balanced cross-over 
experimental design. The 3-min all-out cycling protocol used in this study 
replicated the procedures described previously by Vanhatalo et al. (2007, 
2008). The fixed resistance for the all-out sprint was set using the linear mode 
of the ergometer such that upon reaching their preferred cadence, the 
participants would achieve a power output equivalent to 50% of the difference 
between GET and V̇O2peak (linear factor = 50%∆ power output/preferred 
cadence2).  
 
Measurements 
Breath-by-breath pulmonary gas exchange 
Throughout all laboratory tests, participants wore a mask connected to an 
impeller turbine transducer assembly (Cortex Metalyzer, Cortex, Leipzig, 
Germany). Inspired and expired gas volume and concentration signals were 
continuously sampled at 100 Hz. ThFo raFe analyser was calibrated before 
each test with gases of known concentration (O2 15%, CO2 4.5%), and a 
calibration syringe of known volume (3-L; Hans Rudolph, KS).  
 
Electromyography  
Neuromuscular function was assessed pre-, during- and immediately post each 
of the trials. Pre- and post-trial neuromuscular function was tested with the 
participant cycling at 80 rpm with a low resistance (20 W) as described below. 
Surface EMG activity was measured from m. vastus lateralis, m. vastus 
medialis, m. rectus femoris and m. biceps femoris muscles of the right leg to 
continuously record muscle activity during exercise using active bipolar bar 
electrodes with a single differential configuration (DE2.1, DelSys Inc, Boston, 
MA, USA). Bipolar electrodes were positioned over the muscle belly parallel to 
the longitudinal axis of each muscle (according to guidelines of the SENIAM 
(Surface Electromyography for the Non-Invasive Assessment of Muscles) 
project.). The placement of electrodes was considered optimal on achieving the 
largest and most reproducible M-wave signal from the m.vastus lateralis and 
m.vastus medialis whilst noting minimal activity in the m.bicep femoris.  
Placement of electrodes was optimised during each laboratory visit. Double-
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sided adhesive tape and a hypoallergenic medical tape were used to ensure the 
EMG sensor stability for recording electrodes. The skin area underneath each 
EMG electrode was shaved, then exfoliated and cleaned with alcohol to 
minimise the skin impedance. The EMG signal was pre-amplified (1000 x), 
band-pass filtered (20–450 Hz, Bagnoli-8, DelSys Inc., Boston, Mass., USA), 
and then transferred to a computer with a sampling frequency of 2 kHz. EMG 
data were recorded continuously and digitised synchronously with 16 bit 
resolution via an A/D converter (±5 V range, CED 1401 power, Cambridge, UK). 
EMG was average rectified using the root mean square method (EMGRMS). 
EMGRMS throughout the trial was then normalised to the EMG signal during the 
first 30 s of the 3-min test to provide a percentage of the maximal signal. Finally, 
EMGRMS was normalised to the local (closest) standardised M-wave amplitude 
and presented as a percentage of the maximal signal. In addition, M-wave 
amplitude was normalised by pre-exercise, resting values, and presented as a 
percentage. This method of normalizing the EMG trace to the M-wave may 
enable a more accurate assessment of changes in muscle activation that are 
likely occurring upstream of the neuromuscular junction (e.g., spinal and/or 
supraspinal in origin). The ground electrode was placed over the patella of the 
right leg in an 'electrically quiet' location to minimize extraneous noise. 
 
Peripheral Nerve Stimulation 
Electrical stimulation was applied using a constant current stimulator (Digitimer 
Stimulator DS7AH, Digitimer, Hertfordshire, UK). Initially, the crank angle at 
which peripheral nerve stimulation was to be delivered during the trials was 
determined for each subject as described by Black et al. (2017) and as 
performed by Sidhu et al. (2012). Stimulations were delivered at the identified 
crank angle specific to each trial (62 ± 7° relative to full knee extension, 180°) to 
align with maximal EMGRMS amplitude. A custom written sequencer script 
triggered 3 single stimulations, independently, with at least 1 and up to 10 pedal 
revolutions between stimuli. During the 3-min cycling test, these stimulations 
were delivered every 30 s. M-waves were elicited in m.vastus lateralis and 
m.vastus medialis by supramaximal percutaneous electrical stimulation of the 
femoral nerve (200 µs duration), approximately 3–5 cm below the inguinal 
ligament in the femoral triangle. The cathode was systematically moved 
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vertically and horizontally and the amplitude of the muscle action potential (e.g., 
M-wave) was monitored to identify the optimal position of the cathode for 
attaining maximal peak-to-peak M-wave (Mmax) amplitude. To determine the 
stimulation intensity, single stimuli were delivered in 20 mA step-wise 
increments from 100 mA until a plateau (e.g., Mmax) in the M-wave was 
observed. A supramaximal pulse of 130% Mmax current (Burke, 2002; Goodall et 
al. 2010; Neyroud et al. 2014) was applied during the exercise tests (mean 
stimulation intensity: 251 ± 48 mA). The procedures for determining optimal 
electrode placement and stimulation intensity were completed during each 
laboratory visit (visits 2-5).  
 
Data Analysis 
Data were analysed using a custom written script developed in Spike2 software 
(CED, Cambridge, UK). CP was estimated as the mean power output over the 
final 30 s of the test, and the Wʹ was estimated as the work done above the CP 
(Vanhatalo et al. 2007, 2008). Peak V̇O2 was determined as the highest 15-s 
interval (e.g., V̇O2peak). Total work was calculated as the area under the power-
time curve. Peak power output attained in the 3-min test was defined as the 
maximal 1-s interval. The changes in power output, MMax and EMGRMS, were 
used to quantify neuromuscular fatigue development and changes in muscle 
activation. All neuromuscular parameters and power output were averaged 
across the protocol into 6 × 30-s bin averages. Estimates of CP and Wˈ were 
also used to predict the time taken to complete a range of total work done (W) 
targets (50, 75, 100, 125, 150, 175, 200, 225, 250, 500, 750, 1000 kJ) as 
previously described (Kelly et al. 2013) using equation (1): 
 
Tlim = (W-Wʹ) / CP                                   (equation 1) 
 
Statistics 
Paired-samples t-tests were used to compare the CP, Wʹ, total work done and 
cardiorespiratory responses between ACT and PL conditions. In addition, paired 
samples t-tests were used to assess parameters of neuromuscular function at 
task end between trials (e.g., Mmax and EMGRMS). The profiles of power output, 
M-wave amplitude and EMGRMS before, during and after the 3-min test were 
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analysed using two-way ANOVAs (time × condition) with repeated measures 
(using 30 s averages; e.g., 6 time points) between PL and ACT. A two-way 
repeated-measures ANOVA was also used to assess differences in predicted 
performance times. Where the ANOVA revealed a significant interaction effect, 
post-hoc comparisons were completed using a Bonferroni correction. A 
Pearson’s product moment correlation coefficient was used to determine the 
relationship between the change in EMG amplitude and the change in power 
output between conditions. A one-way ANOVA was used to assess differences 
in V̇O2peak obtained during the incremental ramp test and both 3-min trials (PL 
and ACT). To assess the possibility of an order effect of trials, a paired samples 
t-test was conducted on total work done for visits 4 and 5. For calculation of 
effect size, partial eta squared (η2) was used for omnibus tests. Cohen's d was 
used to calculate the effect size for paired t-tests and post-hoc comparisons. All 
statistical tests were performed both on % change and raw data. Where 
sphericity was violated, a Greenhouse Geisser correction factor was used. For 
all tests, results were considered statistically significant when P<0.05. Data are 
presented as mean ± SD, unless otherwise indicated. All statistical analyses 
were conducted using IBM SPSS Statistics version 24. 
 
RESULTS 
Mean V̇O2peak measured in the ramp incremental test was 4.50 ± 0.41 L·min−1 
(61 ± 6 ml·kg−1·min−1) and the peak aerobic power output was 393 ± 29 W. The 
GET occurred at 1.98 ± 0.26 L·min−1 and 152 ± 22 W. The V̇O2peak achieved 
during the 3-min test following PL (4.51 ± 0.59 L·min−1, 60 ± 7 ml·kg−1·min−1) 
and ACT ingestion (4.53 ± 0.57 L·min−1, 61 ± 8 ml·kg−1·min−1) were not 
significantly different to the values achieved during the ramp incremental test 
(P=0.77).  
 
3-min all-out cycling test 
The V̇O2 profile during the 3-min test for PL and ACT conditions is shown in 
figure 5.1 (panel A). In addition, the mean power output profile for all 
participants (and differences in CP) during the 3-min all-out cycling test is 
shown in figure 5.1 (panel B) for the PL and ACT conditions. Panel C 
represents changes to power output throughout the duration of the 3-min test in 
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all trials and is provided in 30-s averages. During the PL trial, power output 
declined from 820 ± 139 W during the first 5 s of the test to 288 ± 31 W during 
the last 30 s of the 3-min test (P<0.0001, η2=0.99; table 5.1). However, during 
the ACT trial, power output declined from 838 ± 127 W during the first 5 s of the 
test to 297 ± 32 W during the final 30 s of the test (table 5.1). There was a 
significant interaction effect (time × condition; P=0.04, η2=0.26) with the mean 
power output in the 3-min cycling test being greater in ACT (368 ± 36 W) 
compared to PL (363 ± 36 W, P=0.007, d=0.13). CP (ACT: 297 ± 32 W vs. PL: 
288 ± 31 W, P<0.0001, d=0.28) and total work done (ACT: 66.4 ± 6.5 kJ vs. 
65.4 ± 6.4 kJ; P=0.03, d=0.15) was higher with ACT compared to PL (table 5.1; 
figure 5.2). However, there was no difference in peak power output (ACT: 838 ± 
127 W vs. PL: 820 ± 139 W, P=0.10, d=0.16) or Wʹ (ACT: 13.1 ± 2.9 vs. PL: 
13.6 ± 2.4 kJ; P=0.19, d=0.20) during the 3-min cycling test between conditions. 
No order effect was observed between visit 4 and visit 5 for total work done 
(Visit 4: 65.8 ± 6.5 kJ vs. Visit 5: 66.0 ± 6.4 kJ; P=0.75, d=0.03). 
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Figure 5.1. Group mean ± SE V̇O2 during acetaminophen (ACT, filled circles) 
and placebo (PL, clear circles) is presented in panel A. The dashed line 
represents the V̇O2peak attained in the incremental ramp test. Panel B illustrates 
the mean ± SE power output profile during the 3-min maximal cycling protocol 
for placebo (clear circles) and acetaminophen (filled circles) trials derived from 
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15 s averages.  Note that after attainment of peak power output a few seconds 
into the test, power output falls over the first ~90-120 s before reaching stable 
values (the end-test power output; e.g., CP). CP is significantly elevated in the 
last 30 s of the ACT condition. Significant changes to power output over time 
(derived from 30 s averages) throughout the 3-min cycling test for both ACT and 
PL conditions are shown in panel C. *Significantly different from PL (e.g., main 
effect of condition); asignificantly different from 30 s; bsignificantly different from 
60 s; csignificantly different from 90 s; dsignificantly different from 120 s (main 
effect of time, P<0.05). 
 
 
Figure 5.2. Group mean total work done in the placebo (PL) and 
acetaminophen (ACT) conditions are shown in the open and closed bars, 
respectively (Panel A). Individual responses in the PL and ACT conditions are 
shown by the open circles and linked with dashed lines. *Significantly different 
from PL (P<0.05). Panel B represents the group mean critical power (CP) in the 
PL and ACT conditions in the open and closed bars, respectively. Individual 
responses in the PL and ACT conditions are shown by the open circles and 
linked with dashed lines. 
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Table 5.1: Performance and neuromuscular function parameters during the 3 min test 
following placebo and acetaminophen ingestion.   
 Placebo Acetaminophen 
 
3-min test performance 
  
Peak power output (W) 820 ± 139 838 ± 127 
Mean power output (W) 363 ± 36 368 ± 36* 
Total work done (kJ) 65.4 ± 6.4 66.4 ± 6.5* 
CP (W) 288 ± 31 297 ± 32* 
Wʹ (kJ) 13.6 ± 2.4 13.1 ± 2.9 
   
Neuromuscular function   
End-exercise M-wave amplitude (mVL, %) 84 ± 21 83 ± 22 
End-exercise M-wave amplitude (mVL, mV) 3.94 ± 1.9 4.15 ± 1.60 
End-exercise EMGRMS amplitude (mVL, %) 54 ± 17 72 ± 18* 
End-exercise EMGRMS amplitude (mVL, mV) 0.09 ± 0.03 0.12 ± 0.03* 
   
Data are presented as Mean ± SD. CP, critical power; Wʹ, the work done above CP; 
M-wave, amplitude of M-wave response; EMG, electromyography; mVL, vastus 
lateralis muscle *Significantly different from placebo (P<0.05). 
When the CP and Wʹ were combined to predict the time required to complete 
fixed work targets between 50 and 1000 kJ, using equation 1, the ANOVA 
revealed a main effect by condition (P<0.0001, η2=0.56) and an interaction 
effect (P<0.0001, η2=0.86, table 5.2). Post-hoc analysis revealed that the 
performance times were lower in the ACT condition compared with the PL 
condition for all time-trials with the exception of the two shortest (e.g., 50 and 75 
kJ), with the improvement ranging from 1.1% (100 kJ) to 3.0% (1000 kJ). 
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Table 5.2: Predicted time to complete fixed work targets (50 – 1000 kJ) as 
calculated using the CP and W′ estimates following placebo and 
acetaminophen ingestion. 
 Placebo Acetaminophen 
 
Fixed work targets (kJ) 
  
50 kJ  128 ± 17 126 ± 17 
75 kJ 216 ± 25 211 ± 25 
100 kJ 303 ± 34 296 ± 33* 
125 kJ 391 ± 43 381 ± 42* 
150 kJ 479 ± 52 466 ± 50* 
175 kJ 567 ± 61 552 ± 59* 
200 kJ 655 ± 70 637 ± 68* 
225 kJ 743 ± 80 722 ± 76* 
250 kJ 831 ± 89 807 ± 85* 
500 kJ 1709 ± 182 1659 ± 172* 
750 kJ 2588 ± 276 2510 ± 259* 
1000 kJ 3466 ± 369 3362 ± 346* 
   
Data are presented as Mean ± SD. kJ, kilojoules; s, seconds (predicted time to 
complete ‘target work’); *Significantly different from placebo (P<0.05). 
 
Neuromuscular Function 
From pre to post exercise, there was a main effect for time on M-wave 
amplitude in the m.vastus lateralis (P=0.003, η2=0.29, figure 5.3), which 
declined as the protocol progressed. However, there was no main effect by 
condition (P=0.66, η2=0.01) or time × condition interaction effect (P=0.70, 
η2=0.03). EMGRMS in the m.vastus lateralis decreased from 94 ± 4% over the 
first 30 s to 54 ± 17% over the final 30 s of the 3-min all-out test in the PL trial 
(P<0.0001, η2=0.50; figure 5.4). However, this decline in EMGRMS was 
attenuated following ACT ingestion (from 92 ± 5 over the first 30 s to 72 ± 18% 
over the final 30 s of the 3-min all-out test), with there being a time × condition 
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interaction effect (P=0.04, η2=0.23). Post-hoc analysis revealed EMGRMS was 
elevated at 150 s (P=0.02, d=0.84) and 180 s (P=0.001, d=1.31) in ACT 
compared to PL (figure 5.4). There was a significant positive correlation 
between the change in EMG amplitude and the change in power production 
over the last 30 s of exercise between conditions (r=0.88, P=0.04, figure 5.5). 
 
 
Figure 5.3. M-wave amplitude responses in the m.vastus lateralis during the 3-
min cycling test for placebo (clear circles) and acetaminophen (filled circles) 
trials.  Mean ± SE M-wave responses are presented in panel A with the M-wave 
response from a representative individual presented in panel B, for PL (grey 
line) and ACT (black line), for the first 30 and final 30 s, respectively of the 3-
min protocol. asignificantly different from baseline; bsignificantly different from 30 
s (P<0.05). 
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Figure 5.4. Surface electromyography (EMG) responses (expressed relative to 
M-wave amplitude) in the m.vastus lateralis during the 3-min cycling test for 
placebo (clear circles) and acetaminophen (filled circles) trials.  Mean ± SE 
EMG responses are presented in panel A with the EMG response from a 
representative individual presented in panel B, for PL (grey line) and ACT (black 
line), for the first 30 and final 30 s, respectively of the 3-min protocol. 
*Significantly different from placebo; asignificantly different from 30 s; 
bsignificantly different from 60 s; csignificantly different from 90 s; dsignificantly 
different from 120 s; esignificantly different from 150 s (P<0.05). 
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Figure 5.5. Correlation between the change in electromyography amplitude 
(EMG, %) and the change in critical power (CP) between conditions 
(acetaminophen and placebo). The solid line represents the line of best fit. 
 
DISCUSSION 
Consistent with our hypotheses, the principal original findings of this study were 
that acute ACT ingestion enhanced total work done and CP, and attenuated the 
decline in EMG amplitude, in trained individuals during a 3-min all-out cycling 
test. The ACT-induced increase in CP was predicted to translate into a 1-3% 
reduction in the time required to complete a range of target work cycling trials 
(100-1000 kJ). The results of this study provide some insight into the 
mechanisms by which ACT ingestion is ergogenic during large muscle mass 
exercise and suggest that enhanced performance following ACT ingestion is 
attributable, at least in part, to increases in CP and muscle activation.   
 
Power-duration relationship 
Our finding of an increase in total work done following acute ACT ingestion in 
the 3-min all-out cycling test is consistent with previous observations of 
enhanced exercise performance following acute ACT ingestion of similar doses 
(~1-1.5 g; Foster et al. 2014; Mauger et al. 2010, Morgan et al. 2018). In the 
present study, neuromuscular fatigue development was assessed during the 
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completion of a 3-min all-out cycling test to offer insight into the potential 
underlying mechanisms for the ergogenic effects of ACT ingestion. Consistent 
with our previous finding of a 4% increase in critical torque when utilising a 
single-limb knee-extension model (Morgan et al. 2018), CP achieved during a 3-
min all-out cycling test was improved by ~3% following the acute ingestion of 
ACT in the present study. Moreover, and consistent with our previous findings 
(Morgan et al. 2018), W′ was not altered following ACT ingestion in the current 
study.  
 
The potential practical significance of the 3% improvement in CP becomes clear 
when applied to an exercise performance scenario. An important practical 
application of the CP is that this parameter, in conjunction with W′, can be used 
to robustly predict cycling TT performance (Black et al. 2014, 2017; Burnley et 
al. 2012; Chidnok et al. 2013; Florence & Weir, 1997; Skiba et al. 2012; Smith 
et al. 1999). Accordingly, the influence of a given intervention on CP and W′ can 
be used to predict the effect that that intervention might have on endurance 
exercise performance. For example, although Kelly et al. (2013) reported no 
statistically significant increase in either CP (+1.4%) or W′ (+8.4%) following 
dietary nitrate supplementation, when the combined effect on these parameters 
was integrated, an improvement of 2-3% in cycling time-trial performance was 
predicted. Similarly, in the current study, endurance performance was predicted 
to be improved by ~1-3% following acute ACT ingestion in the work trial 
simulations (~5-60 min). Since this magnitude of performance enhancement 
following acute ACT ingestion exceeds 0.6%, which is suggested to be the 
smallest ‘worthwhile’ improvement in road TT cycling (Paton & Hopkins, 2006), 
our results suggest that acute ACT ingestion may enable a practically 
meaningful improvement in endurance exercise performance. It should also be 
noted that, although we did not directly assess the effect of acute ACT ingestion 
on cycling TT performance in the current study, the predicted 1-3% is similar to 
the empirically demonstrated 1.8% improvement in 10-mile cycling TT 
performance reported previously (Mauger et al. 2010). 
 
Interestingly, improvements in exercise performance with acute ACT ingestion 
have been reported in trained participants in both the current study and in 
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previous studies (Mauger et al. 2010) despite evidence that endurance training 
increases pain tolerance (Jones et al. 2014; O’Leary et al. 2017) such that 
trained individuals are more likely to have a greater tolerance to pain (Janal et 
al. 1994; Tesarz et al. 2013). However, it should be stressed that, although the 
current and previous studies support an ergogenic effect of acute ACT 
consumption (Foster et al. 2014; Mauger et al. 2010, 2014; Morgan et al. 2018), 
regular ACT use, or exceeding a single dose of 1 g, is not recommended given 
the hepatotoxicity of ACT (Graham et al. 2013).  
          
Neuromuscular function 
In addition to influencing the degree of muscle metabolic perturbation and the 
trajectory of the V̇O2 slow component during exercise (Jones et al. 2008, 2010; 
Poole et al. 1988; Vanhatalo et al. 2011), CP is linked to muscle activation 
characteristics during exercise, as inferred from EMG responses, and 
represents a critical threshold for neuromuscular fatigue development (Burnley 
et al. 2012). Indeed, concomitant with our observation of an increased CP in the 
current study, the decline in EMG amplitude during the 3-min all-out test was 
attenuated in ACT compared to PL. These findings are strikingly similar to our 
recent study, which reported a blunted decline in the EMG amplitude and an 
increased critical torque during a 5-min maximal intermittent single-legged knee 
extension exercise task (Morgan et al. 2018). Together, these results suggest 
that improved maintenance of muscle activation contributes to the elevated CP 
and total work done following ACT ingestion. However, the blunting of 
neuromuscular fatigue development following ACT ingestion was not 
accompanied by improvements in peripheral muscle excitability, as inferred 
from measurements of M-wave amplitude between the ACT and PL trials, 
suggesting that this alteration occurred due to mechanisms upstream of the 
neuromuscular junction.  
 
Our results support the notion that the ergogenic effect of ACT is principally 
mediated centrally (Anderson, 2008; Andersson et al. 2011; Graham et al. 
2013; Mauger & Hopker, 2013; Ottani et al. 2006; Smith, 2009; Toussaint et al. 
2010). However, while we are not aware of any evidence to suggest that ACT 
might influence peripheral muscle excitability (Mauger & Hopker, 2013), or that 
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interventions aimed at reducing inflammation improve performance during 
whole body exercise (e.g., Cleak, & Eston. 1992; Da Silva et al. 2015; Nosaka & 
Clarkson, 1996; Tokmakidis et al. 2003), we cannot exclude that peripheral 
factors that were not assessed in the current study, such as inflammation and/or 
alterations to muscle metabolism, may have contributed to the ergogenic effect 
of ACT. Moreover, due to the nature of cycling exercise, it is technically 
challenging to directly test cortical alterations via changes to voluntary activation 
using the interpolated twitch technique (Doyle-Baker et al. 2018).  
 
Whilst we have previously investigated the contribution of central and peripheral 
factors to the improved performance following ACT ingestion in a small muscle 
mass model (Morgan et al. 2018), the mechanisms underpinning fatigue 
development, and therefore ACT’s potential ergogenic effect, could differ for 
large muscle mass exercise (Rossman et al. 2012, 2014).  We observed a 
strong correlation between the change in end-exercise EMGRMS and the change 
in power output (e.g., CP) within the last 30 s of the 3-min cycling test (r=0.88) 
following ACT ingestion compared to placebo. However, the change in EMGRMS 
was much larger than the change in CP. Although the mechanisms for this 
effect remain to be defined, this observation is in agreement, with Felippe et al. 
(2018).  Specifically, these authors reported that, compared to placebo, caffeine 
ingestion increased mean power output by ~4% during a 4-km cycling test, 
resulting in a 2% reduction in time to complete the 4-km distance, alongside a 
~17% increase in muscle recruitment (as inferred by EMG). 
 
It is possible that, through lowering pain sensation (Foster et al. 2014; Mauger 
et al. 2010), ACT might have permitted the development of, and/or tolerance to, 
a greater degree of intramuscular metabolic perturbation beyond that required 
to evoke a ‘critical’ threshold of peripheral fatigue, thereby permitting improved 
exercise performance (Blain et al. 2016). Alternatively, since the effects of ACT 
are believed to be largely centrally mediated (Anderson, 2008; Graham et al. 
2013; Smith, 2009; Toussaint et al. 2010), it is possible that ACT ingestion 
attenuated the development of central fatigue. A blunting in central fatigue 
development following ACT ingestion would be expected to permit enhanced 
central motor output, possibly through a reduction in inhibitory feedback via 
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cyclooxygenase inhibition and a resultant decline in the synthesis of 
prostaglandins. 
 
The higher EMGRMS during the latter stages of the 3-min all-out cycling test 
observed following ACT ingestion may also have been a consequence of 
enhanced excitability  of the corticospinal tract (Mauger & Hopker, 2013). 
Greater corticospinal excitability following ACT ingestion, as inferred from a 
greater motor-evoked potential from cortical stimulation in the study of Mauger 
& Hopker (2013), may be linked to enhanced firing of motor units, and 
increased spinal excitability, as has been reported with caffeine consumption 
(e.g., Kalmar & Cafarelli, 2004; Walton et al. 2003). This is particularly pertinent 
as fatigue has been associated with impaired corticospinal excitability (Ross et 
al. 2010). Together, these effects on motor cortical and/or spinal excitability may 
explain the enhanced muscle activation and the subsequent greater amount of 
work performed with ACT ingestion in the current study. However, since cortical 
and peripheral contributions to fatigue development were not directly tested in 
this study, further research is required to resolve the underlying mechanisms for 
the ACT-mediated enhancement in muscle activation and performance during 
maximal exercise, particularly during locomotion which has the most relevance 
to sporting performance.  
 
In conclusion, acute ACT ingestion increased total work done during a 3-min all-
out cycling test in agreement with earlier reports of an ergogenic effect of ACT 
ingestion on cycling performance. The improved performance in the 3-min all-
out test was accompanied by an increase in CP and better preservation of the 
EMG amplitude during the latter stages of the protocol. When the ACT-induced 
increase in CP was used to predict the effects of acute ACT ingestion on cycling 
performance, the estimated 1-3% improvement was in line with previous 
experimental observations. Therefore, our results extend previous reports by 
revealing that ACT ingestion improves performance concomitant with enhanced 
CP and muscle activation during a 3-min all-out cycling test.  These 
observations provide insight into the ergogenic effect of ACT ingestion during 
large muscle mass exercise. 
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ABSTRACT 
Purpose: Acetaminophen (ACT) ingestion has been suggested to improve 
exercise performance by blunting central fatigue development.  Since 
exhaustive single-leg exercise can lower time to task failure (Tlim) during 
subsequent exhaustive exercise in the contralateral limb by exacerbating 
central fatigue development, this study tested the hypothesis that ACT ingestion 
would be more effective at improving Tlim during single-leg exercise completed 
with, compared to without, prior contralateral fatigue. Methods: Fourteen 
recreationally-active men performed constant-load, single-leg, severe-intensity 
knee extensor exercise to exhaustion on the left (Leg1) and right (Leg2) legs 
without prior contralateral fatigue, and on Leg2 immediately following Leg1 (Leg2-
CONTRA).  These tests were all completed following ingestion of 1 g ACT or 
maltodextrin (PL) capsules or no capsule ingestion (CON).  Intramuscular 
phosphorous-containing metabolites (adenosine diphosphate and inorganic 
phosphate) and substrates (phosphocreatine), and muscle activation were 
assessed using 31P-MRS and electromyography, respectively. Results: Tlim 
was not different between the Leg1ACT and Leg1PL conditions (402 ± 101 vs. 390 
± 106 s; P>0.05).  There was also no difference in Tlim between Leg2ACT-CONTRA 
and Leg2PL-CONTRA (324 ± 85 vs. 311 ± 92 s; P>0.05), but Tlim was shorter in both 
these tests compared to Leg2CON (385 ± 104 s; P<0.05).  There were no 
differences in muscle activation, intramuscular phosphorous-containing 
metabolites and substrates or ratings of perceived exertion (RPE) between the 
Leg1ACT and Leg1PL or the Leg2ACT-CONTRA and Leg2PL-CONTRA conditions (P>0.05).  
Conclusion: These findings suggest that acute ACT ingestion does not alter 
RPE, muscle activation and metabolic perturbation, or Tlim during single-leg 
severe-intensity knee extensor exercise completed with or without prior 
exhaustive exercise in the contralateral limb.  
 
Key words: Paracetamol, 31P-magnetic resonance spectroscopy; non-local 
muscle fatigue; muscle activation; muscle metabolic; neuromuscular  
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INTRODUCTION 
The mechanisms of exercise-induced fatigue can be attributed to processes 
within the central nervous system, termed central fatigue, and within the 
contractile elements of the working muscle, termed peripheral fatigue (for 
review Davis & Walsh, 2010, Enoka & Duchateau, 2008; Gandevia, 2001; 
Taylor et al. 2016).  It is now recognised that peripheral and central fatigue 
development are interlinked, in part, via group III/IV muscle afferent feedback.  
Empirical support for a role of group III/IV muscle afferent feedback in 
modulating the mechanisms of neuromuscular fatigue is provided by reports 
that inhibiting group III/IV muscle afferent feedback, via lumbar intrathecal 
administration of fentanyl, lowers central fatigue development and results in 
increased skeletal muscle metabolic perturbation [greater and/or more rapid 
increases in adenosine diphosphate (ADP) and inorganic phosphate (Pi) 
accumulation and declines in phosphocreatine (PCr) and pH] and thus 
peripheral fatigue development (i.e., Amann et al. 2009, 2011; Blain et al. 2016; 
Broxterman et al. 2017a, b, 2018; Sidhu et al. 2014, 2017, 2018).  Conversely, 
whilst the mechanisms for non-local muscle fatigue are not yet entirely 
understood (Halperin et al. 2015 for review), prior fatiguing single-limb exercise 
has been reported to accentuate central fatigue development and lead to lower 
peripheral fatigue development during subsequent fatiguing exercise in a 
contralateral or non-local (previously rested) muscle group, when group III/IV 
muscle afferent feedback would be expected to be elevated (Amann et al. 2013; 
Johnson et al. 2015; Halperin et al. 2014, 2015; Rattey et al. 2006; Sidhu et al. 
2014).  Based on these observations, whilst the locus of fatigue during high-
intensity single-leg exercise is predominantly peripheral (i.e., Burnley et al. 
2012), it is possible that a contralateral limb task may elevate the proportional 
contribution of central fatigue to impaired performance. However, the effect of 
prior fatiguing single-limb exercise on skeletal muscle metabolic perturbation 
during subsequent fatiguing exercise in a contralateral or non-local muscle 
group has yet to be investigated. Moreover, while lumbar intrathecal 
administration of fentanyl and prior fatigue of a contralateral or non-local muscle 
group can alter group III/IV muscle afferent feedback and the physiological 
bases of exercise-induced neuromuscular fatigue, the effect of such 
interventions on exercise performance is equivocal (i.e., Amann et al. 2009, 
Chapter 6: Contralateral fatigue during severe-intensity 
single-leg exercise: influence of acute acetaminophen ingestion 
 
120 
 
2011, 2013; Blain et al. 2016; Broxterman et al. 2017a, b, 2018; Johnson et al. 
2015; Kennedy et al. 2015; Halperin et al. 2014, 2015; Rattey et al. 2006). 
 
There is an emerging body of evidence to suggest that oral ingestion of 
acetaminophen (ACT) can blunt the development of exercise-induced 
neuromuscular fatigue and improve exercise capacity and/or performance 
(Foster et al. 2014; Mauger et al. 2010; Morgan et al. 2018a, b).  It is generally 
accepted that the principal mechanism of action of ACT is the inhibition of 
cyclooxygenase, the enzyme that catalyses the synthesis of prostaglandins 
(Anderson, 2008). Since prostaglandins sensitize nociceptors (Rueff and Dray, 
1993; Schaible et al. 2011), and since blocking cyclooxygenase attenuates 
group III/IV muscle afferent discharge during dynamic exercise (Hayes et al. 
2006), this might account for reports of increased work output for the same level 
of perceived pain and exertion (Foster et al. 2014; Mauger et al. 2010) and 
elevated muscle activation (Morgan et al. 2018a, b) during exercise after ACT 
ingestion.  Therefore, ACT administration might be ergogenic by reducing, but 
not abolishing, the net magnitude of group III/IV muscle afferent feedback, 
leading to a blunting of exercise-induced central fatigue.  and improvement in 
exercise performance. This is particularly pertinent to note given the complex 
intensity and task specific behaviour of group III/IV muscle afferent feedback. 
Specifically, muscle afferent feedback has been shown to inhibit neural drive 
and facilitate cardiopulmonary function during maximal and sub-maximal 
exercise, respectively (i.e., Sidhu et al. 2017). Moreover, since ACT appears to 
attenuate exercise-induced neuromuscular fatigue by abating aspects of central 
fatigue development (Foster et al. 2014; Mauger et al. 2010; Morgan et al. 
2018a, b), ACT might be more effective at lowering exercise-induced 
neuromuscular fatigue following prior exhaustive exercise in a contralateral 
limb, where the locus of fatigue is primarily central (Amann et al. 2013; Johnson 
et al. 2015; Halperin et al. 2014; Rattey et al. 2006), compared to unilateral 
exercise without prior exhaustive exercise in a contralateral limb, where the 
predominant locus of fatigue is more likely to be peripheral (Burnley et al. 2012).  
The effects of ACT ingestion on exercise-induced fatigue development and its 
underlying mechanisms following prior exhaustive exercise in a contralateral 
limb has yet to be investigated.  
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The purpose of this study was to assess the effects of ACT ingestion on 
exercise-induced neuromuscular fatigue and some of its underlying 
mechanisms during single-leg severe-intensity knee extensor exercise 
completed with and without prior exhaustive severe-intensity knee extensor 
exercise in the contralateral limb.  It was hypothesised that: 1) prior exhaustive 
exercise would impair subsequent exercise tolerance in the contralateral limb by 
lowering muscle activation and the degree of muscle metabolic perturbation that 
could be attained; 2) ACT ingestion would enhance single-leg knee extensor 
exercise tolerance by increasing muscle activation (higher surface EMG) and 
permitting the attainment of a greater degree of muscle metabolic perturbation 
[lower muscle pH and PCr concentration ([PCr]) and higher ADP ([ADP]) and Pi 
([Pi]) concentrations]; and 3) ACT ingestion would improve exercise tolerance to 
a greater extent with, compared to without, the completion of prior exhaustive 
exercise by the contralateral limb. 
 
METHODS 
Subjects 
Fourteen active males volunteered to participate in this study (mean ± SD: age 
23.8 ± 4.7 y, height 1.80 ± 0.10 m, body mass 81.6 ± 14.9 kg). All procedures 
were approved by the Ethics Committee of the Department of Sport and Health 
Sciences, University of Exeter. Subjects completed a health questionnaire, 
which was checked by a medical doctor, to ensure it was safe to consume ACT 
prior to performing exhaustive exercise. The questionnaire incorporated 
questions pertaining to: known allergies to medications, current intake of 
medication and prior use of ACT as well as any history of illnesses, cigarette 
and illegal drug use, alcohol consumption and chronic illnesses (personal and 
family history). Prior to each visit, subjects were required to refrain from caffeine 
(for at least 12 h), strenuous exercise and alcohol (for at least 24 h), analgesics 
and any form of anti-inflammatory drug (for the duration of the experimental 
trial) and to arrive in a fully rested, hydrated state. With the exception of these 
restrictions, subjects were instructed to maintain their usual diet and exercise 
regime during the study. All tests were performed at a similar time of day (± 2 
h).  
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Pre-experimental procedures 
Subjects visited the laboratory on twelve occasions over an 8-12 week period to 
complete the experimental testing, with a minimum of 72 h separating all tests 
(figure 6.1).  The experimental testing incorporated 4 pre-experimental trials 
(visits 1-4) and 8 experimental trials (visits 5-12).  Visits 1-4 were completed 
within a replica of an MRI scanner (with no magnetic field present).  Initially, 
subjects completed a single-limb incremental test on the left leg (visit 1, Leg1) 
and right leg (visit 2, Leg2) to exhaustion to establish the limb-specific work 
rates that would be applied in subsequent experimental visits (as described 
below).  Following these preliminary tests, subjects completed a familiarisation 
session on visits 3 and 4 which comprised a single-leg severe-intensity constant 
work rate (CWR) test to exhaustion with the left leg (Leg1), a single-leg severe-
intensity CWR test to exhaustion with the right leg (Leg2), and a crossover limb 
test where the Leg1 exhaustive protocol was repeated and immediately followed 
by the Leg2 exhaustive protocol to assess contralateral fatigue in Leg2.  In these 
preliminary tests, the exhaustive Leg1, Leg2 and Leg2 contralateral protocols 
were interspersed by 10 min of passive recovery to minimise the time burden on 
participants.  
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Figure 6.1. Protocol schematic. Visits 1-4 were completed within a replica of the 
MRI scanner.  Subjects completed a single-limb incremental test on the left leg 
(visit 1, Leg1) and right leg (visit 2, Leg2).  Subjects then completed a 
familiarisation session on visits 3 and 4 which comprised a single-leg severe-
intensity constant work rate (CWR) test to exhaustion with Leg1, Leg2 and a 
crossover limb test where the Leg1 exhaustive protocol was repeated and 
immediately followed by the Leg2 exhaustive protocol.  During visits 5 and 6, 
subjects completed the Leg1 and Leg2 protocols, respectively, without oral 
consumption of any capsules.  On visits 7 and 8, subjects commenced the 
crossover limb test, 45 mins following the consumption of 1 g maltodextrin (PL) 
and 45 mins following the consumption of 1 g ACT. Visits 5-8 were completed 
within the bore of an MRI scanner for assessment of intramuscular 
phosphorous substrates and metabolites and then replicated within a replica of 
the MRI scanner (visits 9-12) to assess muscle electromyography (EMG) and 
ratings of perceived exertion (RPE). The dashed lines represent the limit of 
tolerance (i.e., Tlim) for each limb, respectively. 
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Experimental procedures 
During visits 5 and 6, subjects completed the Leg1 and Leg2 protocols without 
oral consumption of any capsules (Leg1CON and Leg2CON, respectively).  On 
visits 7 and 8, subjects completed the crossover limb tests described above, 45 
mins following the consumption of 1 g maltodextrin (placebo, PL) to determine 
time to task failure (Tlim) values for Leg1 (Leg1PL) and Leg2 contralateral (Leg2PL-
CONTRA), and 45 mins following the consumption of 1 g ACT, to determine Tlim 
values for Leg1 (Leg1ACT) and Leg2 contralateral (Leg2ACT-CONTRA).  PL and ACT 
were administered in the form of 2 identically coloured pills.  The placebo was 
made from maltodextrin powder inserted into gelatine capsules designed to 
have a similar appearance to ACT without inducing any analgesic or antipyretic 
effects. The oral consumption of PL and ACT ~45 min prior to commencing 
exercise was selected to broadly coincide with attainment of the peak plasma 
[ACT], which occurs ~60 min post ACT ingestion (Anderson et al. 2008; Forrest 
et al. 1982), at the onset of the Leg2-CONTRA exhaustive tests.  The PL and ACT 
conditions were administered double-blind in a counterbalanced cross-over 
experimental design.  Visits 5-8 were completed within the bore of an MRI 
scanner for assessment of exercise-induced changes in intramuscular 
phosphorous-containing substrates and metabolites. Visits 5-8 were replicated 
in visits 9-12 within a replica of the MRI scanner (with no magnetic field present) 
to assess muscle electromyography (EMG) and ratings of perceived exertion 
(RPE).   
 
Experimental set-up  
Exercise tests were performed in a prone position within the bore of a 1.5 T 
superconducting magnet (Gyroscan Clinical Intera, Philips, The Netherlands) 
using a custom-built ergometer for the assessment of intra-muscular [PCr], [Pi], 
[ADP] and pH (visits 5-8) or within a replica of the MRI scanner for preliminary 
testing (visits 1-4) and the assessment of EMG and RPE responses (visits 9-
12). Subjects’ feet were fastened securely to padded foot braces using Velcro 
straps and connected to the ergometer load baskets via a rope and pulley 
system. The sprocket arrangement was such that when a bucket containing 
non-magnetic weights was attached, it provided a concentric-only resistive load, 
allowing for the performance of rhythmic knee-extension exercise. Single-leg 
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knee-extensions over a distance of ∼0.22 m were performed continuously at a 
constant frequency which was set in unison with the magnetic pulse sequence 
(40 pulses min−1) to ensure the quadriceps muscle was in the same phase of 
contraction during each magnetic resonance pulse acquisition. To prevent 
displacement of the quadriceps relative to the magnetic resonance 
spectroscopy (MRS) coil, Velcro straps were also fastened over the subject's 
thighs, hips and lower back.  
 
Experimental protocol 
To determine peak work rate (WRpeak) for each leg, subjects initially completed 
single-leg incremental knee-extensor exercise on visits 1 and 2 until they were 
unable to continue the prescribed work rate, as described previously (Vanhatalo 
et al. 2011). The load for the initial increment was 4 kg and this was increased 
by 0.5 kg·min-1 thereafter until Tlim. Tlim was recorded when subjects were 
unable to sustain the required contraction frequency for 3 consecutive 
repetitions. Following these initial tests, subjects were familiarized with the 
different exercise tests that comprised the experimental testing protocol. During 
these visits, a limb-specific, high-intensity work rate (between 85% and 110% 
WRpeak), which was expected to elicit Tlim in approximately 5–8 min, was 
prescribed for each subject.  
 
The experimental exercise protocol consisted of CWR, single-leg knee-
extension exercise (94 ± 7% WRpeak) to Tlim.  Initially, subjects completed single-
leg knee-extension exercise for each limb individually over two separate 
laboratory visits.  Subsequently, to investigate the influence of ACT on 
contralateral limb fatigue, subjects completed single-leg knee-extension 
exercise until exhaustion with Leg1, followed consecutively (<3 s) by the 
identical task with the contralateral limb (i.e., Leg2).  These crossover limb tests 
to assess contralateral fatigue in Leg2 were completed 60 min following the 
consumption of PL and ACT over two separate laboratory visits. For all trials, 
subjects received strong verbal encouragement to continue for as long as 
possible but no feedback was given on the elapsed time.   
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MRS measurements 
31P-MRS data were acquired every 1.5 s with a spectral width of 1,500 Hz and 
1,000 data points. Phase cycling with four phase cycles was used, leading to a 
spectrum being acquired every 6 s. The subsequent spectra were quantified by 
peak fitting, using the AMARES fitting algorithm in the jMRUI (v3) software 
package. Absolute values of [PCr] and [Pi] concentrations were subsequently 
calculated via the ratio of PCr:adenosine triphosphate (ATP) and Pi:ATP 
assuming an ATP concentration of 8.2 mM .  Intracellular pH was calculated 
using the chemical shift of the Pi spectra relative to the PCr peak.  The ADP 
concentration was calculated as described by Kemp et al. (2001). In all cases, 
relative amplitudes were corrected for partial saturation resulting from the short 
repetition time relative to T1 relaxation time, via a spectrum consisting of 24 
averages that was acquired with a TR of 20s prior to the beginning of exercise 
testing. 
 
Electromyography 
Throughout visits 9-12, muscle activity of the right and left m.vastus lateralis 
was recorded using active bipolar bar electrodes with a single differential 
configuration (DE2.1, DelSys Inc, Boston, MA, USA). Initially, the leg was 
shaved and cleaned with alcohol to minimize skin impedance. The electrodes 
were placed over the respective muscle bellies parallel to the longitudinal axis 
of each muscle (SENIAM guidelines). Double-sided adhesive tape and a 
hypoallergenic medical tape were used to ensure the EMG sensor stability. The 
position of the EMG electrodes was measured with respect to the location of the 
patella and the anterior superior iliac spine and marked with indelible ink to 
ensure placement in the same location on subsequent visits. The ground 
electrode was placed over the patella of the respective leg. The EMG signals 
were pre-amplified (1,000x), band-pass filtered (20–450 Hz, Bagnoli-8, DelSys 
Inc, Boston, MA, USA), and then transferred to a computer with a sampling 
frequency of 2 kHz. EMG data were recorded continuously and digitised 
synchronously with 16 bit resolution via an A/D converter (± 5 V range, CED 
1401 power, Cambridge, UK) using Spike2 software (CED, Cambridge, UK). 
During these trials, ratings of perceived exertion (RPE) was measured at 2-min 
intervals from the onset of exercise using Borg’s 6-20 scale (Borg, 1985). 
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Data Analysis 
Baseline values for [PCr], [Pi], [ADP], and pH were defined as the mean values 
measured over the final 60 s of rest (i.e., prior to initiation of the severe-intensity 
exercise bout). Baseline values for Leg2 during the crossover protocol (for both 
PL and ACT) were calculated during the final 60 s of exhaustive Leg1 exercise. 
End-exercise values for these variables were defined as the mean values 
measured over the final 30 s of exercise. The changes (Δ) in [PCr], [Pi], [ADP] 
and pH across the protocol were then calculated as the difference between end-
exercise and baseline values. [PCr], [Pi] and [ADP] were expressed as absolute 
concentrations and as a percentage change relative to resting baseline (i.e. 
100%). The overall rate of change for [PCr], [Pi], [ADP] and pH was calculated 
as the difference between end-exercise and baseline values divided by Tlim. 
EMG was average rectified and normalised to the first 30 s of each trial 
(aEMG).  
 
Statistics 
Differences in Tlim, baseline and end-exercise aEMG and muscle [PCr], [Pi], 
[ADP], and pH  between control limbs (i.e. Leg1 vs. Leg2) were assessed using 
paired samples t-tests. A two-way repeated measures ANOVA (time x 
condition) was employed to test for differences in the profiles of muscle PCr], 
[Pi], [ADP], and pH and aEMG (using 30 s mean values), and RPE (using 120 s 
mean values). Where the ANOVA revealed a significant main or interaction 
effect, post-hoc tests were completed using a Bonferroni correction. For 
calculation of effect size, partial eta squared (η2) was used for omnibus tests. 
Cohen's d was used to calculate the effect size for paired t-tests and post-hoc 
comparisons. Where sphericity was violated, a greenhouse-geisser correction 
factor was used. For all tests, results were considered statistically significant 
when P<0.05. Data are presented as means ± SD unless otherwise indicated. 
All statistical analyses were conducted using IBM SPSS Statistics version 24. 
 
RESULTS 
There was no difference in Tlim during the Leg1CON (396 ± 105 s) and Leg2CON 
(385 ± 104 s) protocols (P>0.05, d=0.10, figure 6.2). Moreover, there were no 
differences in [PCr], [Pi], [ADP], pH (table 6.1, figure 6.3), aEMG amplitude 
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(table 6.2, figure 6.5) and RPE (figure 6.6) between Leg1CON and Leg2CON at any 
time (all P>0.05). Compared to Leg2CON, Tlim was reduced by 19% when Leg2 
was preceded by a CWR test to exhaustion in Leg1 following the consumption 
of PL (Leg2CON: 385 ± 104 s vs. Leg2PL-CONTRA: 311 ± 92 s, P<0.01, d=0.76, 
figure 6.2).  
 
Effect of ACT on single-limb exercise tolerance and contralateral limb fatigue 
There was no difference in Tlim between the Leg1CON (396 ± 105 s), Leg1ACT (402 
± 101 s) and Leg1PL (390 ± 106 s) conditions (P>0.05, η2=0.07, figure 6.2). Both 
Leg2PL-CONTRA and Leg2ACT-CONTRA Tlim were significantly lower compared to 
Leg2CON (P<0.05, η2=0.71, figure 6.2).  However, there was no difference in Tlim 
between Leg2PL-CONTRA and Leg2ACT-CONTRA (311 ± 92 s vs. 324 ± 85 s, 
respectively, d=0.15, P>0.05, figure 6.2).  
 
Figure 6.2. Exercise tolerance (time to exhaustion, s) in Leg1CON, Leg2CON, 
Leg1PL, Leg2PL-CONTRA, Leg1ACT and Leg2ACT-CONTRA conditions.  Data are 
presented as mean ± SD *significantly different from Leg1CON, Leg2CON; Leg1PL 
and Leg1ACT (P<0.05). 
 
Muscle metabolic measurements 
The [PCr], [Pi], [ADP] and pH profiles are illustrated in figure 6.3 for Leg1PL and 
Leg1ACT and in figure 6.4 for Leg2CON, Leg2PL-CONTRA and Leg2ACT-CONTRA, 
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respectively. There were no significant differences in [PCr], [Pi], [ADP] or pH 
measured at any time points between Leg1CON and Leg2CON (P>0.05, table 6.1, 
figure 6.3). Similarly, there were no differences in end-exercise [PCr] (Leg2CON: 
44 ± 8,  Leg2PL-CONTRA: 45 ± 7, Leg2ACT-CONTRA: 44 ± 8%, η2=0.13), [ADP] 
(Leg2CON: 1024 ± 401, Leg2PL-CONTRA: 980 ± 316, Leg2ACT-CONTRA: 978 ± 312%, 
η2=0.09) and pH (Leg2CON: 6.83 ± 0.15, Leg2PL-CONTRA: 6.83 ± 0.20, Leg2ACT-
CONTRA: 6.80 ± 0.15, η2=0.05) between the Leg2CON, Leg2PL-CONTRA and Leg2ACT-
CONTRA conditions (P>0.05, table 6.1, figure 6.4). However, end-exercise [Pi] was 
significantly lower in Leg2PL-CONTRA and Leg2ACT-CONTRA compared to Leg2CON 
(Leg2CON: 588 ± 177, Leg2PL-CONTRA: 459 ± 110, Leg2ACT-CONTRA: 460 ± 109%, 
P=0.04, η2=0.89, table 6.1, figure 6.4). Baseline [PCr] was significantly higher 
(PCr: 100 ± 0 vs. 93 ± 5 vs. 93 ± 4%, P<0.0001, η2=3.04), and [Pi] and [ADP] 
were significantly lower, in Leg2CON when compared to Leg2PL-CONTRA and 
Leg2ACT-CONTRA, respectively (Pi: 100 ± 0  vs. 125 ± 24 vs. 126 ± 23%, P<0.01, 
η2=2.13; ADP: 100 ± 0 vs. 200 ± 78 vs. 201 ± 77%, P<0.01, η2=2.55, table 6.1, 
figure 6.4). The rate of change for [Pi] (0.05 ± 0.01 vs. 0.05 ± 0.02 vs. 0.05 ± 
0.02 mmol/s, P>0.05, η2=0.10), [PCr] (-0.06 ± 0.02 vs. -0.06 ± 0.04 vs. -0.06 ± 
0.03 mmol/s, P>0.05, η2=0.11), [ADP] (0.15 ± 0.09 vs. 0.17 ± 0.10 vs. 0.15 ± 
0.09 µmol/s, P>0.05, η2=0.17) and pH (P>0.05, η2=0.08) was not different 
between the Leg2CON, Leg2PL-CONTRA and Leg2ACT-CONTRA conditions, respectively.  
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Figure 6.3. Intramuscular phosphocreatine concentration ([PCr]; panel A), 
inorganic phosphate concentration ([Pi]; panel B), adenosine diphosphate 
([ADP]; panel C) and pH (panel D) during severe-intensity, single-limb knee-
extensor exercise in the left leg following PL ingestion (Leg1PL, filled circles) and 
ACT (Leg1ACT, clear circles) ingestion. Data are expressed as group mean ± SE. 
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Figure 6.4. Intramuscular phosphocreatine concentration ([PCr]; panel A), 
inorganic phosphate concentration ([Pi]; panel B), adenosine diphosphate 
([ADP]; panel C) and pH (panel D) during severe-intensity, single-limb knee-
extensor exercise in the right control leg (Leg2CON, open triangles) and in the 
right leg following prior exhaustive exercise in the left leg after PL ingestion 
(Leg2PL-CONTRA, filled circles) and ACT (Leg2ACT-CONTRA, clear circles) ingestion.  
Data are expressed as group mean ± SE. *Tlim significantly different from 
Leg2PL-CONTRA and Leg2ACT-CONTRA (P<0.05); #significantly different from Leg2PL-
CONTRA and Leg2ACT-CONTRA (P<0.05). 
 
Electromyography (n=10) 
aEMG amplitude of m. vastus lateralis rose significantly from the first minute of 
exercise to end-exercise in all conditions (figure 6.5; P<0.01, η2=3.8). However, 
there were no differences in aEMG between Leg1CON, Leg1PL and Leg1ACT at Tlim 
(Leg1CON: 229 ± 54, Leg1PL: 224 ± 43, Leg1ACT: 238 ± 51%, P=0.69, η2=0.09, 
table 6.2, figure 6.5). End-exercise aEMG in Leg2CON was also similar to Leg2PL-
CONTRA and Leg2ACT-CONTRA, respectively (Leg2CON: 234 ± 52, Leg2PL-CONTRA: 226 ± 
58, Leg2ACT-CONTRA: 242 ± 52%, P=0.69, η2=0.20, table 6.2, figure 6.5). However, 
absolute aEMG was elevated at the start of Leg2PL-CONTRA and Leg2ACT-CONTRA 
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exercise when compared to Leg2CON (Leg2CON: 0.04 ± 0.02, Leg2PL-CONTRA: 0.05 ± 
0.02, Leg1ACT-CONTRA: 0.05 ± 0.02 mV, P<0.05, η2=0.58, table 6.2, figure 6.5). 
 
 
Figure 6.5. Surface electromyography (EMG) of the m.vastus lateralis muscle 
during severe-intensity, single-limb knee-extensor exercise in Leg1PL (filled 
circles) and Leg1ACT (clear circles) (panel A), and in the right control leg 
(Leg2CON, open triangles), and in Leg2 following prior exhaustive exercise in 
Leg1 after PL (Leg2PL-CONTRA, filled circles) and ACT (Leg2ACT-CONTRA, clear circles) 
ingestion (panel B). Mean values for average rectified EMG (aEMG) during 
each muscle contraction were calculated and averaged over each 30-s period. 
Data are expressed as group mean ± SE relative to the first 30 s of each trial. 
*Tlim significantly different from Leg2PL-CONTRA and Leg2ACT-CONTRA (P<0.05). 
 
Ratings of perceived exertion 
RPE increased in all trials following the onset of exercise (figure 6.6). However, 
despite the prior ingestion of ACT, there were no differences in reported RPE 
between Leg1CON, Leg1PL and Leg1ACT at any time point (P>0.05, η2=0.08, figure 
6.6). The rate of rise and end-exercise RPE was also similar during the Leg2CON 
trial compared with the Leg2PL-CONTRA and Leg2ACT-CONTRA trials (P>0.05, 
η2=0.18). However, at the onset of exercise, RPE was significantly higher in 
Leg2PL-CONTRA and Leg2ACT-CONTRA when compared to Leg2CON (P<0.05, η2=0.55, 
figure 6.6). Specifically, during the first 2 min of exercise, there was a 14% and 
13% elevation in RPE in Leg2PL-CONTRA and Leg2ACT-CONTRA, respectively, 
compared to Leg2CON (P<0.05). There were no differences in RPE at any time 
points between Leg2PL-CONTRA and Leg2ACT-CONTRA (P>0.05, η2=0.21, figure 6.6).  
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Figure 6.6. Ratings of perceived exertion (RPE) during severe-intensity, single-
limb knee-extensor exercise of the left leg in Leg1PL (filled circles) and Leg1ACT 
(clear circles) (panel A), in the right control leg (Leg2CON, open triangles), and in 
the right leg following prior exhaustive exercise in the left leg after PL ingestion 
(Leg2PL-CONTRA, filled circles) and ACT (Leg2ACT-CONTRA, clear circles) ingestion 
(panel B). Data are expressed as group mean ± SE. *Tlim significantly different 
from Leg2PL-CONTRA and Leg2ACT-CONTRA (P<0.05); #RPE significantly different from 
Leg2CON (P<0.05). 
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Table 6.1. Muscle metabolic responses in Leg1CON, Leg1PL, Leg1ACT, Leg2CON, Leg2PL-CONTRA and Leg2ACT-CONTRA conditions. 
 Leg1CON Leg1PL Leg1ACT Leg2CON Leg2PL-CONTRA Leg2ACT-CONTRA 
Muscle metabolic response       
[PCr]       
Baseline PCr (%) 100 ± 0 100 ± 0 100 ± 0 100 ± 0 92 ± 5* 93 ± 4* 
PCr at 120 s (%) 70 ± 8 70 ± 8 71 ± 47 71 ± 8 62 ± 9* 63 ± 7* 
End-exercise PCr (%) 42 ± 9 41 ± 9 41 ± 8 44 ± 8 45 ± 7 44 ± 8 
Rate of change PCr (mmol/s) -0.06 ± 0.01 -0.06 ± 0.03 -0.06 ± 0.02 -0.05 ± 0.03 -0.06 ± 0.04 -0.06 ± 0.03 
       
[Pi]       
Baseline Pi (%) 100 ± 0 100 ± 0 100 ± 0 100 ± 0 125 ± 24* 126 ± 23* 
Pi at 120 s (%) 310 ± 66 313 ± 71 306 ± 62 312 ± 66 316 ± 70 318 ± 64 
End-exercise Pi (%) 590 ± 149 590 ± 137 594 ± 156 588 ± 177 459 ± 110* 460 ± 109* 
Rate of change Pi (mmol/s) 0.05 ± 0.02 0.05 ± 0.02 0.05 ± 0.02 0.05 ± 0.02 0.05 ± 0.02 0.05 ± 0.02 
       
[ADP]       
Baseline ADP (%) 100 ± 0 100 ± 0 100 ± 0 100 ± 0 200 ± 78* 201 ± 77* 
ADP at 120 s (%) 404 ± 161 415 ± 183 400 ± 148 412 ± 170 538 ± 176 516 ± 154* 
End-exercise ADP (%) 1028 ± 386 1036 ± 421 1046 ± 409 1024 ± 401 980 ± 316 978 ± 312 
Rate of change ADP (µmol/s) 0.15 ± 0.08 0.15 ± 0.09 0.14 ± 0.07 0.15 ± 0.09 0.17 ± 0.10 0.15 ± 0.09 
       
pH       
Baseline pH 7.04 ± 0.01 7.03 ± 0.02 7.05 ± 0.04 7.04 ± 0.03 7.04 ± 0.03 7.05 ± 0.02 
pH at 120 s 6.96 ± 0.09 6.94 ± 0.07 6.92 ± 0.08 6.95 ± 0.08 6.93 ± 0.10 6.94 ± 0.08 
End-exercise pH 6.77 ± 0.18 6.76 ± 0.15 6.76 ± 0.16 6.83 ± 0.15 6.83 ± 0.20 6.80 ± 0.15 
       
PL, placebo; ACT, acetaminophen; EMG, electromyography; PCr, Phosphocreatine; Pi, Inorganic Phosphate; ADP, Adenosine 
diphosphate; *significantly different from Leg2CON,, P<0.05 
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Table 6.2. Electromyography (EMG) responses of m. vastus lateralis in Leg1CON, Leg1PL, Leg1ACT, Leg2CON, Leg2PL-CONTRA and 
Leg2ACT-CONTRA conditions.  
 Leg1CON Leg1PL Leg1ACT Leg2CON Leg2PL-
CONTRALATERAL 
Leg2ACT-
CONTRALATERAL 
       
Neuromuscular function       
Baseline EMGRMS 
amplitude (mV) 
 
0.04 ± 0.01  0.04 ± 0.02 0.04 ± 0.02 0.04 ± 0.02 0.05 ± 0.02* 0.05 ± 0.02* 
End-exercise EMGRMS 
amplitude (%) 
 
229 ± 54 224 ± 43 238 ± 51 234 ± 52 226 ± 58 242 ± 52 
EMGRMS amplitude at 120 s 
(%) 
150 ± 27  160 ± 25 166 ± 26 158 ± 29 155 ± 32 158 ± 34 
       
PL, placebo; ACT, acetaminophen; EMG, electromyography; RMS, root mean square; *significantly different from Leg2CON, P<0.05. 
Data are from 10 subjects. 
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DISCUSSION 
The principal original finding of this study was that, while time to task failure was 
shorter during severe-intensity single-leg knee extensor exercise after the 
completion of prior fatiguing exercise in the contralateral limb, this effect was 
not mitigated by acute ACT ingestion. Moreover, there was no difference in the 
rates of change and end-exercise values for skeletal muscle activation (via 
EMG), metabolic perturbation (via 31P-MRS) and perceived exertion (via RPE) 
during exercise after prior contralateral leg fatigue following ACT and PL 
ingestion.  There were also no differences in time to task failure (Tlim), skeletal 
muscle activation, metabolic perturbation and RPE during single-leg exercise 
without the completion of prior fatiguing exercise in the contralateral limb 
following ACT and PL ingestion.  These findings do not support our 
experimental hypotheses and suggest that acute 1 g ACT ingestion does not 
improve time to task failure, skeletal muscle activation, metabolic perturbation 
or RPE during single-leg severe-intensity knee extensor exercise completed 
with or without prior fatiguing exercise by the contralateral limb.  Collectively, 
these results contribute to our understanding of fatigue development during 
exercise, performed with or without prior contralateral limb exercise, and in the 
presence or absence of analgesia elicited by ACT ingestion.  
 
In the present study, Tlim in the Leg2PL-CONTRA protocol was shorter than the 
Leg2CON protocol, indicative of an earlier task failure after completing exhaustive 
exercise in the contralateral limb compared to no prior fatiguing contralateral 
limb exercise.  This observation is consistent with some (i.e., Amann et al. 
2013; Doix et al. 2013; Halperin et al. 2014; Halperin et al. 2014; Kennedy et al. 
2013; Rattey et al. 2006; Takahashi et al. 2011), but not all (i.e., Elmer et al. 
2013; Grabiner & Owings, 1999; Regueme et al. 2007; Todd et al. 2003; 
Zijdewind et al. 1998), previous studies reporting greater fatigue development 
after prior contralateral or non-local muscle fatigue.  While the neuromuscular 
bases of contralateral fatigue development have yet to be resolved, there is 
evidence to suggest that greater central fatigue makes an important contribution 
to this phenomenon (Amann et al. 2013).  In the current study, RPE was higher 
at baseline and over the initial stages of the Leg2PL-CONTRA test compared to the 
Leg2CON test, leading to an earlier attainment of peak RPE and Tlim, consistent 
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with previous observations (i.e., Amann et al. 2013) and the notion that afferent 
feedback may contribute to increased pain and effort sensation (Amann et al. 
2011; Gagnon et al. 2012).  Amann and colleagues (2013) also previously 
reported a lower EMG response at task failure and reduced peripheral fatigue 
development after prior contralateral leg fatigue.  Although the EMG amplitude 
was not different at task failure in the current study between the Leg2CON and 
Leg2PL-CONTRA tests, baseline EMG was elevated in the Leg2PL-CONTRA condition, 
presumably due to isometric stabilisation, leading to the earlier attainment of the 
same peak EMG amplitude.  The greater muscle activation in the non-
exercising contralateral limb during the baseline ‘resting’ period in the Leg2PL-
CONTRA condition was accompanied by lower muscle [PCr], and higher muscle 
[Pi] and [ADP] compared to the Leg2CON condition.  Since there were no 
differences in muscle [PCr] and [ADP] at Tlim, and since the rates of change in 
[PCr] and [ADP] were not different between the Leg2CON and Leg2PL-CONTRA tests, 
the muscle [PCr] nadir and [ADP] peak were attained earlier in the Leg2PL-CONTRA 
test.  These observations cohere with reports that the end-exercise values of 
muscle [PCr], [ADP] and pH are consistent both when several bouts of 
exhaustive exercise of differing duration are completed within the severe-
intensity domain (Vanhatalo et al. 2010) and when Tlim is altered via prior 
passive heating of the legs (Bailey et al. 2012) or by hyperoxic gas inhalation 
(Black et al. 2017; Vanhatalo et al. 2010).  Interestingly, however, and despite a 
higher baseline muscle [Pi] in the Leg2PL-CONTRA condition compared to the 
Leg2CON condition, muscle [Pi] was lower at the point of task failure in the 
Leg2PL-CONTRA test.  These novel observations suggest that the ergolytic effect of 
prior contralateral fatigue may be related, at least in part, to a limitation in the 
attainment of peak intramuscular [Pi].   
 
It is unclear why prior contralateral limb fatigue limited the attainment of peak 
[Pi] in the Leg2PL-CONTRA condition compared to the Leg2CON condition, whereas 
the peak [ADP] and the nadir in pH and [PCr] were not different between these 
conditions.  However, our observations of a limited peak perturbation of muscle 
[Pi], but not pH, [PCr] and [ADP], when group III/IV muscle afferent feedback 
would be expected to be enhanced via prior contralateral fatigue (Amann et al. 
2013), are in accord with  studies from another group who observed greater 
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peak perturbation of muscle [Pi], but not pH, [PCr] and [ADP], when muscle 
group III/IV afferent feedback was abolished via lumbar intrathecal 
administration of fentanyl (Blain et al. 2016; Broxterman et al. 2017b, 2018).  
Taken together, these complementary observations suggest that intramuscular 
phosphorous-containing metabolites and substrates do not respond in a uniform 
manner to manipulations in skeletal group III/IV muscle afferent feedback and 
that muscle [Pi] might be a more sensitive marker of muscle afferent feedback 
and peripheral fatigue development.  However, it should be acknowledged that, 
since inter-test variability is greater for contracting skeletal muscle [Pi] than for 
pH, [PCr] and [ADP] (Edwards et al. 2012), further research is required to verify 
these observations as this variation may explain these differences.  
 
Although the completion of prior single-leg fatiguing exercise lowered Tlim during 
subsequent exercise in the contralateral limb in the current study, there were no 
differences between the Leg2ACT-CONTRA and Leg2PL-CONTRA conditions in Tlim, 
RPE, or muscle activation and phosphorous-containing metabolites and 
substrates.  Similarly, and also in contrast to our hypothesis, acute ACT 
ingestion did not alter Tlim, RPE, or muscle activation, pH, [PCr], [ADP] or [Pi], 
during single-leg severe-intensity knee extensor exercise completed without 
prior fatiguing exercise in the contralateral limb, with these responses being 
similar between the Leg1CON, Leg1PL and Leg1ACT conditions.  These findings 
conflict with reports that acute ACT consumption can improve exercise 
performance by increasing pain tolerance (Foster et al. 2014; Mauger et al. 
2010) and muscle activation (Morgan et al. 2018a, b).  The lack of an ergogenic 
effect of ACT administration in the current study might be due to differences in 
the ACT administration procedure compared to previous studies reporting 
improved performance and delayed neuromuscular fatigue development (Foster 
et al. 2014; Mauger et al. 2010; Morgan et al. 2018a, b).  In the present study, 
ACT was ingested 45 min prior to the start of the Leg1ACT test, which 
immediately transitioned into the Leg2ACT-CONTRA protocol that was the primary 
focus of the current study.  Since peak plasma [ACT] is attained ~60 min post 
oral ACT ingestion (Anderson et al. 2008; Forrest et al. 1982), we elected to 
administer ACT in the current study such that peak plasma [ACT] was expected 
to coincide with the onset of the Leg2ACT-CONTRA protocol rather than the Leg1ACT 
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protocol.  This might account for the lack of an ergogenic effect of ACT during 
the Leg1ACT protocol compared to other studies that administered ACT 60 min 
prior to the performance trial (Foster et al. 2014; Mauger et al. 2010; Morgan et 
al. 2018a, b).  Therefore, we cannot exclude the possibility that earlier ACT 
ingestion (Foster et al. 2016), at the same or a greater dose (Foster et al. 2014; 
Mauger et al. 2010), might have resulted in improved single-leg severe-intensity 
exercise tolerance. However, it should also be noted that differences between 
participants (i.e., training status, familiarity with the exercise task, different 
responses to analgesic medication) may have also contributed to the lack of 
ergogenic effect observed. Future research should continue to explore these 
potential explanations. 
 
In addition to differences in the ACT dosing procedure, the lack of an ergogenic 
effect of ACT administration in the current study might be linked to the nature of 
the fatiguing exercise test administered.  In the present study, subjects 
completed continuous single-leg severe-intensity (~95% WRpeak) knee extensor 
exercise until task failure with no pre-determined end point (i.e., an ‘open loop’ 
exercise test).  This differs from situations in which ACT ingestion has been 
reported to be ergogenic, such as completion of a fixed distance (16.1-km) time-
trial (Mauger et al. 2010), a fixed number of maximal effort repetitions (Foster et 
al. 2014; Morgan et al. 2018a), or a fixed duration of maximal effort (Morgan et 
al. 2018b), all of which have a predetermined end point (i.e., a ‘closed loop’ 
exercise task).  Moreover, since exercise-induced pain sensation is positively 
associated with exercise intensity (Astokorki & Mauger, 2017; Cook et al. 1997), 
and since ACT ingestion is suggested to be ergogenic by mitigating pain 
sensation (Foster et al. 2014; Mauger et al. 2010), this might account for the 
improved exercise performance reported during maximal-intensity exercise 
following ACT ingestion (Foster et al. 2014; Morgan et al. 2018a, b), and the 
lack of improvement in performance in the longer duration, continuous severe-
intensity exercise test employed in the current study.  With regard to 
contralateral fatigue development, we cannot exclude the possibility that ACT 
might have been effective at attenuating the effects of prior single-leg fatigue on 
Tlim during subsequent exercise had a greater degree of contralateral fatigue 
been attained.  For example, Tlim was lowered by 19% in Leg2PL-CONTRA 
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compared to Leg2CON in the current study, whereas Amann and colleagues 
(2013) reported a much larger (49%) reduction in Tlim following contralateral 
limb fatigue, which would have provided greater scope for an ergogenic effect 
with ACT ingestion.  Moreover, since RPE is higher and Tlim is shorter at the 
same relative exercise intensity when a larger muscle mass is recruited 
(Rossman et al. 2012), it is possible that ACT ingestion might have improved 
Tlim during exercise after prior fatigue had a larger muscle mass been recruited 
in either the initial or the subsequent fatiguing exercise task.  Further research 
is required to assess the exercise settings in which ACT administration is more 
or less likely to be ergogenic (and its mechanistic underpinnings). 
 
In conclusion, the completion of prior single-leg fatiguing exercise compromised 
exercise tolerance during subsequent exercise in the contralateral leg.  This 
ergolytic effect of prior contralateral limb fatigue was accompanied by elevated 
RPE, muscle activation and [ADP], and lower [PCr], at baseline leading to the 
earlier attainment of peak (RPE, muscle activation and [ADP]) or nadir (muscle 
[PCr]) values in these variables, and the attainment of a submaximal end-
exercise [Pi].  However, acute ACT ingestion was not effective at lowering RPE, 
increasing muscle activation or intramuscular perturbation or enhancing Tlim 
during single-leg severe-intensity exercise completed with or without prior 
fatigue in the contralateral leg.  These findings do not support an ergogenic 
effect of analgesia, at least using the ACT administration and exercise testing 
procedures employed in the current study. 
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ABSTRACT  
Purpose: Recent research suggests that acute consumption of 
pharmacological analgesics can improve exercise performance, but the 
ergogenic potential of ibuprofen (IBP) administration is poorly understood. This 
study tested the hypothesis that IBP administration would enhance maximal 
exercise performance. Methods: In one study, 13 physically active males 
completed 60 × 3-s maximum voluntary contractions (MVC) of the knee 
extensors interspersed with a 2-s passive recovery period, on two occasions, 
with the critical torque (CT) estimated as the mean torque over the last 12 
contractions (part A). In another study, 16 active males completed two 3-min all-
out tests against a fixed resistance on an  electrically-braked cycle ergometer 
with the critical power (CP) estimated from the mean power output over the final 
30-s of the test (part B). All tests were completed 60 min after ingesting 
maltodextrin (placebo, PL) or 400 mg of IBP. Peripheral nerve stimulation was 
administered at regular intervals and electromyography was measured 
throughout. Results: For part A, mean torque (IBP: 60 ± 12 vs. PL: 58 ± 14% of 
pre-exercise MVC) and CT (IBP: 41 ± 16 vs. PL: 40 ± 15% of pre-exercise 
MVC) were not different between conditions (P>0.05). For part B, end-test 
power output (IBP: 292 ± 28 W vs PL: 288 ± 31 W) and work done (IBP: 65.9 ± 
5.9kJ vs PL: 65.4 ± 6.4kJ) during the 3-min all-out cycling tests were not 
different between conditions (all P>0.05). For both studies, neuromuscular 
fatigue declined at a similar rate in both conditions (P>0.05). Conclusion: 
Acute ingestion of 400 mg IBP does not improve single-leg or maximal cycling 
performance in healthy humans.  
 
Key words: Electromyography; neuromuscular fatigue; non-steroidal anti-
inflammatory drugs; single leg exercise; whole-body cycling exercise
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INTRODUCTION 
Ibuprofen (IBP), a non-steroidal anti-inflammatory drug (NSAID) predominantly 
used to treat pain and reduce inflammation and fever, is considered safe for oral 
ingestion within healthy populations at the standard therapeutic dose (Albert & 
Gernaat, 1984; García-Martín et al. 2004). Consequently, utilisation of analgesic 
(e.g., pain relieving) and anti-inflammatory medication, such as IBP, has 
emerged as a popular pre-competition strategy amongst elite athletes 
attempting to enhance athletic performance (Alaranta et al. 2008; Corrigan & 
Kazlauskas, 2003; Da Silva et al. 2015; Gorski et al. 2011; Huang et al. 2006). It 
is believed that NSAIDs act centrally and peripherally to reduce the perception 
of pain and tissue inflammation, respectively (Fridén & Lieber, 1992). The 
therapeutic effect of NSAIDs in treating inflammation and pain has largely been 
ascribed to inhibited synthesis of prostaglandins (e.g., PGE2, Fridén & Lieber, 
1992). Specifically, IBP limits the metabolism of arachidonic acid, a precursor 
for the synthesis of prostaglandins, by inhibiting the enzyme, cyclooxygenase 
(Albert & Gernaat, 1984).   
  
Following the onset of muscle contractions, changes in contraction-induced 
mechanical stimuli and noxious chemicals (including an increased PGE2 
release) activate and/or sensitise molecular receptors located on the terminal 
end of group III and IV nerve fibers, contributing to an increased sensation of 
muscle pain during exercise (McCord & Kaufman, 2010; O’Connor & Cook, 
1999; Pollak et al. 2014). The activation of these receptors appears to play a 
role in neuromuscular fatigue development through modulating both central and 
peripheral fatigue. Indeed, when the ascending projection of group III and IV 
muscle afferents is attenuated via intrathecal fentanyl administration, central 
motor drive is increased (as inferred via electromyography, EMG) and 
peripheral fatigue development is expedited (Amann et al. 2009, 2011; Blain et 
al. 2016).  Therefore, it is possible that an intervention that is able to reduce the 
magnitude of afferent feedback, such as NSAID administration, may attenuate 
the decline in skeletal muscle activation during intense exercise and thus 
improve exercise performance (Amann & Calbet, 2008; Morgan et al. 2018a; 
Morgan et al. 2018b). Indeed, elevating the magnitude of muscle afferent 
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feedback is known to impair endurance exercise capacity (e.g., Amann et al. 
2013). 
 
Acute consumption of analgesics (e.g., acetaminophen, ACT) has been shown 
to improve exercise performance (Foster et al. 2014; Mauger et al. 2010; 
Morgan et al 2018a; Morgan et al. 2018b). Mauger et al. (2010) administered an 
acute dose of 1.5 g ACT to trained cyclists and reported a 2% improvement in 
16.1-km time-trial (TT) performance. Moreover, an acute dose of ACT has been 
shown to improve exercise tolerance in the heat (Mauger et al. 2014), repeated 
sprint performance (Foster et al. 2014), repeated maximal voluntary contraction 
(MVC) performance of the knee extensors (Morgan et al. 2018a) and maximal 
cycling performance (Morgan et al. 2018b). However, while these studies 
suggest that oral administration of a commercially-available pharmaceutical 
analgesic can delay fatigue development and improve exercise performance 
(Foster et al. 2014; Mauger et al. 2010; Morgan et al 2018a, b), the ergogenic 
effects of IBP are unclear despite widespread use of IBP as a putative 
performance aid (Cleak, & Eston. 1992; Nosaka & Clarkson, 1996). 
 
In contrast to the effects of ACT consumption on exercise performance, there is 
currently very limited published research on NSAID and NSAID-like compounds 
during exercise when muscle damage is not present. Despite the prevalence of 
its use amongst athletic populations, it is unclear whether IBP will provide an 
ergogenic benefit to performance in a ‘fresh’ state. Other NSAID-like 
compounds have elicited no ergogenic effect on endurance performance (e.g., 
aspirin, Cook et al. 1997; ginger, Black & O’Connor, 2008). In contrast, 
enhanced aerobic exercise performance following caffeine ingestion has been 
related, at least in part, to altered pain perception and enhanced endurance 
performance (e.g., Gonglach et al. 2016). In addition, whilst exercise has been 
shown to increase PGE2 release (Trappe et al. 2001; Nowak & Wennmalm, 
1978; Wilson & Kapoor, 1993; Viinikka et al. 1984), the extent to which it plays 
an important role, especially following interventions aimed at reducing PGE2 
synthesis, during endurance exercise in the absence of muscle damage is 
unclear.  
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The purpose of this study was to test the hypotheses that, compared to a 
placebo, acute consumption of 400 mg IBP would increase total work done, and 
reduce the rate of fatigue development by enabling a better maintenance of 
muscle activation during exercise. Two studies are presented using two 
different types of exercise: a 5-min single-leg intermittent MVC test and a 3-min 
maximal whole body cycling test to provide a more comprehensive 
understanding of the ergogenic potential of IBP.  
 
METHODS  
Participants 
Two independent groups of thirteen recreationally-active males (mean  ±  SD: 
age 31  ±  7 years, height 1.76  ±  0.08 m, body mass 75  ±  11 kg), and sixteen 
recreationally-active males (mean  ±  SD: age 29  ±  9 years, height 1.79  ±  
0.07 m, body mass 77  ±  8 kg, V̇O2peak 60.8  ±  7.8 ml·kg-1·min-1), volunteered 
for the first (A) and second (B) part of this study, respectively. All participants 
provided written, informed consent to participate in this study, which was 
approved by the Sport and Health Sciences Ethics Committee at the University 
of Exeter. After being informed of the experimental procedures and associated 
risks, all participants completed a medical health questionnaire to ensure it was 
safe for them to consume IBP prior to performing exhaustive exercise, due to 
the potential contraindications associated with IBP ingestion. Participants were 
not consumers of any ‘pain relief’ or anti-inflammatory medication (prescription 
or non-prescription) over the course of the study. None of the participants had a 
history of motor or neurological disorders. Participants were instructed to arrive 
at the laboratory in a rested and fully hydrated state, at least 3 h post-prandial, 
and to avoid strenuous exercise and refrain from consuming caffeine and 
alcohol in the 24 h preceding each testing session. Participants were also 
instructed to consume their habitual diet and continue normal training activities 
for the experimental period. For part A and B, participants recorded their diet 
and physical activity for 7 d prior to the first experimental visit and then 
replicated this for all remaining experimental visits, respectively.   
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Experimental Design 
Both protocols (part A and B) followed identical experimental designs to 
previous research conducted within our laboratory (Morgan et al. 2018a, 
2018b). For part A (Morgan et al. 2018a), participants visited the laboratory on 
three occasions over a 3-4 week period with tests being conducted on an 
isokinetic dynamometer (Biodex System 3, Shirley, NY, USA). For part B 
(Morgan et al. 2018b), participants visited the laboratory on five occasions over 
a 5-6 week period and tests were conducted on an electronically braked cycle 
ergometer (Lode Excalibur Sport, Groningen, the Netherlands). Experimental 
tests were separated by at least 7, but no more than 9, days (part A) and for at 
least 72 h (part B), and were completed at a similar time of day (± 90 mins). The 
first laboratory visits for each study were used to familiarise participants to the 
measurements and experimental protocols described below. Subsequently, 
participants performed the fatiguing protocol (s) under two conditions (see 
‘Experimental Protocol’): placebo (PL) and IBP.  
 
Experimental Protocol A (60 MVC protocol) 
The isokinetic dynamometer was initially adjusted so that the axis of rotation of 
the lever arm was in line with the lateral epicondyle of the right femur. 
Participants were seated with the hip and knee joints at relative angles of 155° 
and 90°, respectively. The remainder of the chair settings were recorded (during 
familiarisation) and replicated in all subsequent tests to ensure identical body 
position throughout the experimental trials. Inelastic padded Velcro straps were 
fastened at the ankle, quadriceps, hip and shoulders to maintain a stable body 
position.  
 
Following the familiarisation trial, visits 2 and 3 were completed in a double-
blind, randomised fashion using a cross-over experimental design. 1000 mg of 
maltodextrin (placebo, PL) or 400 mg IBP (combined with 600 mg maltodextrin) 
was ingested orally, 60 minutes prior to the exercise bout such that the start of 
the exercise trial was expected to coincide with peak plasma [ibuprofen] 
concentration (Janssen & Venema, 1985). For IBP, 2 identical capsules 
containing 200 mg ibuprofen and 300 mg maltodextrin each were ingested. The 
placebo was made from dextrose powder inserted into 2 gelatine capsules (500 
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mg in each capsule) designed to have a similar appearance and the weight to 
IBP capsules. The trials started with a standardised isometric warm-up routine 
(10 isometric contractions for 3 s at 50% of pre-exercise MVC as measured 
during familiarisation testing) and testing of the optimal EMG electrode, anode, 
and cathode placement and stimulation intensity for peripheral nerve 
stimulation. The experimental protocol consisted of 60 brief MVCs (3 s 
contraction, 2 s rest), in response to a visual prompt to ‘go’ and ‘relax’, 
accompanied by the same verbal instructions from the experimenter. Every 6th 
contraction was accompanied by peripheral nerve stimulation during and 1 s 
post MVC (as described for pre-trial measurements below). Participants were 
not made aware of the time or the number of MVCs that had elapsed during the 
protocol and were instructed to continue to perform maximal contractions 
throughout. 
 
Experimental protocol B (3-min cycling test) 
For the 3-min cycling protocol, participants initially completed an incremental 
ramp test to exhaustion for the determination of gas exchange threshold (GET), 
linear factor, peak aerobic power output and peak oxygen uptake V̇O2peak as 
previously described (Black et al. 2014; Morgan et al. 2018b). The fixed 
resistance for the 3-min cycling protocol was set using the linear mode (e.g., 
linear factor) of the ergometer such that on reaching their preferred cadence, 
the participants would achieve a power output equivalent to 50% of the 
difference between GET and V̇O2peak (linear factor = 50%∆ peak aerobic power 
output/preferred cadence2). During this visit, the seat and handlebar positions 
were adjusted for comfort and replicated for all tests. During the second and 
third laboratory visits, participants completed a 3-min all-out test with these 
serving as familiarization trials to the experimental protocol as described below 
and to ensure the coefficient of variation for work done and critical power (CP) 
between visits was <1%. Participants then performed the 3-min all-out cycling 
test under two conditions: placebo (PL) and IBP.  
 
The experimental protocol consisted of a 3-min period of unloaded pedalling at 
each participant’s preferred cadence (85-100 rpm), followed by a 3-min all-out 
sprint, 60 min following ingestion of either placebo (1000 mg maltodextrin) or 
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400 mg of IBP. The order of trials on visits 4 and 5 were administered in a 
double-blind, randomised fashion using a cross-over experimental design. The 
3-min all-out cycling protocol used in this study replicated the procedures 
described previously by Vanhatalo et al. (2007, 2008).  
 
Neuromuscular function (Parts A and B) 
For part A and B, neuromuscular function was assessed pre-, during- and post-
trial (< 10 s). Single peripheral nerve stimulation pulses were manually triggered 
at rest to determine pre-exercise neuromuscular function, namely the 
characteristics of the M-wave response (M-wave amplitude; Mmax) to supra-
maximal nerve stimulation, voluntary activation (for part A only) and potentiated 
twitch torque (pTw, for part A only). During MVCs, peripheral nerve stimulation 
pulses were triggered to occur as soon as a peak torque was achieved (typically 
1.5 s into a 3 s contraction) and were each separated by a 45 s rest period. The 
stimuli were also delivered 1-s after the cessation of the contraction to provide a 
resting pTw. Identical measurements were repeated as soon as possible (< 
10s) after the fatiguing exercise to determine post-exercise neuromuscular 
function (see figure 7.1).  
 
 
 
 
Chapter 7: Acute ibuprofen ingestion does not attenuate fatigue 
during maximal intermittent knee extensor or all-out cycling exercise 
 
149 
 
 
Figure 7.1. Schematic of the procedures used prior to (panel a), during (panel 
b) and within 10 s following (panel c) the 60 maximal isometric voluntary 
contraction (MVC) protocol (part A). 10 s separated each single pulse 
stimulation administered at rest (small dashed arrows). A, C 45 s rest period 
separated maximal efforts (MVCs). Single pulse stimuli were administered 
during peak force production of MVCs (large solid arrow) and immediately (<1-
s) post MVCs (small grey arrows). B: 60 MVC protocol of the knee extensors. 
The figure presents a period of 30 s which is repeated sequentially for 5 min. 
Each MVC was held for 3 s and interspersed by a 2 s passive recovery period. 
Every 6th MVC was accompanied by single pulse stimuli administered during 
peak force production (large solid arrow) and immediately following (<1-s) post 
MVCs (small grey arrows). This cycle was repeated 10 times such that the 
protocol spanned 5 minutes requiring the completion of 60 MVCs. Surface 
electromyography (EMG) was measured throughout.  
 
Torque (Part A) 
For part A, knee-extensor torque from the Biodex isokinetic dynamometer was 
sampled at 1000 Hz and low-pass filtered at 40 Hz, before being displayed on a 
Chapter 7: Acute ibuprofen ingestion does not attenuate fatigue 
during maximal intermittent knee extensor or all-out cycling exercise 
 
150 
 
wide screen monitor using Spike2 (CED, Cambridge, UK).  Torque was 
expressed throughout as a percentage (%) of initial pre-exercise MVC. 
 
Breath-by-breath pulmonary gas exchange (Part B) 
For the 3-min maximal cycling protocol, participants wore a face mask 
connected to an impeller turbine transducer assembly (Cortex Metalyzer, 
Cortex, Leipzig, Germany). Inspired and expired gas volume and concentration 
signals were continuously sampled at 100 Hz. The analyser was calibrated 
before each test with gases of known concentration, and a calibration syringe of 
known volume (3-L; Hans Rudolph, KS, USA).  
 
Electromyography (Parts A and B) 
For parts A and B, surface EMG activity was recorded from m.vastus lateralis, 
m.vastus medialis and m.rectus femoris of the quadriceps and m.biceps femoris 
of the hamstring of the right leg using active bipolar bar electrodes in a single 
differential configuration (DE2.1, DelSys Inc, Boston, MA, USA). The electrodes 
were placed over the respective muscle bellies (SENIAM guidelines). Double-
sided adhesive tape and a hypoallergenic medical tape were used to ensure the 
EMG sensor stability. The skin area underneath each EMG electrode was 
shaved, then exfoliated and cleaned with alcohol to minimise the skin 
impedance. The EMG and torque signals were pre-amplified (1,000 x), band-
pass filtered (20–450 Hz, Bagnoli-8, DelSys Inc, Boston, MA, USA), and then 
transferred to a computer with a sampling frequency of 2 kHz. EMG and torque 
data were recorded continuously and digitised synchronously with 16 bit 
resolution via an A/D converter ( ± 5 V range, CED 1401 power, Cambridge, 
UK). EMG was average rectified using the root mean square method (EMGRMS). 
EMGRMS was then normalised to the pre-exercise maximum (or maximal EMG 
signal) and the local M-wave amplitude (closest time point measure of the M-
wave) in order to exclude any changes to the EMG trace to changes in local 
excitability. The ground electrode was placed over the patella of the right leg.  
 
Peripheral Nerve Stimulation (Parts A and B) 
Electrical stimulation was applied with a constant current stimulator (Digitimer 
Stimulator DS7A, Digitimer, UK) for the assessment of M-waves (parts A and B) 
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and potentiated twitch force (part B). M-waves were elicited by supramaximal 
percutaneous electrical stimulation of the femoral nerve (200 μs duration). The 
cathode was placed over the femoral nerve in the inguinal fossa, approximately 
3–5 cm below the inguinal ligament in the femoral triangle. The cathode was 
systematically moved vertically and horizontally and the amplitude of the muscle 
action potential (e.g., M-wave) was monitored to identify the optimal position of 
the cathode for attaining maximal peak-to-peak M-wave amplitude. Once the M-
wave was elicited, the maximum amplitude (peak-to-peak) of the M-wave was 
determined (Mmax) for the vastus lateralis and vastus medialis. To determine the 
stimulation intensity, single stimuli were delivered in 20 mA step-wise 
increments from 100 mA until plateaus in quadriceps pTw (part A only) and M-
wave were observed. To ensure a supramaximal response, the current was 
increased by an additional 30% (mean ± SD current = 214 ± 66 mA; 251 ± 46 
mA, part A and B, respectively). The average Mmax was obtained from 3 stimuli, 
with ~8-10 s separating each pulse at rest. For the 3-min maximal cycling 
protocol (part B), single peripheral nerve stimulation pulses were manually 
triggered at ‘rest’ (defined as 80 rpm at 20 W) to determine pre-exercise 
neuromuscular function. Initially, the crank angle at which peripheral nerve 
stimulation was to be delivered during the trials was determined for each 
subject as described by Black et al. (2017) and as performed by Sidhu et al. 
(2012). Peripheral nerve stimulation pulses were triggered to coincide with 
maximal muscle activation around the crank cycle (typically around 50-60º from 
top-dead centre) 3 times, randomly, during a 10 s period using a custom written 
sequencer script. Identical measurements were repeated every 30 s in the all-
out sprint.  
 
Data Analyses 
Data were analysed using a custom written script developed in Spike2 software 
(CED, Cambridge, UK). For part A, mean torque for each 3 s contraction during 
the 60 MVC protocol was determined as the mean value over a 1-s period 
which approximated the plateau level of the highest torque (e.g., 500 ms before 
and after the peak torque). The pTw was calculated as the peak torque 
achieved following the single pulse delivered 1-s post-MVC. The twitch torque 
superimposed onto the peak force production of the MVC (sTw) was calculated 
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as the increment in torque immediately following the pulse during MVCs. The 
end-test torque (e.g., critical torque, CT) during the 60 MVC test was defined as 
the mean of the last 12 contractions (e.g., the last 60 s; Burnley, 2009; Morgan 
et al. 2018a). The torque-impulse was calculated as the area under the torque-
time curve by accumulating the time integral of each MVC (3 s).  
 
Voluntary activation (VA, %) was calculated using the interpolated twitch 
method from peripheral nerve stimulation (Merton, 1954; Goodall et al. 2010). 
Specifically, the increment in torque evoked during the MVCs was expressed as 
a fraction of the amplitude of the potentiated twitch produced with the same 
stimulus in the relaxed muscle post-MVC. The level of voluntary drive was then 
quantified as a percentage: [1 – evoked torque (superimposed on voluntary 
torque, sTw)/ (mean control evoked response, pTw) × 100] (e.g., Allen at al. 
1998). The changes in voluntary torque and pTw, were used to assess global 
fatigue and peripheral fatigue, respectively with VA, MMax and EMGRMS used to 
assess central fatigue.  The maximal EMG was taken from the first MVC during 
the 60 MVC task and compared to the last MVC at task end. The 
neuromuscular parameters extracted from the three sets of maximal 
contractions completed post-exercise were tested for statistical differences 
between sets of contractions and then compared to the first set of MVCs 
completed pre-exercise (Doyle-Baker et al. 2018; Froyd et al. 2013; Pageaux et 
al. 2015). Neuromuscular function was also measured for each of the stimulated 
contractions during the exercise and normalised to the corresponding pre-
exercise values at 100% MVC.  
 
For the 3-min cycling protocol (part B), the end-test power (e.g., CP) during the 
3-min test was defined as the mean of the last 30 s (Vanhatalo et al. 2007; 
2008). The Wʹ was calculated as the area above the CP from the power-time 
curve. Power output was recorded second-by-second, and the peak power was 
determined as the highest 1-s value. The changes in power output, MMax and 
EMGRMS, were used to quantify neuromuscular fatigue development and 
changes in muscle activation. Peak V̇O2 was determined as the highest value 
recorded in a 15-s interval. The achievement of V̇O2peak was an essential 
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criterion for a valid 3-min test. All neuromuscular parameters and torque were 
averaged across the protocol using 30-s bin averages. 
 
Statistics 
Paired-samples t-tests were used to compare the mean torque, total work done, 
CT, Wʹ and pTw between IBP and PL in part A. In addition, paired-samples t-
tests were used to compare the total work done, CP, Wʹ and cardiorespiratory 
responses between IBP and PL obtained from the 3-min maximal cycling test. 
For the 60 MVC test, the profiles of VA and Ms-wave amplitude were analysed 
using two-way ANOVAs with repeated measures (using 12 contraction 
averages; e.g., 6 time points). In addition, a two-way ANOVA with repeated 
measures (condition × work rate) was used to assess differences in end 
exercise V̇O2 and the profiles of EMG and M-wave amplitude. Normalised 
EMGRMS were analysed using two-way ANOVAs with repeated measures using 
30-s means (e.g., 10 time points). Where sphericity was violated, Greenhouse-
Geisser correction factor was used. For all tests, results were considered 
statistically significant when P<0.05. Data are presented as means ± SD unless 
otherwise indicated. All statistical analyses were conducted using IBM SPSS 
Statistics version 23. 
 
RESULTS 
Part A (60 MVC test) 
The mean MVC torque achieved prior to the 60 MVC protocol was 232 ± 47 and 
230 ± 55 N·m for PL and IBP, respectively. VA of the knee extensors achieved 
during the preliminary MVCs was 88 ± 7 and 89 ± 6% for PL and IBP, 
respectively. Baseline MVC and VA were not different between conditions 
(P>0.05). The profile for mean torque during each contraction across all 
participants for the 60 MVC protocol is illustrated in figure 7.2a. During the PL 
trial, torque declined from a peak of 99  ±  3% MVC (relative to pre-exercise 
MVC) during the first contraction to 40  ±  15% MVC during the last 12 
contractions (P<0.01, table 7.1, figure 7.2a). During the IBP trial torque declined 
from a peak of 99 ± 3% to 41 ± 16% MVC. The mean torque (relative to pre-
exercise MVC) achieved across the 60 MVCs not different with IBP (60 ± 13%, 
87.1 ± 22.2 N·m,) compared to PL (58 ± 14%, 83.8 ± 22.7 N·m, P=0.39). There 
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was no difference in CT (PL: 40 ± 15% vs. IBP: 41 ± 16%. P=0.74), Wʹ (PL: 
6971 ± 2432 vs. IBP: 7231 ± 3570 N·m·s; P=0.69) or total impulse, the 
surrogate measure of total work done (PL: 22,055 ± 3,885 vs. IBP: 22,919 ± 
3,394 N·m·s; P=0.26) between the PL and IBP conditions.  
 
 
Figure 7.2. The torque profile during the 60 maximal contractions for placebo 
(PL, clear circles) and ibuprofen (IBP, filled circles) trials in protocol (a) is 
demonstrated in panel A. The torque during all contractions was normalized to a 
control maximal voluntary contraction (MVC) performed before the test 
commenced. Note that torque falls over the first ~150 s before reaching stable 
values between 240 and 300 s (the end-test torque; last 12 MVCs). Panel B 
illustrates the mean ± SE power output profile during the 3-min maximal cycling 
Chapter 7: Acute ibuprofen ingestion does not attenuate fatigue 
during maximal intermittent knee extensor or all-out cycling exercise 
 
155 
 
protocol for placebo (clear circles) and ibuprofen (filled circles) trials.  Note that 
power output falls over the first ~120-150 s before reaching stable values (the 
end-test power output; e.g., CP).  
 
Table 7.1: Performance and neuromuscular function parameters of the 60 MVC 
(protocol A) and 3-min all-out cycling (protocol B) tests following placebo and 
ibuprofen ingestion. 
 
 
 
Placebo (PL) 
 
Ibuprofen (IBP) 
Protocol A 
Performance 
  
Peak MVC (N·m) 232  ±  47 230  ±  55 
Mean torque (% MVC) 58  ±  14 60  ±  13 
Total Impulse (N·m·s) 22055  ±  3885 22919  ±  3394 
Critical torque, CT (% MVC) 40  ±  15 41  ±  16 
Wʹ (N·m·s) 6971  ±  2432 7231  ±  3570 
   
Neuromuscular function   
Change in pTw (N·m) 44  ±  27 43  ±  25 
End-exercise pTw (N·m) 30  ±  21 31  ±  23 
End-exercise VA (%) 59  ±  19 60  ±  18 
End-exercise M-wave amplitude (%) 96  ±  14 95  ±  12 
End-exercise EMG amplitude (%) 59  ±  17 64  ±  20 
Protocol B 
Performance 
  
Peak power output (W) 820  ±  139 816  ±  131 
Total Work Done (kJ) 65.4  ±  6.4 65.9  ±  5.9 
Critical power, CP (W) 288  ±  31 292  ±  28 
Wʹ (kJ) 13.6  ±  2.4 13.7  ±  2.8 
   
Neuromuscular function   
End-exercise M-wave amplitude (%) 84  ±  21 83  ±  18 
End-exercise EMG amplitude (%) 54  ±  17 57  ±  14 
 
 
MVC, maximal voluntary contraction; CT, critical torque measured in the last 6 
contractions; CP, critical power measured in the last 30 s of the 3-minute maximal 
cycling test; pTw, potentiated twitch force; VA, voluntary activation measured using 
the interpolated twitch method technique; EMG, electromyography; N·m, newton 
metres; N·m·s, newton metres per second; ms, milliseconds. 
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Part A (Neuromuscular Function) 
Alongside the decline in voluntary force (figure 7.2a), pTw (figure 7.3a), VA 
(figure 7.3b), EMGRMS (figure 7.3c) and MMax (figure 7.3d) were also reduced as 
protocol A progressed (main effect of time, all P<0.01). There were no 
differences between PL and IBP in pTw, VA, EMG amplitude or M-wave 
amplitude at any time point (all P>0.05). pTw declined from 63  ±  14 to 30  ±  
21 N·m and from 68  ±  17 to 31  ±  23 N·m, VA declined from 89  ±  8 to 59  ±  
19% and from 88  ±  7  to 60  ±  18%, EMG declined from 99  ±  4 to 59  ±  17% 
and 100  ±  2 to 64  ±  20% (from first 6 to last 6 contractions) and M-wave 
amplitude declined from 100  ±  1 to 96  ±  14% and 100  ±  1 to 95  ±  12% in 
the PL and IBP conditions, respectively (P<0.05), with no differences between 
PL and IBP for any of these variables (P>0.05).  
 
Figure 7.3. Mean  ±  SE potentiated twitch (A), voluntary activation (B), and 
EMG amplitude (C) and M-wave amplitude (D) responses during the 60 MVC 
test for placebo (clear circles) and ibuprofen (filled circles) trials for protocol a.  
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Part B (3-min cycling test) 
The mean power output profile for all participants during the 3-min all-out 
cycling test is shown in figure 7.2b for the PL and IBP conditions. During the PL 
trial, power output declined from 820  ±  139 W to 288  ±  31 W during the last 
30 s of the 3-min test (P<0.01; table 7.1, figure 7.2b). During the IBP trial, power 
output declined from 816 ± 131 W to 292 ± 28 W during the last 30 s of the 3-
min test. There were no differences in CP (PL: 288  ±  31 vs. IBP: 292  ±  28 W, 
P=0.11), total work done (PL: 65.4  ±  6.4 vs. IBP: 65.9  ±  5.9 kJ, P=0.11) or Wʹ 
(PL: 13.6  ±  2.4 vs. IBP: 13.7  ±  2.8 kJ, P=0.84) between conditions.  
 
Part B (Neuromuscular Function) 
Similar to the 60 MVC protocol, alongside the decline in power output, there 
was a progressive decline in M-wave (P<0.01, figure 7.4b) and EMG amplitudes 
(P<0.01, figure 7.4a). The profiles of the M-wave and EMG amplitudes were not 
altered following IBP ingestion at any time point (both P>0.05). Using 30 s 
mean values, EMG decreased from 94  ±  4 to 54  ±  17% and from 96  ±  6 to 
57  ±  14% (figure 7.4a) in PL and IBP, respectively.  
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Figure 7.4. Mean ± SE M-wave amplitude (A) and EMG amplitude (B) 
responses during the 3-minute maximal cycling exercise for placebo (clear 
circles) and ibuprofen (filled circles) trials for protocol b. 
 
DISCUSSION 
Contrary to our experimental hypotheses, the principal findings of this study 
were that acute ingestion of 400 mg of IBP in a ‘fresh’ state had no effect on 
fatigue development or neuromuscular function during either a 5-min single-leg 
intermittent MVC test or a 3-min maximal cycling test. Across both protocols, 
power output and torque declined, and neuromuscular fatigue was evident in 
both the IBP and PL conditions.  However, there were no differences in CT or 
CP, total work done or neuromuscular fatigue markers between the IBP and PL 
conditions.  These findings do not support the acute ingestion of IBP as a 
strategy to blunt fatigue development during exercise in healthy, recreationally 
active adults.  
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Effects of acute IBP ingestion on exercise performance  
In contrast with our previous findings of improved CT and CP following the 
acute ingestion of ACT (Morgan et al. 2018a; Morgan et al. 2018b), these 
variables were not improved in the current study following the acute ingestion of 
IBP. However, our findings in the current study are in line with some previous 
observations that IBP ingestion does not improve performance during whole 
body exercise in humans (e.g., Cleak, & Eston. 1992; Da Silva et al. 2015; 
Nosaka & Clarkson, 1996; Tokmakidis et al. 2003). Previous studies that have 
reported improved exercise performance following IBP administration have 
typically assessed exercise performance following muscle damage. 
Nonetheless, while there is some evidence to suggest that the increases in 
muscle soreness, pain, damage and contractile dysfunction after contraction-
induced muscle damage can be attenuated following NSAID administration 
(Ebbeling & Clarkson, 1989; Hasson et al. 1993; Pizza et al. 1999; Tokmakidis 
et al. 2003), there is also evidence that NSAID administration does not impact 
these variables after muscle damage is induced (Da Silva et al. 2015; Donnelly 
et al. 1990; Grossman et al. 1995; Tokmakidis et al. 2003; VanHeest et al. 
2002).  Taken together, these observations suggest that the ergogenic potential 
of administering IBP, a purported analgesic and anti-inflammatory agent (Fridén 
& Lieber, 1992), is limited without prior induction of muscle damage, and even 
when muscle damage is induced, and inflammation and pain sensation are 
correspondingly increased, the effect of IBP ingestion on exercise performance 
is equivocal.    
 
One explanation for the lack of performance improvement following IBP 
ingestion in our study may be the reduced ability to regulate the distribution of 
effort (e.g., pacing strategy) in the maximal protocols employed in response to a 
potential modulation of pain.  For example, Mauger et al. (2010) reported that 
pain` sensation was reduced (e.g., a greater power output was possible for the 
same pain sensation) and cycling time trial performance was enhanced 
following ingestion of ACT. Similarly, Gonglach et al. (2016) reported that 
manipulating pain perception via caffeine ingestion lead to higher power outputs 
when participants were asked to pace their effort based upon pain perception. 
Therefore, we cannot exclude the possibility that IBP consumption could be 
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ergogenic in situations wherein pacing strategy is self-selected such as during 
longer duration endurance exercise.  
 
Another possible explanation for the absence of an ergogenic effect of IBP in 
our study is that inhibiting cyclooxygenase may induce secondary effects that 
may limit the cardiopulmonary response to exercise including a reduction in 
exercise-induced hyperaemia (Bradford et al. 2007; Schrage et al. 2004).  If 
skeletal muscle perfusion was impaired following IBP ingestion as a function of 
cyclooxygenase inhibition (Albert & Gernaat, 1984), this could have negated 
any potential ergogenic effects following IBP ingestion. However, given that 
performance was not enhanced during either smaller (single-leg exercise) or 
larger (double leg cycling) muscle mass exercise following acute IBP ingestion 
in the current study, and that skeletal muscle perfusion is less likely to be a 
limiting factor for performance in a single leg model (Joyner & Casey, 2015), 
this seems unlikely.    
 
Effects of acute IBP ingestion on neuromuscular function 
The ingestion of 400 mg of IBP was not associated with attenuation of 
neuromuscular fatigue development as estimated with peripheral muscle 
excitability (part A and B), voluntary activation (part A), potentiated twitch (part 
A) or EMG amplitude (part A and B), consistent with the lack of change in 
exercise performance. We previously investigated the influence of acute 
ingestion of 1 g of ACT on neuromuscular function during exercise and reported 
that, whilst EMG declined across the 3-min cycling protocol in both conditions, 
EMG declined to a lesser extent in the ACT (~72 %) compared to the PL (~54 
%) condition (Morgan et al. 2018b). The magnitude of this effect was 
remarkably similar to the results we obtained during a 60 MVC protocol 
completed in a single leg exercise model (ACT: 87% vs. PL: 59 %, Morgan et 
al. 2018a). This observation suggests that improved maintenance of muscle 
activation contributed to the ergogenic effect of ACT (Morgan et al. 2018a). It is 
of interest, therefore, that similar effects were not evident following IBP 
ingestion. We are not aware of any research to suggest that ACT acts as a 
more potent stimulus to reduce pain sensation or alter muscle activation. 
However, it is possible that a combination of the higher ACT dose administered 
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(1000 mg vs 400 mg for IBP), ACT’s potential as an antipyretic (Foster et al. 
2014) and differences in pharmacokinetics (Anderson, 2008; Albert & Gernaat, 
1984) may have contributed to the disparate effects of IBP in our current study 
and ACT in our previous studies (Morgan et al. 2018a; Morgan et al. 2018b) on 
exercise performance and neuromuscular fatigue development. It is also 
pertinent to note that ACT ingestion has been reported to increase corticospinal 
excitability at rest, a factor which may contribute to its ergogenic potential 
(Mauger & Hopker, 2013).  
 
Experimental considerations 
Whilst our study contributes to a further understanding of the effect of IBP on 
exercise-induced fatigue and some of its underlying mechanisms, there are 
some limitations that require consideration. Firstly, it is acknowledged that we 
did not measure pain sensation or biomarkers of inflammation. Pain was not 
assessed due to the protocols requiring the completion of maximal exercise. 
Asking participants to rate pain sensation may have compromised their ability to 
focus on the exercise task and to provide a true maximal effort. The effect of 
IBP on exercise performance when pacing is permitted, and the individual can 
adjust their pacing strategy in response to potential differences in pain 
sensation, warrants further investigation. In addition, the extent to which 
prostaglandin synthesis during endurance exercise plays a role in pain 
perception in the absence of muscle damage requires further consideration. It is 
also important to point out that individuals intending to ingest IBP need to 
consider its potential side effects and be aware that it could impair the adaptive 
response to exercise (Schoenfeld et al. 2012) and aspects of the beneficial 
remodelling of skeletal muscle to exercise training (Mikkelsen et al. 2009).  
Therefore, individuals wishing to explore the use of pain relievers to enhance 
exercise performance should do so infrequently, with caution, and at the 
recommended therapeutic doses.  
 
In conclusion, acute ingestion of IBP did not attenuate the decline in 
neuromuscular function or improve CT or CP during a 60 MVC protocol of the 
knee extensors or a 3-min maximal cycling test. Therefore, our results indicate 
that IBP ingestion does not attenuate neuromuscular fatigue development, 
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during either single-limb or whole-body cycling exercise, and do not support IBP 
ingestion as an ergogenic aid.  
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CHAPTER 8 
GENERAL DISCUSSION 
 
The overall aim of this thesis was to investigate the effect of acutely consuming 
the standard therapeutic dose of non-specific COX-inhibitors (i.e., ACT, IBP) on 
neuromuscular fatigue development and performance during a variety of 
different exercise tasks. In the first experimental chapter (chapter 4), a well-
controlled single-leg model was employed to assess the effect of acute ACT 
consumption on performance (total impulse), the parameters of the torque-time 
relationship (CT and Wʹ) and neuromuscular fatigue development during 60 
MVCs of the knee extensors. The findings from this study revealed that ACT 
consumption increased total impulse, and CT and EMG amplitude over the 
latter stages of the test. Subsequently, the second experimental chapter 
(chapter 5) assessed whether these findings could be replicated during a 3-min 
maximal cycling bout when a larger muscle mass was recruited, which would 
have greater implications for ‘real-world’ exercise performance.  Consistent with 
study 1, acute ACT consumption increased total work done, and CP and EMG 
amplitude over the later stages of the test.  The third experimental chapter 
(chapter 6) assessed whether acute ACT consumption could improve 
performance during single-leg severe-intensity knee extensor exercise after 
prior fatigue of the contralateral limb, where afferent feedback and central 
fatigue development are exacerbated, and whether the potential ergogenic 
effect of ACT ingestion in this setting would be greater than the same exercise 
completed without prior contralateral fatigue. In this study, ACT did not improve 
performance during severe-intensity single-leg knee extensor exercise 
completed with or without prior fatigue of the contralateral limb. Finally, the 
fourth experimental chapter (chapter 7) assessed whether acute IBP 
consumption could improve performance during the maximal-intensity single-leg 
and cycling exercise protocols that were administered in studies 1 and 2.  In 
contrast with ACT ingestion, IBP ingestion did not alter performance in either of 
these protocols.  Collectively, these four original research studies advance 
understanding of the effects of non-specific COX-inhibitors on exercise 
performance, and the bases of neuromuscular fatigue development during 
exercise. This chapter (chapter 8) will summarise the main findings of this 
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thesis, place these findings in context within the existing literature, and outline 
the novel contributions, and potential limitations and implications of the work 
conducted in this thesis. 
 
8.1 Main findings 
8.1.1 ACT and small muscle mass exercise 
It is believed that the effects of ACT ingestion are predominantly mediated by 
central factors (Anderson, 2008; Andersson et al. 2011; Graham et al. 2013; 
Jóźwiak-Bębenista & Nowak 2014; Smith 2009; Ottani et al. 2006; Pickering et 
al. 2006; 2008; Toussaint et al. 2010). Specifically, ACT is known to prevent the 
metabolism of arachidonic acid into PGs, by non-selectively blocking COX 
enzymes and reducing nociceptor discharge (and thus the magnitude of group 
III/IV muscle afferent feedback), which provides analgesic and antipyretic 
effects. The analgesic effect of ACT has also been attributed to the potentiation 
of descending serotoninergic pathways (Pickering et al. 2006; 2008), and the 
modulation of opioid and cannabinoid receptors (Graham et al. 2013; Ottani et 
al. 2006). These mechanisms likely interact to lower pain sensation following 
acute ACT ingestion by increasing the nociceptive stimuli required to evoke a 
given pain sensation. ACT may also help to maintain cortical excitability, 
enhance muscle activation and/or reduce cortical inhibition by modulating pain 
sensation (e.g., Dubé & Mercier 2011). Evidence also exists to suggest that 
reducing group III/IV afferent feedback by fentanyl administration attenuates 
intracortical inhibition and thus the development of central fatigue (Hilty et al. 
2011). However, it should also be acknowledged that acute ACT ingestion may 
improve exercise performance independent of its effect on pain (and effort) 
sensation by, for example, enhancing corticospinal excitability and thus 
alleviating the development of central fatigue (Mauger & Hopker, 2013),  
 
Given the association between the sensation of pain and exercise performance 
(i.e., Astokorki & Mauger, 2017a; 2017b; Cook et al. 1997), recent 
investigations have attempted to assess the effect of acute ACT ingestion on 
performance. ACT ingestion has previously been shown to improve cycling TT 
performance (Mauger et al. 2010), exercise tolerance during cycling in the heat 
(Mauger et al. 2014) and repeated sprint cycling performance (Foster et al. 
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2014). Specifically, acute consumption of ACT has been shown to improve 
exercise performance by increasing pain tolerance/lowering pain sensation 
(e.g., Foster et al. 2014; Mauger et al. 2010; 2014) and reducing thermal stress 
in the heat (Mauger et al. 2014). However, it is important to note that for the 
studies presented in this thesis, performance would not be expected to be 
enhanced by improved thermoregulation as they were all short-duration and 
performed in temperate conditions. More recently, data has also been 
presented to suggest ACT may reduce exercise-induced pain during the latter 
stages of sprint interval treadmill running but without influencing performance 
(Park et al. 2016), possibly highlighting a task (and/or individually) specific effect 
of ACT on performance and/or that the effects of ACT ingestion on performance 
and pain sensation can be dissociated in certain exercise settings. It is also 
possible that in the study by Park et al. (2016) that, because afferent feedback 
is ‘permitted’ to accumulate to a higher magnitude in exercise tasks where less 
muscle mass is engaged (i.e., Rossman et al. 2012; 2014), a higher degree of 
neuromuscular fatigue development is observed in cycling exercise (compared 
to running), affording a higher ability for ACT to influence exercise performance 
(Park et al. 2016). We also speculate that, during treadmill running, the 
regulation of work output is likely more restricted and involves more conscious 
regulation and awareness in altering speed than in cycling exercise (or running 
which is not constrained to a treadmill) which is freely controllable and may help 
explain the lack of observed effects in the study by Park and colleagues (2016). 
 
In addition, Chapter 4 sought to assess the ergogenic potential of ingesting an 
acute dose of ACT (1 g) during a 5 min single-leg maximal intermittent knee-
extension test. This approach was adopted as it afforded the opportunity to 
robustly assess performance, and neuromuscular, peripheral and central fatigue 
development to examine some of the underpinning mechanisms for the 
ergogenic effect of ACT ingestion (Chapter 4). In addition to investigating the 
neurophysiological bases of a potential improvement in exercise performance 
following ACT ingestion, this study assessed how ACT ingestion impacted the 
parameters of the torque-time relationship, CT and W′. Therefore, the purpose 
of this initial study was to test the efficacy of acute ACT consumption to improve 
Chapter 8: General discussion 
 
166 
 
total work (impulse), CT and muscle activation and the rate of neuromuscular 
fatigue development, using a controlled experimental model.  
 
Consistent with previous research using a similar design (Burnley, 2009; 
Broxterman et al. 2017; 2018; Fulford et al. 2013), this study demonstrated that 
torque (-60%), pTw (-30%), EMG (-41%) and VA (-59%) declined during the 60 
MVC protocol affirming neuromuscular, peripheral and central fatigue 
development, respectively (Chapter 5). We also demonstrated that mean torque 
(61 ± 11 vs. 58 ± 14% pre-exercise MVC) and end-test torque, reflective of CT 
(44 ± 13 vs. 40 ± 15% pre-exercise MVC), were greater following ACT 
compared to PL ingestion. VA and pTw declined at a similar rate in both 
conditions. However, the decline in EMG was attenuated in the ACT trial with 
EMG being significantly greater compared to PL from 210 s onwards (end 
exercise EMG 87 ± 28 vs. 59 ± 17%), suggesting that improved muscle 
activation likely contributed to the ergogenic effect of ACT ingestion. This 
interpretation was strengthened by our observation of a strong positive 
correlation between the inter-trial changes in EMG and performance (r=0.85). 
Our findings are in line with previous observations that acute ACT ingestion can 
improve performance during whole body exercise (Foster et al. 2014; Mauger et 
al. 2010). Specifically, Mauger et al. (2010) demonstrated a similar ~2% 
improvement (vs. 3% improvement in total impulse, Chapter 4) in 10-mile TT 
cycling performance following a 1.5 g dose of ACT. However, our observations 
offer novel insights into the mechanisms for the ergogenic effect of ACT 
reported previously (Foster et al. 2014; Mauger et al. 2010) by demonstrating a 
28% increase in end-exercise EMG (measure of muscle activation) and a 4% 
improvement in CT, which reflects the maximal sustainable rate of oxidative 
metabolism, represents a critical threshold for neuromuscular fatigue 
development (Burnley et al. 2012) and has been identified as a significant 
predictor of endurance performance (Jones & Vanhatalo, 2017 for review). 
Furthermore, this increase in CT occurred without influencing the Wʹ, the 
curvature constant of the hyperbolic power-duration (or torque-time) 
relationship. Our findings are in contrast with previous work using an identical 
experimental model (i.e., 60 MVC test) but with intrathecal fentanyl to abolish 
pain and afferent feedback, where no improvement in CT was observed 
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(Broxterman et al. 2018). In addition, whilst the abolition of afferent feedback 
accelerated the rate of ATP cost per contraction, an initial increase in the ATP 
cost of contraction (in the first minute of exercise) was not observed which 
coincided with a significant increase in force production, perhaps providing 
further support of a ‘lag-time’ in afferent feedback and/or that muscle afferent 
feedback protects a metabolic reserve related to W ʹ rather than the CT 
(Broxterman et al. 2018). However, whilst cardiopulmonary function was not 
limiting in this mode of exercise, the use of ACT causes a reduction, as 
opposed to abolition, of afferent feedback which may have important 
consequences for maintaining skeletal muscle efficiency (Broxterman et al. 
2018).  
 
As we observed no differences in our main measures of peripheral (i.e., pTw) 
and/or central (i.e., VA) fatigue, we were unable to identify the precise 
mechanism for the ergogenic effect of ACT ingestion on muscle activation. It is 
possible that ACT ingestion enhanced cortical function (Dubé & Mercier, 2011; 
Mauger & Hopker, 2013) and this, potentially alongside a reduction in group 
III/IV muscle afferent feedback, permitted further muscle activation (i.e., Mauger 
et al. 2011). Since there was no difference in peripheral membrane excitability 
(i.e., M-wave) between conditions, the enhanced EMG amplitude following ACT 
ingestion might have been linked to processes upstream of the neuromuscular 
junction (i.e., spinal and/or supraspinal in origin). This postulate is strengthened 
by observations of ACT enhancing spinal and supraspinal excitability at rest 
(Mauger & Hopker, 2013) and attenuating corticospinal inhibition during 
exercise (Pageaux & Mauger, 2018). In addition, previous research suggests 
that acute pain increases corticospinal inhibition (Dubé & Mercier, 2011), which 
would prevent optimal activation of the motor cortex during voluntary movement 
and impair muscle function and exercise performance. In further support for a 
role of ACT ingestion in supressing central fatigue development, other methods 
of reducing group III/IV afferent feedback have been linked to reduced 
intracortical inhibition (e.g., Hilty et al. 2011) and enhanced spinal and 
supraspinal excitability (e.g., Sidhu et al. 2014; 2017) which would be expected 
to increase voluntary neural drive during exercise (Amann et al. 2009; 2011; 
Blain et al. 2016; Hilty et al. 2011; Sidhu et al. 2014; 2017).  
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Since ACT ingestion improved performance in study 1, and this effect would 
have been expected to be a function of reduced inhibitory feedback, improved 
cortical function and greater peripheral fatigue development, it was surprising 
that the attenuation in neuromuscular fatigue development was not 
accompanied by changes in central (i.e., VA) or peripheral (i.e., pTw) fatigue 
markers. Since muscle activation and torque were increased, this might be 
expected to result in greater intramuscular metabolic perturbation and, by 
extension, greater peripheral fatigue development. Although we cannot exclude 
the possibility that ACT enhanced systemic physiological responses or skeletal 
muscle efficiency to mitigate this potential for greater peripheral fatigue 
development, we are not aware of any published evidence to support such 
effects. It should, however, be acknowledged that in the face of a relatively 
small (< 5%) improvement in torque, it is possible that our indirect measures of 
central and peripheral fatigue in this study were not sensitive enough to detect 
potentially small changes in CNS and peripheral muscle function. Moreover, 
while ACT increased EMG during the latter stages of the 60 MVC protocol 
compared to PL, which might be linked to increased muscle activation and 
CMD, VA was not impacted by ACT. This might have been a function of the 
continuous assessment of the EMG response and torque throughout the 60 
MVC protocol, compared to every 6th MVC for VA, such that EMG might have 
provided a more ‘complete picture’ of central fatigue development across the 
protocol. 
 
According to previous work (e.g., Foster et al. 2014; Mauger et al. 2010), we 
would have also expected pain and effort sensation to be similar in the ACT trial 
despite an increase in work output. However, it is acknowledged that a limitation 
of this study was that pain sensation was not assessed.  This was due to the 
protocol requiring the completion of 60 MVCs with a short (2 s) recovery period 
such that asking participants to rate their pain sensation would likely have 
compromised their ability to focus on the exercise task to provide a true 
maximal effort. In addition, previous work has highlighted the difficulties with 
measuring exercise-induced pain and accurately dissociating this from 
perceived exertion (Astokorki & Mauger, 2017a), further complicating pain 
assessment during such exercise tasks.  
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8.1.2 ACT and large muscle mass exercise 
Chapter 5 was completed to investigate whether the effect of ACT on 
performance in a small muscle mass model reported in chapter 4 was 
transferable to a larger muscle mass model.  Therefore, a standard therapeutic 
dose of ACT (1 g) was, again, administered but prior to assessing performance 
in an experimental model with improved translation to whole body exercise 
performance by conducting whole-body cycling exercise during a 3-min all-out 
test (Chapter 5). This is important since the exercise modality (more specifically, 
the systemic challenge) employed, and volume of skeletal muscle mass 
engaged, is known to influence the extent, and underpinning mechanisms, of 
neuromuscular fatigue development (i.e., Rossman et al. 2012; 2014). The 
femoral nerve was stimulated every 30 s to measure peripheral membrane 
excitability and surface EMG was recorded continuously to measure muscle 
activation using novels methods during locomotion. Although this experimental 
model offered greater translation to exercise performance, assessments of 
neuromuscular function were restricted to on-bike measurements as the 
recovery of neuromuscular function has been shown to occur rapidly following 
the completion of exercise (Carroll et al. 2017). In addition, given the task-
specific nature of fatigue, assessment of neuromuscular function on a 
dynamometer during an isometric contraction (as traditionally adopted when 
assessing fatigue) would have provided an invalid assessment of 
neuromuscular function (rendering the measurements of limited use) and so 
was avoided in this study. 
 
Compared to PL, ACT ingestion increased end-test power, reflective of CP (297 
± 32 vs. 288 ± 31 W), and total work done (66.4 ± 6.5 vs. 65.4 ± 6.4 kJ) without 
impacting Wʹ (13.1 ± 2.9 vs. 13.6 ± 2.4 kJ) or the M-wave amplitude (end-
exercise: 4.15 ± 1.60 vs. 3.94 ± 1.9 mV) during a 3-min all-out cycling test.  
These findings demonstrated a similar improvement in exercise performance 
(total work and CP) compared to chapter 4 but in a group of trained individuals 
(group mean V̇O2peak: >60 ml·kg-1·min-1). In addition, EMG declined throughout 
the 3-min protocol in both the PL and ACT conditions; however, the decline in 
EMG was attenuated in the ACT condition, with the EMG amplitude being 
greater compared to PL over the last 60 s of the test (end-exercise EMG 72 ± 
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18 vs. 54 ± 17%).  These observations were consistent with those reported in 
chapter 4. Our observation of no difference in M-wave amplitude in chapters 4 
and 5 is also in agreement with previous findings that peripheral membrane 
excitability is not altered at rest following ACT ingestion (Mauger & Hopker, 
2013). Moreover, and also in agreement with chapter 4, CP (exercise-modality 
equivalent of CT) was increased without influencing the Wʹ following ACT 
ingestion. This is an important finding as when the parameters of the power-
duration relationship are known (i.e., CP and Wʹ), they can be used to robustly 
predict TT performance (e.g., Black et al. 2014; Poole et al. 2016 for review). 
Indeed, in agreement with the magnitude of improvement (2%) in TT 
performance empirically demonstrated by Mauger et al. (2010), the ACT-
induced increase in CP was predicted to translate into a 1-3% reduction in the 
time required to complete a range of target work cycling trials (100-1000 kJ). 
Interestingly, improvements in exercise performance with acute ACT ingestion 
have been reported in trained participants in this chapter (Chapter 5) and in the 
previous study by Mauger et al. (2010) despite evidence that endurance training 
increases pain tolerance (i.e., O’Leary et al. 2017) and that trained individuals 
are more likely to have a greater tolerance to pain (Janal et al. 1994; Tesarz et 
al. 2013) and rely less on afferent signals to regulate (or ‘pace’) work output 
(Mauger, 2014; Tucker, 2009). This demonstrates the clear potential for ACT 
(and by extension, pain suppression) to enhance performance in trained 
individuals as well as providing further support for pain having a role in 
regulating exercise performance by utilising a ‘metabolic reserve’ (e.g., Foster 
et al. 2014; Mauger, 2014; Mauger et al. 2010; 2011). Indeed, it has recently 
been suggested that pain sensation arising from exercise may play a combined 
role in the regulation of work output and preservation of a metabolic reserve by 
the central nervous system (Mauger, 2014). 
 
8.1.3 ACT and contralateral fatigue 
Based on the findings from chapters 4 and 5 , and other studies assessing the 
effect of ACT ingestion on performance (Foster et al. 2014; Mauger et al. 2010) 
and neuromuscular function (Dubé & Mercier, 2011; Mauger & Hopker, 2013), 
as well as studies reporting enhanced cortical function during fatiguing exercise 
after reducing group III/IV afferent feedback (i.e., Amann et al. 2009; 2011; 
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Blain et al. 2016; Hilty et al. 2011; Sidhu et al. 2014; 2017), we postulated that 
the mechanisms responsible for the ergogenic effect and enhanced muscle 
activation of ACT was a blunting of central fatigue. The development of non-
local muscle fatigue is thought to be predominantly centrally mediated (see 
Halperin et al. 2015 for review). Indeed, despite the mechanisms of 
contralateral limb fatigue still remaining entirely unknown, the exacerbation of 
central fatigue during a contralateral limb task has been suggested to be 
mediated by increased group III/IV muscle afferent feedback (e.g., Amann et al. 
2013) leading to a ~49% reduction in Tlim during a contralateral limb task. 
Amann et al. (2013) suggested that the reduced exercise tolerance after prior 
contralateral fatigue was achieved by elevating perceived exertion (i.e., RPE) 
and “restricting CMD” (inferred from a reduced end-exercise EMG amplitude 
despite a similar rate of rise during the exercise task), preventing further 
peripheral fatigue development (i.e., reduced pTw). Collectively, considering 
these observations, it was proposed that the premature restriction of CMD was 
likely due to participants reaching their ‘sensory tolerance limit’, a hypothetical 
construct that might coincide with an individually specific degree of peripheral 
fatigue and associated intramuscular metabolic milieu, at an earlier time point 
due to afferent feedback being elevated at the end of the prior leg exercise task 
(Amann et al. 2013). Since the circulatory and ventilatory responses during 
such small muscle mass exercise are well within the respective maximal 
capacities, the authors concluded that the any impact of muscle afferents on 
performance during such a task was likely independent of the established role 
of muscle afferent feedback in regulating peripheral hemodynamic responses 
during whole-body exercise.  
 
Since the prevailing mechanism by which ACT ingestion is purported to be 
ergogenic is through a blunting of central fatigue development (e.g., Foster et 
al. 2014; Mauger et al. 2010; Mauger & Hopker, 2013; Chapters 4-5), chapter 6 
sought to test the hypotheses that ACT ingestion would attenuate contralateral 
limb fatigue and that this effect would be greater compared to short-duration 
unilateral severe-intensity exercise in which fatigue development is 
predominantly peripherally mediated (i.e., Froyd et al. 2013; Matkowski et al. 
2011). To test this hypothesis, participants performed CWR single-leg severe-
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intensity knee extensor exercise to exhaustion with one leg and consecutively 
with the contralateral rested limb, 60 mins after ingesting PL or 1 g of ACT. This 
study used 31P-MRS to assess whether acute ACT ingestion permitted the 
attainment of a greater degree of perturbation to intramuscular phosphorous 
substrates and metabolites during exercise to provide novel insight into the 
mechanisms by which acute ACT ingestion might be ergogenic. We observed a 
19% reduction in Tlim during severe-intensity exercise in the contralateral limb 
(Leg2CONTRA) after completing prior severe-intensity knee extensor exercise to 
exhaustion in the opposite limb (Leg1) following PL ingestion (Leg2PL-CONTRA) 
compared to no prior fatigue in Leg1 (Leg2CON) (Leg2CON: 385 ± 104 vs. Leg2PL-
CONTRA: 311 ± 92 s). In addition, ACT ingestion did not improve Tlim in Leg1 (i.e., 
without prior contralateral fatigue, Leg1ACT) compared to the PL condition 
(Leg1PL) (Leg1PL: 390 ± 106 vs. Leg1ACT: 402 ± 101 s). Moreover, ACT ingestion 
did not improve Tlim in Leg2 following prior contralateral fatigue in Leg1 (Leg2ACT-
CONTRA) compared to the PL condition (Leg2PL-CONTRA) (Leg2ACT-CONTRA: 324 ± 85 
vs. Leg2PL-CONTRA: 311 ± 92 s). There were also no changes in intramuscular 
phosphorous substrates and metabolites, ratings of perceived exertion (i.e., 
RPE) or EMG amplitude after ACT ingestion compared to PL ingestion in the 
severe-intensity single-leg knee extensor exercise tests completed with or 
without prior contralateral fatigue. Therefore, these findings did not support our 
experimental hypotheses and, instead, suggest that acute ACT ingestion does 
not alter Tlim during single-leg constant work rate severe-intensity knee extensor 
exercise. 
 
Although ACT ingestion did not blunt the effect of prior contralateral fatigue, our 
findings offer some novel insights into the potential mechanisms for the ergolytic 
effect of prior contralateral limb fatigue. This is important since the existence of 
contralateral limb fatigue is equivocal and the mechanisms of its existence are 
poorly understood (see Halperin et al. 2015 for review). Our observations of 
compromised exercise performance after prior contralateral limb fatigue are 
consistent with some (i.e. Amann et al. 2013; Doix et al. 2013; Halperin et al. 
2014; Halperin et al. 2014; Kennedy et al. 2013; Rattey et al. 2006; Takahashi 
et al. 2011), but not all (i.e. Elmer et al. 2013; Grabiner & Owings, 1999; 
Regueme et al. 2007; Todd et al. 2003; Zijdewind et al. 1998), previous studies 
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reporting enhanced fatigue development after prior contralateral or non-local 
muscle fatigue. However, the magnitude of change was not consistent in the 
contralateral limb across the group (range +1.6 to -48.5%), potentially 
highlighting an individually specific conscious and/or sub-conscious response to 
sensory input. In addition, the similar end-exercise metabolic perturbation in 
Leg2PL-CONTRA (i.e., PCr, ADP, pH) is not in agreement with Amann et al. (2013) 
who demonstrated reduced peripheral fatigue development at Tlim. These 
findings from Amann et al. (2013) are consistent with an afferent-feedback 
mediated model whereby afferent feedback from the prior leg exercise 
contributes to the earlier attainment of the ‘sensory tolerance limit’ and reduced 
Tlim in the contralateral limb. Interestingly, however, and despite the higher 
baseline muscle [Pi] in the Leg2PL contralateral conditions compared to the 
Leg2CON condition, muscle [Pi] was lower at the point of task failure in the former 
compared to the latter. This observation, however, is in accord with studies from 
another group who observed greater peak perturbation of muscle [Pi], but not 
pH, [PCr] and [ADP], when group III/IV muscle afferent feedback was abolished 
via lumbar intrathecal administration of fentanyl (Blain et al. 2016; Broxterman 
et al. 2017b; 2018). Taken together, these complementary observations 
suggest that intramuscular phosphorous metabolites do not respond in a 
uniform manner to manipulations in skeletal type III/IV muscle afferent feedback 
and that muscle [Pi] might be a more sensitive predictor of muscle afferent 
feedback, peripheral fatigue development and Tlim. Our findings compliment 
recent research which implicates metabolites (specifically [Pi] and [H+]), to play 
a more critical role in peripheral fatigue development (Blain et al. 2016; Nielsen 
et al. 2014). 
 
The lack of an effect of ACT ingestion on single limb or contralateral limb 
performance in this study was an interesting finding and conflicts with recent 
reports that acute ACT consumption can improve exercise performance by 
increasing pain tolerance (Foster et al. 2014; Mauger et al. 2010) and muscle 
activation (Chapters 4-5). However, these disparate findings might be due to 
differences in the ACT administration procedure compared to previous studies 
reporting improved performance and delayed neuromuscular fatigue 
development following ACT ingestion (Foster et al. 2014; Mauger et al. 2010; 
Chapter 8: General discussion 
 
174 
 
Chapters 4-5). Indeed, ACT was ingested 45 min prior to the start of the Leg1ACT 
test, which immediately transitioned into the Leg2 contralateral protocol that was 
the primary focus of the current study. Since peak plasma [ACT] is attained ~60 
min post oral ACT ingestion (Anderson et al. 2008; Forrest et al. 1982), we 
elected to administer ACT in the current study such that peak plasma [ACT] 
was expected to coincide with the onset of the Leg2ACT-CONTRA protocol rather 
than the Leg1ACT protocol.  This might account, in part, for the lack of an 
ergogenic effect of ACT ingestion during the Leg1ACT protocol compared to other 
studies that acutely administered ACT ~60 min prior to the performance trial 
(Foster et al. 2014; Mauger et al. 2010; Chapters 4-5). This postulate is 
supported by recent observations that plasma [ACT] might actually peak 80-100 
min post ingestion (Foster et al. 2016).  Therefore, we cannot exclude the 
possibility that earlier ACT ingestion (Foster et al. 2016) at the same or a 
greater dose (Foster et al. 2014; Mauger et al. 2010) than consumed in the 
current study, might have elicited improved single-leg severe-intensity exercise 
tolerance. The lack of effect might also be explained partially by the low dose (1 
g) of ACT not acting as a sufficient stimulus to attenuate group III/IV muscle 
afferents in this specific task (i.e. CWR single-leg sub-maximal exercise). 
However, it is also pertinent to note that since ACT ingestion does not 
selectively inhibit PG production at the location where production of these pain 
provoking stimuli is greatest, ACT ingestion might not provide an appropriately 
targeted approach to sufficiently reduce afferent feedback during single-leg sub-
maximal exercise. In addition, whilst we observed a 19% reduction in exercise 
tolerance of the contralateral limb, this was not comparable to the magnitude of 
effect (~49%) reported by Amann et al. (2013). Therefore, the scope for 
mitigating the ergolytic effect of prior contralateral fatigue was lower in our study 
compared to that of Amann et al. (2013) which might have accounted for the 
lack of an effect of ACT ingestion in our study.  
 
In addition to differences in the ACT dosing procedure, the lack of an ergogenic 
effect of ACT administration in the current study might be linked to the fatiguing 
exercise test administered. In the present study, participants completed 
continuous single-leg severe-intensity (~95% WRpeak) knee extensor exercise 
until task failure. Since exercise-induced pain sensation is positively associated 
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with exercise intensity (Astokorki & Mauger, 2017a; Cook et al. 1997), and since 
ACT ingestion is suggested to be ergogenic by mitigation pain sensation (Foster 
et al. 2014; Mauger et al. 2010) this might account for the improved exercise 
performance during all-out maximal-intensity exercise following ACT ingestion 
(Foster et al. 2014; Chapters 4-5), and the lack of improvement in performance 
in the continuous severe-intensity submaximal exercise test employed in the 
current study.  Moreover, the fatiguing exercise protocol administered in the 
current study, which was a fixed-work-rate test continued until task failure with 
no pre-determined end point (i.e., open loop), differed from the completion of a 
fixed-distance (16.1-km) TT (Mauger et al. 2010) or a set number of maximal 
(all-out) effort repetitions (Foster et al. 2014; Chapter 4) or duration of maximal 
(all-out) effort (Chapter 5) with a predetermined end point (i.e., closed loop).  
Since the development of exercise-induced pain is correlated with performance 
in closed loop tasks (Astokorki and Mauger, 2017a) and pharmacological 
interventions that attenuate, but not completely abolish, exercise-induced pain 
appear to be more effective at enhancing performance in closed loop tasks, this 
could explain the lack of an ergogenic effect of ACT ingestion in the current 
study compared to previous studies (Foster et al. 2014; Mauger et al. 2010; 
Chapters 4-5).   
 
8.1.4 Factors determining the efficacy of ACT ingestion 
The acute consumption of ACT was associated with improved performance in 
some (chapters 4-5) but not all (chapter 6) experimental chapters in this thesis. 
A consistent observation in this thesis was that performance was enhanced 
when muscle activation, assessed via EMG amplitude, was better preserved 
(Chapters 4-5), while performance was not enhanced in exercise settings where 
muscle activation was not improved compared to the placebo condition (chapter 
6). As pain likely needs to be elevated before any impact on performance is 
observed following an analgesic intervention (i.e., ACT), it is plausible to 
suggest that the effect we observed on CT and CP in experimental chapters 4 
and 5, may have been a consequence of elevated pain during the latter portion 
of the test (i.e., when CT and CP are calculated) which is absent in the former 
(when W′ is calculated). These observations may also be explained by the ‘lag 
time’ of afferent feedback (particularly mechanosensitive group IV afferents) 
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(Ulmer, 1996). However, whilst this seems unlikely to fully explain our 
observations, whether the effect of ACT is simply an artefact of the respective 
tests, requires further investigation (see 8.4 Directions for future research). 
Importantly, the exercise tests used in these chapters have been validated and 
are sensitive to improvements in endurance performance, with the CT and CP 
representing a critical threshold for metabolic and neuromuscular control 
(Burnley, 2009; Burnley et al. 2012; Vanhatalo et al. 2008). Moreover, we 
observed strong correlations between the inter-trial changes in EMG and 
performance (and CT and/or CP) in experimental chapter 4 (r=0.85) and 5 
(r=0.88) which lends further support to the notion that performance 
enhancement following ACT ingestion is associated with an increase in muscle 
activation and CT and/or CP. This improvement in muscle activation following 
ACT ingestion may arise from mechanisms dependent and independent of pain 
sensation and may also be linked to conscious (i.e., reduced pain sensation) 
and subconscious (i.e., reduced intracortical inhibition and enhanced cortical 
excitability) processes. Specifically, in addition to observations of enhanced 
muscle activation (Chapters 4-5), ACT has also been shown to alter pain and 
effort sensation during cycling exercise (Foster et al. 2014; Mauger et al. 2010; 
2014). ACT may also alleviate the development of central fatigue in the 
absence of pain by enhancing corticospinal excitability (Mauger & Hopker, 
2013) and attenuating intracortical inhibition associated with reduced group 
III/IV afferent feedback (Hayes et al. 2006, COX-inhibitor; Hilty et al. 2011, 
fentanyl administration) as well as helping to maintain cortical excitability and/or 
reduce cortical inhibition in the presence of acute pain (e.g., Dubé & Mercier, 
2011) and thus voluntary activation. It is also possible that by reducing the 
magnitude of group III/IV muscle afferent feedback (via reducing PG synthesis), 
the development of central fatigue may be slowed by attenuating intracortical 
inhibition during fatiguing exercise (Hilty et al. 2011, fentanyl administration). 
 
However, whilst our observation of improved performance following ACT 
ingestion is in agreement with previous research implicating altered pain and 
effort sensation during exercise (Foster et al. 2014; Mauger et al. 2010; 2014), it 
should be noted that these studies used a higher dose of ACT (~1.5 g) than 
those presented in this thesis (chapters 4-6). Indeed, a study by Burtscher et al. 
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(2013) failed to observe any effect of a 500 mg dose of ACT during running 
exercise in the heat. In contrast to findings presented in these studies (Foster et 
al. 2014; Mauger et al. 2010; 2014), not all research has observed 
improvements in exercise performance following ACT ingestion (using a similar 
dose) when pain sensation is reduced (Chapter 6; Park et al. 2016). Indeed, 
whilst Park et al. (2016) observed reductions in exercise-induced pain during 
the latter stages of a sprint interval running protocol with ACT ingestion, no 
effect was observed on performance between groups. It has, however, 
previously been suggested that exercise-induced pain (and thus reducing pain 
sensation) is a moderator of ’permissible’ exercise intensity (i.e., Mauger, 2014). 
This may be more important during tasks whereby there is an ability to self-
regulate or ‘pace’ effort such as in a TT scenario or when continued ‘maximal’ 
effort and/or maximal level of exertion is required from the participant (i.e., in 
closed loop tasks) and may help partly explain the absence of effect observed 
in chapter 6 whereby the intensity of exercise was dictated by the experimenter 
(i.e., in open loop tasks). In addition, these observations may also be explained 
by the inter-study differences in the relative intensity of exercise (i.e., maximal, 
chapters 4-5 vs. sub-maximal, chapter 6). It was surprising, however, that 
following prior contralateral limb fatigue, which, seemingly, increases central 
fatigue development (i.e., Amann et al. 2013), ACT ingestion did not enhance 
performance despite previous studies reporting its ability to potentially increase 
corticospinal excitability (i.e., Mauger & Hopker, 2013), attenuate afferent 
feedback (Hayes et al. 2006) and increase intracortical facilitation (i.e., Hilty et 
al. 2011, fentanyl), important components of central fatigue development. 
However, it should be noted that establishing a direct causative role for group 
III/IV feedback to regulate exercise performance is highly complex and, as with 
the mechanisms underpinning the existence of non-local muscle fatigue, 
evidence to support such an effect is equivocal (Amann et al. 2012; 2015; 
Halperin et al. 2015 for review). The inter-study differences in the effects of 
acute ACT ingestion in this thesis might also be explained, at least in part, by 
inter-individual responses in the effect of analgesic medication (Cregg et al. 
2013 for review), pain sensation during exercise (i.e., Mogil, 1999) and ACT 
pharmacokinetics and pharmacodynamics (i.e., Foster et al. 2016).  
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Finally, whilst we are not aware of any evidence to support altered 
pharmacokinetics and pharmacodynamics of ACT after prior fatiguing exercise, 
we cannot discount that the prior exercise may have influenced the metabolism 
of ACT in the contralateral limb and thus altered its pharmacodynamics in 
chapter 6. Moreover, although recent research suggests that the attainment of 
peak plasma [ACT] is achieved >60 mins post ACT ingestion (Foster et al., 
2016), performance and muscle activation were enhanced in chapters 4 and 5 
when ACT was ingested 60 min prior to these fatigue exercise tasks. However, 
it is possible that the relative importance of peak [ACT] and/or peak pain 
suppression following ACT consumption might differ between the exercise tests 
administered (i.e., maximal vs. submaximal exercise; without vs. without prior 
existence of contralateral limb fatigue) and differences in training status (i.e., 
trained vs. untrained) across chapters 4-6. Given the disparate effect of 
contralateral limb fatiguing exercise, as evidenced by a range of +1.6 to -48.5% 
in chapter 6, and as reported in numerous previous studies (see Halperin et al. 
2015 for review), the magnitude of group III/IV muscle afferent feedback and the 
conscious and sub-conscious responses to a given degree of group III/IV 
muscle afferent feedback, are likely to be highly variable between individuals. 
Therefore, further investigation is required to improve understanding of the 
specific role of group III/IV muscle afferents in exercise-induced neuromuscular 
fatigue, particularly since it is not currently possible to accurately quantify the 
magnitude of group III/IV muscle afferent feedback.  
 
8.1.5 IBP and performance 
Having determined the effect of ACT on small (chapter 4) and large muscle 
mass maximal exercise (chapter 5), and severe-intensity single limb exercise 
completed with and without prior fatiguing contralateral exercise (chapter 6), it 
was important to investigate the effect of other non-specific COX-inhibitors, 
such as IBP, on performance and neuromuscular function to determine whether 
these effects were specific to ACT (chapter 7). Indeed, whilst research suggests 
that acute consumption of pharmacological analgesics can improve exercise 
performance (Foster et al. 2014; Mauger et al. 2010; Chapters 4-5), the 
ergogenic potential of IBP administration is poorly understood, particularly when 
muscle damage is not present, or inflammation is not elevated above baseline 
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levels (see Chpater 7). This is an important research question to address as 
IBP is regularly consumed by athletes to enhance performance (Alaranta et al. 
2008; Corrigan & Kazlauskas, 2003; Da Silva et al. 2015; Gorski et al. 2011; 
Huang et al. 2006). In a similar fashion to ACT, IBP limits the metabolism of 
arachidonic acid by inhibiting the COX enzymes, and thus the synthesis of PGs 
(Albert & Gernaat, 1984). However, IBP, a non-steroidal anti-inflammatory drug, 
is known to act both centrally and peripherally to respectively reduce the 
sensation of pain and tissue inflammation, whereas ACT is thought to act 
predominantly centrally (Fridén & Lieber, 1992). It would, therefore, be of 
interest to determine whether IBP had any additive effects on performance 
beyond what has been demonstrated by ACT ingestion (e.g., Foster et al. 2014; 
Mauger et al. 2010; Chapters 4-5). Chapter 7, therefore, tested the efficacy of a 
standard therapeutic dose of IBP (400 mg) to improve performance and 
neuromuscular function using the same protocols as administered in studies 1 
and 2 (chapters 4-5) to facilitate a direct comparison between these COX 
inhibitors. However, in contrast to our previous observations following ACT 
ingestion mean torque (IBP: 60 ± 12 vs. PL: 58 ± 14% of pre-exercise MVC) 
and end-test torque (IBP: 41 ± 16 vs. PL: 40 ± 15% of pre-exercise MVC) were 
not different between the IBP and PL conditions when completing 60 MVCs of 
the knee extensors. Similarly, end-test power output (IBP: 292 ± 28 vs. PL: 288 
± 31 W) and work done (IBP: 65.9 ± 5.9 vs. PL: 65.4 ± 6.4 kJ) during the 3-min 
all-out cycling tests were not different between the IBP and PL conditions. 
Neuromuscular fatigue markers also developed at a similar rate in both exercise 
tests in the PL and IBP conditions (i.e., pTw, VA, M-wave, EMG). Importantly, 
these findings were observed despite the participants being the same as those 
who took part in experimental chapters 4 and 5, respectively, whereby we 
observed improved performance following ACT consumption.  
 
The lack of an ergogenic effect of IBP ingestion in chapter 7 is in line with 
previous observations that IBP ingestion does not improve performance during 
whole body exercise in humans (i.e., Cleak, & Eston. 1992; Da Silva et al. 2015; 
Nosaka & Clarkson, 1996; Tokmakidis et al. 2003). In addition, previous studies 
that have reported improved exercise performance following IBP administration 
have typically assessed exercise performance following muscle damage, the 
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findings of which are equivocal (Da Silva et al. 2015; Ebbeling & Clarkson, 
1989; Hasson et al. 1993; Pizza et al. 1999; Tokmakidis et al. 2003). Despite 
anecdotal evidence of athletes consuming IBP to enhance performance, to our 
knowledge, no studies had assessed its efficacy to improve performance in a 
‘fresh’ state. Whilst a recent study demonstrated IBP improved swimming 
performance during a TTE test in rats (Lima et al. 2016), these observations 
have not been reproduced in humans. Taken together, the findings from chapter 
7 suggest that the ergogenic potential of administering 400 mg IBP is limited. 
We are not aware of any research to support ACT as a more potent drug to 
alter muscle activation and performance compared to IBP; however, a 
combination of the higher dose (1000 mg vs 400 mg), the potential of ACT as 
an antipyretic (Foster et al. 2014; Mauger et al. 2014), and the differences in the 
pharmacokinetics (Anderson, 2008; Albert & Gernaat, 1984), may have 
contributed to the lack of performance improvement following IBP ingestion in 
this thesis. In addition, whilst the mechanisms of action of ACT and IBP are 
thought to be similar, more recently it has been suggested that ACT may also 
act to inhibit ‘COX-3’, an enzyme thought to be expressed in the cortex (Roos et 
al. 2002) as well as to modulation of serotonergic pathways and opioid and 
cannabinoid receptors (see Chapter 2: Literature review). Indeed, as ACT can 
pass the blood brain barrier, it’s possible that central inhibition of COX (i.e., via 
ACT) is more effective that peripheral inhibition (i.e., via IBP), particularly in 
enhancing performance. Indeed, it would seem that ACT cerebrospinal 
concentrations track pain suppression better than plasma concentrations 
(Anderson, 2008). However, such speculation requires further investigation. 
Nonetheless, it is likely that the use of IBP is more important for pain associated 
with inflammation (Olesen et al. 2012). In addition, the role of inflammation 
during exercise and the use of anti-inflammatory medication as a performance 
aid are not clear. In contrast, it is possible to speculate that NSAIDs may 
actually impair exercise performance via an increase in gastrointestinal stress. 
Indeed, currently, our data do not support the use of IBP to enhance exercise 
performance.  
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8.1.6 Exercise-induced pain  
Previous studies have reported a higher power output for the same level of pain 
sensation at a given work output during cycle ergometry exercise, suggestive of 
a reduction in the sensation of pain (i.e., Foster et al. 2014; Mauger et al. 2010).  
Therefore, pain sensation was not a primary focus of this thesis.  Instead this 
thesis focused on the physiological neuromuscular bases for any ergogenic 
effect of commonly consumed pain relief medications (ACT and IBP), as this 
had received limited research attention prior to the completion of this thesis. 
Whilst acute ACT ingestion may improve exercise performance irrespective of 
its well-known effect on pain sensation by, for example, altering neuromuscular 
function in the absence of pain (i.e., Mauger & Hopker, 2013), ACT may also 
help to maintain cortical excitability and/or reduce cortical inhibition in the 
presence of acute pain (i.e., Dubé & Mercier 2011). Though the focus of this 
thesis was to assess the efficacy of COX-inhibitors on performance and its 
neurophysiological basis, it is acknowledged that a limitation of the current line 
of investigations was that pain sensation, per se, was not directly assessed 
(perceived exertion was only assessed in chapter 6). As we have alluded to 
within the experimental chapters (Chapters 4, 5 and 7), asking the subjects to 
rate pain (and effort) sensation in this setting may have compromised their 
ability to focus on the exercise task and provide a true maximal effort, which 
would have confounded our primary outcome variable.  
 
As work output has previously been shown to increase for the same level of 
pain sensation during closed loop tasks following ACT ingestion (i.e., Foster et 
al. 2014; Mauger et al. 2010), the assessment of exercise-induced pain may 
have been most insightful in experimental chapters 4 and 5. However, whilst an 
intervention that reduces pain during exercise has the potential to enhance 
performance during closed-loop tasks (i.e., Foster et al. 2014; Mauger et al. 
2010), when pain sensation is completely abolished during such exercise tasks 
pacing strategy is adversely impacted, peripheral fatigue development is 
exacerbated and cardiopulmonary function is impaired (i.e., Amann et al. 2009). 
In contrast, if the analgesic stimulus is too low to significantly reduce PG 
synthesis (i.e., low vs. high ACT dose), this will likely not have a sufficient 
impact on alleviating the sensitisation of nociceptors via the use of COX-
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inhibitors. Together, these observations offer important considerations 
regarding the efficacy of ACT, and other interventions that can modulate 
exercise-induced pain and group III/IV muscle afferent feedback, to impact 
exercise performance.  Specifically, it appears that reducing but not abolishing 
pain and type III/IV muscle afferent feedback may be an important consideration 
for optimising exercise performance. Interestingly, this effect can also be 
achieved by sprint interval training (O’Leary et al. 2017), perhaps suggesting a 
non-pharmacological alternative.  
 
Whilst not a direct assessment of perceived pain, it is important to note that we 
observed no differences in RPE in chapter 6 following ACT ingestion (1 g) as 
well as no improvement in performance during an open loop task. It should be 
noted, however, that exercise-induced pain (i.e., a muscle ‘burn’ or ache) and 
perceived exertion and/or effort (i.e., effort to drive a muscle and/or the relative 
level of exertion associated with this effort), whilst having considerable 
similarities, can be dissociated (Astokorki & Mauger, 2017a; Groslambert et al. 
2006; O’Connor & Cook, 2001; Pageaux et al. 2015; Pageaux, 2016). In 
addition, it should also be noted that a recent study has also suggested that 
perceptions of effort and perceptions of exertion may differ (Peñailillo et al. 
2018), an opinion in which there is no consensual agreement. Whilst, by 
definition, RPE is a measure of perceived exertion, throughout this thesis we 
use ‘exertion’ and ‘effort’ interchangeably such that it is likely they represent 
similar (or identical) sensations. However, more research is required for 
understanding the development of such perceptions during exercise. Whilst we 
cannot draw specific conclusions regarding pain sensation with ACT in this 
study (chapter 6), the lack of effect on performance is, perhaps, in support of 
the likelihood that pain sensation is not an important determinant of 
performance in this type of task (i.e., closed loop, single-leg sub-maximal CWR 
exercise). However, the discrepancies in our observations might also be 
explained, at least in part by individually specific responses to analgesic 
medication (Cregg et al. 2013 for review) and the specific timing of the 
attainment of peak pain suppression following consumption of an acute dose of 
ACT (i.e., Foster et al. 2016). 
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8.1.7 Novel insights into the mechanisms underpinning the ergogenic effects of 
non-specific COX-inhibitors  
The findings from this thesis offer insights into the potential for non-specific 
COX inhibitors to influence performance and neuromuscular fatigue 
development during different forms of exercise. The original findings from this 
work suggest that acute ACT ingestion, but not IBP ingestion, might have 
important implications for improving exercise performance. However, this effect 
may be specific to maximal-intensity closed-loops tasks (or, at least, tasks 
whereby there is an ability to regulate work output and muscle activation) and 
not submaximal severe-intensity, open-loop exercise. In addition, this ergogenic 
effect was consistently linked to increased muscle activation and, therefore, it 
seems that this is an important mechanism and determinant of the efficacy of 
the ingestion of COX-inhibiting agents. Indeed, acute consumption of 1 g of 
ACT, but not 400 mg of IBP, increased muscle activation and CP (or CT), and 
attenuated fatigue development during maximal-intensity knee extensor and 
cycle ergometry exercise. However, acute ACT ingestion did not influence 
performance during continuous severe-intensity exercise completed with or 
without prior fatigue of the contralateral limb where central fatigue would be 
expected to be elevated.  Whilst we were unable to isolate the precise 
mechanism responsible for the ergogenic effect of ACT in chapters 4 and 5, it is 
likely that the ACT-induced increase in muscle activation (inferred from EMG) 
occurred due to mechanisms upstream of the neuromuscular junction as we 
observed no differences in M-wave characteristics. In addition, given that 
metabolic changes at CP determine the nociceptive signal, ACT likely elevates 
the measurable CP by reducing pain for a given nociceptive signal and/or 
influencing the degree of voluntary activation. Indeed, it is plausible to suggest 
that ACT may permit tolerable exercise closer to the metabolic CP. Therefore, 
CP should not be simply considered as a metabolic boundary but an important 
performance parameter which amalgamates all factors that contribute to 
endurance performance. Ultimately, it is likely that a combination of conscious 
(i.e., reduced pain sensation) and sub-conscious (i.e., attenuated central 
fatigue, enhanced corticospinal excitability) mechanisms relating to both 
afferent and efferent pathways contribute to the ergogenic effect of ACT by 
enhancing muscle activation and CP (or CT). The original research findings 
Chapter 8: General discussion 
 
184 
 
presented in this thesis have advanced knowledge into the effect of acute 
consumption of non-specific COX-inhibitors on neuromuscular fatigue and 
exercise performance, making a novel contribution to understanding of the 
development of exercise-induced fatigue. In combination with the existing body 
of evidence available, we propose a multi-faceted hypothetical approach 
attempting to explain the mechanisms responsible for the ergogenic effect of 
ACT ingestion, as shown in figure 8.1.    
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Figure 8.1. Proposed multi-faceted approach in explaining the mechanisms 
responsible for the ergogenic capability of an acute dose of acetaminophen 
(ACT) consumed prior to performing intense exercise under ‘normal’ conditions. 
The analgesic and antipyretic properties of ACT ingestion are likely to combine 
to enhance exercise performance via a number of different conscious and sub-
conscious mechanisms. The performance improvement is likely manifest 
differently in different types of exercise. The multi-faceted effects of ACT likely 
relate to: 1) reduced pain-sensation (i.e., conscious increase in muscle 
activation, reduced corticospinal inhibition, utilisation of metabolic reserve); 2). 
COX-inhibition (i.e., reduced afferent feedback; reduced corticospinal inhibition); 
3) Serotonergic and cannabinoid pathways (i.e., enhanced corticospinal 
excitability; modulating efferent pain pathways). 
 
8.2 Implications for the applied practitioner and researcher 
This thesis has highlighted the ergogenic potential of acute ACT consumption 
and some of the underpinning mechanisms by which ACT ingestion can 
favourably enhance exercise performance (chapters 4-5). This novel and 
original information has the potential to benefit applied practitioners and 
researchers wishing to use COX inhibitors in the future. However, this thesis 
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has also highlighted that the ergogenic effect of ACT ingestion appears to be 
specific to the task (chapter 6 vs. chapters 4-5) and that acute IBP ingestion is 
unlikely to enhance exercise performance in a ‘fresh’ state (chapter 7). Based 
on the findings presented in this thesis, researchers should ensure that ACT 
ingestion is omitted immediately before exercise trials and should obtain a 
history on participants’ use of ACT prior to completing experimental tests to 
avoid confounding effects on exercise performance measures (see appendix 
9.1 for pre-screening questionnaire). For trained individuals, ACT (and/or the 
suppression but not abolishment of pain) may act as a means to optimise 
exercise performance in events whereby small margins dictate success by 
utilising a ‘metabolic reserve’ which, under normal conditions, is preserved by 
the central nervous system (Mauger, 2014). However, whilst the current thesis 
is consistent with previous studies reporting an ergogenic effect of acute ACT 
consumption, it is pertinent to note that we do not advocate regular ACT use (or 
chronic use during a training period) or exceeding a single dose of 1 g given the 
potent hepatotoxicity of ACT ingestion (Yoon et al. 2016). Therefore, individuals 
wishing to explore the use of ACT to enhance exercise performance should do 
so infrequently, and with caution. In addition, as we observed no effect of IBP, 
we do not support its efficacy and thus individuals should reconsider utilising 
IBP to optimise performance particularly when inflammation is not elevated 
above baseline levels. It is also important to note that individuals intending to 
use IBP need to consider its potential side effects and be aware that it could 
impair aspects of the adaptive response to exercise training (Mikkelsen et al. 
2009; Schoenfeld et al. 2012). Indeed, as ACT and IBP ingestion have been 
implicated in changes in molecular responses regulating the activation and 
synthesis of certain proteins (e.g., satellite cell activity, translational signalling 
and lipid mediator response), this may have the potential to impair exercise 
training adaptations (i.e., D'Lugos et al. 2018; Markworth et al. 2014; Mikkelsen 
et al. 2009; Schoenfeld et al. 2012; Trappe et al. 2011; Trappe et al. 2002).  It is 
also worth highlighting that ACT and IBP can cause gastrointestinal 
complications and severe bleeding under certain circumstances (Andrade et al. 
1998).  
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As a more sustainable method to obtain analgesic, antipyretic and ergogenic 
effects similar to ACT ingestion, athletes and researchers should consider 
consuming and investigating foods and the use of training interventions (i.e., 
high-intensity sprint interval training, O’Leary et al. 2017) that might provide 
such effects.  Further research is required to identify and test such alternatives 
(see section 8.4 below). Finally, the extensive use of these drugs for 
performance enhancement certainly raises significant ethical concerns that 
need to be addressed. Overall, whilst we support the efficacy of ACT (but not 
IBP) to enhance exercise performance, we encourage continued greater 
awareness among coaches and athletes on the potential adverse effects of 
these drugs. However, fundamentally, the world anti-doping association 
(WADA) classifies ACT as a legal substance for sports performance, 
irrespective of the moral considerations. Indeed, and perhaps unsurprisingly, 
throughout this series of experimental investigations we have received 
increasing social media attention as well as attracted attention from publicists 
within cycling wishing to question our moral justification for assessing the 
efficacy of these drugs on exercise performance. However, it should be noted 
that the current advice suggests that ACT use during exercise, where such 
robust controls are not in place, must not be advocated. This is particularly 
pertinent given the risk of interaction with factors that affect performance (as 
well as the interactions with other medications) is not well known (Esh et al. 
2017 for brief review).  
 
8.2.1 Safety and ethical considerations 
ACT and IBP ingestion are known to be safe at standard therapeutic doses (1 g 
and 400 mg per dose up to a maximum of 4 g and 1.6 g per day, respectively). 
Specifically, whilst consumption of ACT may present risk to clinical populations 
(e.g., Aminoshariae & Khan, 2015; Hinz & Brune, 2012), ACT is considered one 
of the safest non-opioid analgesics at therapeutic doses within healthy 
individuals (Bunchorntavakul & Reddy, 2013; Graham et al. 2013; Toussaint et 
al. 2010). Nevertheless, the use of analgesic, antipyretic and anti-inflammatory 
drugs to favourably enhance exercise performance is a highly controversial 
topic and raises significant ethical concerns. Individuals wishing to explore the 
use of these medications for performance should also consider the 
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contraindications and their potential side-effects. An additional concern is that 
relatively little is known of the possible side-effects of chronic ingestion of these 
drugs. It is pertinent to note, however, that despite the many difficulties with 
achieving ethical approval in conducting studies investigating the ergogenic 
capabilities of such drugs, doses of ≥1.5 g have been safely utilised in exercise 
science research (i.e., Foster et al. 2014; Mauger et al. 2010) and acute doses 
of up to 2 g have  been used within research outside exercise science in both 
healthy and clinical populations without adverse side effects (i.e., Benson, 1983; 
Dippel et al. 2001, 2003; Forrest et al. 1979; Skoglund & Pettersen, 1991). In 
addition, studies have also demonstrated peak plasma [ACT] following a 
standard therapeutic dose to be substantially lower than concentrations typically 
associated with a risk of toxicity (Bunchorntavakul & Reddy, 2013) or damage to 
the liver (Prescott, 1983). To reduce the likelihood of any adverse effect, we 
used a questionnaire throughout this thesis to identify any ‘at risk’ populations 
which was checked and signed off by a medical doctor (see questionnaire in 
appendix, 9.1).  
 
It is particularly pertinent to note, however, that whilst there are anecdotal 
accounts of many athletes using these drugs to optimise performance, not all 
studies have observed performance improvements.  Therefore, athletes should 
strongly consider the risk of potential side-effects (especially with IBP ingestion 
given the increase risk of possible adverse side effects and the lack of effect on 
performance observed), particularly when the doses are prolonged and/or 
above the standard therapeutic dosage. In addition, as pain during exercise 
serves as a protective sensation that helps safely regulate exercise 
performance (Mauger, 2014 for brief review), participants wishing to ingest 
analgesics to boost performance should consider the risks associated with the 
exercise task. Specifically, as a result of reducing pain sensation, athletes are 
likely to be at a greater risk of tissue damage and injury. This is particularly 
important for athlete populations who likely exercise at close to their true 
‘physiological limit’ and therefore the use of ACT could prove harmful and put 
these individuals at risk. Indeed, when exercise-induced pain is completely 
abolished via intrathecal fentanyl administration, peripheral fatigue develops 
beyond ‘critical levels’ than with intact ‘pain feedback’, subsequently impairing 
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performance and causing ambulatory problems for up to 2 days after exercise 
(i.e., Amann et al. 2009).  
 
In a recent review on the use of analgesics during exercise, Lundberg & 
Howatson (2018) raised some interesting concerns on the chronic dampening 
of the pain response. Specifically, that use of ACT might lead to athletes 
returning to training and/or competition prematurely, thereby increasing the 
likelihood for injury or tendency for reoccurrence of previous injuries (Lundberg 
& Howatson, 2018). In addition, whilst there have been recent reports strongly 
advocating that ACT should be added to the WADA doping list (Lippi & Sanchis-
Gomar, 2014), this is a complicated issue as many athletes consume analgesic 
and anti-inflammatory medications to therapeutically control pain in order to 
compete. These ethical issues associated with ingestion of analgesic and anti-
inflammatory medication should continue to be addressed.  
 
8.3 Experimental limitations 
An overriding theme of this thesis was to better understand the potential 
neurophysiological alterations following ACT consumption and how this 
subsequently influenced exercise performance. Whilst this thesis has presented 
some novel findings to improve our understanding of the exercise settings in 
which, the mechanisms by which, ACT ingestion might be ergogenic, some 
limitations should be acknowledged. Firstly, we were unable to locate the 
precise mechanism of enhanced exercise performance after ACT ingestion, as 
might have been achieved had we used techniques such as TMS. The use of 
TMS in the exercise sciences requires more standardised protocols to be 
developed and validated in a range of exercise tasks to improve its validity and 
reliability, particularly during exercise. There have, however, been some 
excellent developments in this area (i.e., see recent reviews Goodall et al. 2014; 
Taylor & Gandevia, 2001). Further research using TMS should be conducted to 
provide a comprehensive assessment of the spinal and supraspinal fatigue 
contributions following ACT ingestion (see section 8.4 on the directions for 
future research). In addition, we were likely restricted with the sensitivity of our 
measures in identifying small differences in central and/or peripheral function 
(see chapter 4 for brief discussion) and the measuring of pain sensation (see 
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8.1.6 ‘Exercise-induced pain’). To help inform future research, techniques 
should be developed to overcome the difficulty with measuring muscle afferent 
feedback, particularly during exercise. To do so would significantly improve 
understanding of the central regulation of exercise performance and knowledge 
of the mechanistic bases of the ergogenic effect of ACT (chapter 6). In addition, 
it is acknowledged that PGs were not measured during this thesis as their 
synthesis is well established following ACT consumption. However, future 
research on the effect of ACT should consider investigating the inter-
relationships between physiological and performance alterations and PG 
synthesis to better understand the mechanisms for the ergogenic effect of ACT 
ingestion. Finally, it would have been of interest to assess exercise performance 
in chapters 4 and 5, by ensuring participants were aware of the 
contractions/time elapsed (and contractions/time remaining). Indeed, future 
research should attempt to closely replicate competition (condition and 
participant group) as, despite adding inherent variability to outcome measures, 
ecological validity of research is maximized. Indeed, elite athletes demonstrate 
distinct differences in physiology as well as psychological drives, suggesting 
that the mechanisms in ‘real-life’ sporting situations when compared to the 
majority of research (conducted amongst non-elite populations out of 
competition), likely differ. Further research should consider these limitations as 
well as the limitations associated with animal and isolated muscle models. 
 
8.4 Directions for future research 
Whilst the result of this thesis has provided insight into the efficacy of acute 
consumption of non-specific COX-inhibitors, further research is required to 
explore the exercise settings in which COX-inhibitors are more or less effective 
at enhancing exercise performance. This is particularly pertinent given the 
complex, task-dependent and multi-faceted nature of exercise-induced fatigue 
and exercise performance. This is further complicated by evidence suggesting 
that the ergogenic effect of ACT is also likely multi-faceted (see figure 8.1), 
individual and task-dependent. In addition, whilst a potential ergogenic effect of 
ACT is now recognised in certain exercise settings, the precise physiological 
mechanisms by which ACT is ergogenic has yet to be resolved. Specifically, 
further research is required to ascertain the underlying mechanisms for the 
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ACT-mediated enhancement in muscle activation and performance (associated 
with an increased CT or CP) during maximal exercise observed in chapters 4 
and 5. Whilst we speculate that this effect may be mediated, in-part, by 
reducing group III/IV muscle afferent feedback, support for this theory has only 
been provided by using a COX-inhibitor in cats (Hayes et al. 2006) and/or using 
fentanyl in humans (i.e., Hilty et al. 2011), and the findings on performance are 
equivocal. 
 
Further consideration should also be placed around the safe and optimal dose, 
and timing of intake (i.e., peak plasma [ACT] vs. peak pain suppression) to 
maximise the ergogenic effect of ACT ingestion. As referred to throughout this 
thesis, the use of TMS has previously suggested that acute consumption of 
ACT may enhance corticospinal excitability at rest (i.e., Mauger & Hopker, 
2012). However, this effect needs to be assessed during exercise in a 
controlled setting with minimal disruption to the task. Recent studies have 
attempted to design an ergometer to measure neuromuscular fatigue 
throughout the whole motor pathway during cycling with minimal alterations to 
the demands of the task (i.e., Doyle-Baker et al. 2018). Such methods continue 
to be improved and are likely to enhance research aiming to improve the 
understanding of the mechanistic bases for enhanced performance following 
ACT ingestion, and other potential ergogenic aids as well as our understanding 
of exercise-induced fatigue. From a research perspective in the exercise 
sciences, the use of TMS requires some development, particularly its 
application during locomotion. In addition, given that the use of surface EMG 
has been criticised in identifying differences in neural drive (i.e., Martinez-
Valdes et al. 2018), using TMS (and electroencephalography, EEG) during 
exercise may be of vital importance to advance the field of exercise-induced 
fatigue and the central regulation of exercise performance. Therefore, a further 
comprehensive measurement of alterations to spinal and supraspinal fatigue 
mechanisms following ACT ingestion is required. 
 
In this thesis we also demonstrated that acute IBP consumption is not beneficial 
to performance during small and large muscle mass exercise, despite being 
reported to exhibit a similar effect on PG synthesis compared to ACT at the 
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whole-body level. However, we were restricted by the relatively low-dose of IBP 
(400 mg) compared to ACT (1000 mg) due to the contraindication associated 
with higher doses of IBP. It is possible that IBP may be ergogenic at higher 
doses; however, testing this this would be unethical considering the potential 
side effects and contraindications associated with IBP toxicity. It is important to 
note, though, that for ACT (1000 mg) and IBP (400 mg), these are the effective 
doses that can be taken without serious side effects and that, as they are 
different drugs, the quantity of dose cannot be directly compared. In addition, it 
would be interesting to assess whether the effect of non-specific COX-inhibitors 
on performance is population-specific (i.e., greater or lesser effects are manifest 
in trained or untrained individuals, chronic users and clinical populations).  
 
As discussed throughout this thesis, it is possible that ACT ‘permits’ an 
individual to exercise close to their ‘true’ physiological limit. This suggests that, 
following ACT ingestion, participants are able to exercise at a higher boundary 
of their metabolic CP (or exercise modality equivalent). It is, therefore, plausible 
to suggest that either pain is perhaps not normally tolerable at CP and/or that 
the use of ACT allows participants to ‘utilise’ a previously unused ‘metabolic 
reserve’. It is also possible that peripheral fatigue development is unchanged, 
but that ACT permits exercise at a ‘critical’ level of peripheral fatigue for longer. 
Future research should combine muscle metabolic measurements with multiple 
severe-intensity trials to estimate CP to provide clarity here. In addition, given 
the apparent ability for analgesics to enhance performance and the ability of 
exercise training to elevate pain tolerance, it would be of interest as to whether 
‘pain training’ improves exercise performance independent of a physical training 
programme.  
 
Ultimately, to advance the field of exercise-induced fatigue, rather than 
assessing fatigue as a central vs. peripheral debate, researchers should 
continue to attempt to understand the complex interplay between direct 
physiological impairments (i.e., within the central nervous system and within the 
contractile elements of peripheral muscle), conscious and sub-conscious 
regulatory mechanisms as well as the relative contributions from each, 
respectively, in regulating work output to avoid the risk of a ‘muscle-less’ model 
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to explain exercise-induced fatigue development. Indeed, whilst much of this 
thesis has focussed on the potential central limiting factors to performance and 
Tlim, it is important to note that peripheral fatigue has a profound effect on force-
producing capacity and, by extension, the regulation of performance. Finally, as 
we have stipulated throughout, we do not advocate chronic use of ACT (or IBP) 
or exceeding a single dose of 1 g to enhance performance given the potent 
hepatotoxicity of ACT ingestion. However, such promising data supports the 
potential for safer means to inhibit COX enzyme activity to enhance 
performance. Future research should explore this potential.  
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8.5 Conclusion 
Acute consumption of the recommended therapeutic dose of ACT (1 g), but not 
IBP (400 mg) enhanced performance during maximal-intensity single-leg and 
cycling exercise in healthy participants concomitant with an increase in muscle 
activation and critical torque (and critical power).  However, ACT ingestion did 
not improve Tlim, RPE, muscle activation or the perturbation to intramuscular 
phosphorus substrates and metabolites during severe-intensity single-leg knee 
extension exercise completed with or without prior fatigue of the contralateral 
leg.  Therefore, our findings suggest that acute consumption of the non-specific 
COX inhibitor, ACT, can improve performance, but that the ergogenic efficacy of 
ACT may be task-dependent, and more likely to be beneficial during maximal-
intensity exercise.  These original findings improve understanding of exercise-
induced fatigue development, the ergogenic potential of ingesting non-specific 
COX inhibitors and some of the underpinning mechanisms responsible for these 
effects.     
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Appendix Questionnaire  
 
Study: Influence of acetaminophen and ibuprofen ingestion on parameters of the power-
duration relationship. 
Pre-Screening Questionnaire for Participants 
               Please initial 
box 
Yes / No 
I. Are you allergic to any medications? If yes, please list the drug(s) and the 
reaction it causes when you take it?   
-------------------------------------------------------------------------------------------------- 
II. Do you have any previous illnesses (including asthma, heart disease, stroke, 
diabetes, high blood pressure, operations etc.)? If yes, please write them below, 
along with when you had them    
-------------------------------------------------------------------------------------------------- 
III. Are you currently on any medication? If yes, please list all the drugs you take 
(including both prescribed and off-the-shelf). 
 
-------------------------------------------------------------------------------------------------- 
 
IV. Have you previously used acetaminophen (paracetamol) and/or ibuprofen? If 
yes, have you experienced any side effects? 
-------------------------------------------------------------------------------------------------- 
V. Have you got a history of cigarette use (inc. timing, quantity and type, if 
any)? 
-------------------------------------------------------------------------------------------------- 
VI.   Do you drink alcohol? If yes, how much do you drink per week and have  
you ever drunk excessively? 
 
-------------------------------------------------------------------------------------------------- 
 
SCHOOL OF SPORT AND HEALTH 
SCIENCES 
 
S t .  L u ke ’ s  C a mp u s  
U n i v e r s i t y  o f  E x e t e r  
H e a v i t r e e  R o a d  
E x e t e r  
E X1  2 L U  
U n i t e d  K i n g d o m  
We b  a d d r e s s :  s h s . e x e t e r . a c . u k/  
T e l :  + 4 4  ( 0 ) 1 3 9 2  7 2 2 8 9 6  /  7 2 2 8 8 4  
E ma i l :  s h s - o f f i c e @ e x e t e r .a c . u k      
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VII. Have you ever used illegal drugs? If yes, please describe (this, like all of 
your answers to this questionnaire, is completely confidential) 
------------------------------------------------------------------------------------------------- 
 
VIII.  Do/have you suffered from any of the below? Check All That Apply To 
You. History of: 
Alcohol-related Diseases eg cirrhosis  
Asthma   
Cardiac problems i.e. angina, heart attack or heart 
rhythm disturbances like atrial fibrillation (AF) 
 
Cerebrovascular disease i.e. stroke or TIA  
Connective tissue disorders   
Crohn’s disease  
Heart failure  
Hypertension   
Kidney problems  
Liver Disease  
Peripheral arterial disease  
Stomach bleeds or stomach ulcers  
Ulcerative colitis  
          
IX. Have you a family history of any of the below? Check All That Apply To 
You.  
Asthma   
Cardiac problems i.e. angina, heart attack or heart 
rhythm disturbances like AF 
 
Cerebrovascular disease i.e. stroke or TIA  
Connective tissue disorders   
Crohn’s disease  
Heart failure  
Hypertension   
Kidney problems  
Liver Disease  
Peripheral arterial disease  
Stomach bleeds or stomach ulcers  
Ulcerative colitis  
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If you have answered YES to one or more questions:  
You should consult with your doctor to clarify that it is safe for you to take part in this study at this current 
time and in your current state of health. Medical advice will also be sought via the University.   
If you have answered NO to all questions:  
It is reasonably safe for you to participate in this study, gradually building up your performance from your 
current ability level.  
I have read, understood and accurately completed this questionnaire. I confirm that I am 
voluntarily engaging in the above research, and my participation involves a small risk of injury.  
Signature  
Print name  
Date  
Having answered YES to one of the above, I have sought medical advice and my GP has agreed that 
I may take part in the above study.  
Signature  
Date  
Note: This clearance is valid for a maximum of 12 months from the date it is completed and becomes 
invalid if your condition changes so that you would answer YES to any of the above questions.  
 
________________________ ________________ ________________ 
Name of Participant Date Signature 
________________________ ________________ ________________ 
Researcher Date Signature       
________________________ ________________ ________________ 
Name of Medical Professional Date Signature       
 
 
 
 
